

TENT COOPERATION TRE

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

BERGVALL EFTRING, Stina, Lena
Dr Ludwig Brann Patentbyrå AB
P.O. Box 17192
S-104 62 Stockholm
SUÈDEDate of mailing (day/month/year)
23 October 2001 (23.10.01)Applicant's or agent's file reference
P04646PC00International application No.
PCT/SE00/01079

IMPORTANT NOTIFICATION

International filing date (day/month/year)
26 May 2000 (26.05.00)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address

ACTIVE BIOTECH AB
P.O. Box 724
S-220 07 Lund
Sweden

State of Nationality

SE

State of Residence

SE

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☒ the address ☐ the nationality ☐ the residence

Name and Address

SBL VACCIN AB
Lundagatan 2
S-105 21 Stockholm
Sweden

State of Nationality

SE

State of Residence

SE

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☒ the International Preliminary Examining Authority ☐ other:The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Céline Faust

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

Date of mailing (day/month/year) 20 February 2001 (20.02.01)	
International application No. PCT/SE00/01079	Applicant's or agent's file reference P04646PC00
International filing date (day/month/year) 26 May 2000 (26.05.00)	Priority date (day/month/year) 28 May 1999 (28.05.99)
Applicant FOLKESSON, Anders et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
20 December 2000 (20.12.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer F. Baechler Telephone No.: (41-22) 338.83.38
--	--

REC'D 08 OCT 2001

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

14

Applicant's or agent's file reference P04646PC00/HA	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/SE00/01079	International filing date (<i>day/month/year</i>) 26.05.2000	Priority date (<i>day/month/year</i>) 28.05.1999
International Patent Classification (IPC) or national classification and IPC ₇ C 07 K 14/225, A 61 K 39/12		
Applicant ACTIVE BIOTECH AB et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 20.12.2000	Date of completion of this report 24.09.2001
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-667 72 88 Telex 17978 PATOREG-S	Authorized officer Yvonne Siösteen/EÖ Telephone No. 08-782 25 00

I. Basis of the report**1. With regard to the elements of the international application:***

- ☐ the international application as originally filed
- ☒ the description:
pages 1-3 and 5-13, 67, as originally filed
pages _____, filed with the demand
pages 4, filed with the letter of 05.09.2001
- ☒ the claims:
pages _____, as originally filed
pages _____, as amended (together with any statement) under article 19
pages _____, filed with the demand
pages 15 and 16, filed with the letter of 05.09.2001
- ☒ the drawings:
pages 1-4, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☒ the sequence listing part of the description:
pages 14-66, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheet/fig _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2 (c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 10 and 11

because:

☒ the said international application, or the said claims Nos. 10 and 11

relate to the following subject matter which does not require an international preliminary examination (*specify*):

See PCT Rule 67.1.(iv).: Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____
are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. _____ are so inadequately supported
by the description that no meaningful opinion could be formed.

☐ no international search report has been established for said claims Nos. _____.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	<u>1-9, 12-13</u>	YES
	Claims		NO
Inventive step (IS)	Claims	<u>1-9, 12-13</u>	YES
	Claims		NO
Industrial applicability (IA)	Claims	<u>1-9, 12-13</u>	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

The claimed invention relates to peptides encoded by nucleotide sequences from Salmonella for use in medicine. The sequences encode two fimbrial structures of Salmonella enterica subspecies I and Salmonella enterica subspecies I serovar Typhi. It has been found that SEQ ID NO 1 is specific to all Salmonella enterica subspecies I. The peptides and the nucleotide sequences encoding them are very suitable for use in diagnosis and in vaccine preparations.

It is already known from Folkesson et al., Abstracts of the General Meeting of the American Society for Microbiology 97, page 219 (1997) that the fimbrial genes safA, safB and safC from Salmonella have been identified.

The genes safA, safB and safC are encoded by parts of the nucleotide sequence SEQ ID NO 1 of Sequence listing No.1 of the present application.

The sequences have, however, not been disclosed in the prior art. Neither have the unique specificities of the genes been known before. Because of their specificity they are very useful in vaccine preparations.

Therefore the claims are considered to be novel and to involve an inventive step.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/01079

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 14/225, A61K 39/112

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Abstracts of the 97th General Meeting of the American Society for Microbiology, May 4-8, 1997, Miami Beach, Florida, A. FOLKESSON et al: D-67. "Cloning and Characterization of Genes Encoding a Novel Salmonella spp. Adhesive Structure". See abstract.	1-4, 6, 8, 10, 13-14
P, X	Molecular Microbiology, Volume 33, No 3, 1999, Anders Folkesson et al., "Multiple insertions of fimbrial operons correlate with the evolution of Salmonella serovars responsible for human disease", page 612 - page 622, see entire document	1-14

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

2 October 2000

Date of mailing of the international search report

23 -10- 2000

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Henrik Nilsson/GH
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE00/01079

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10-11
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet *
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a):

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE00/01079

★

Claims 10-11 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/ Rule. 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

BRANN

To
THE SWEDISH PATENT OFFICE
Stockholm

International patent application no PCT/SE00/01079
Our ref: P04646PC00/HA:sd

With reference to our telephone communication of September 13, 2001, we wish to file the enclosed page 16, comprising amended claim 14.

The amendment consists of a specification of the purpose of the diagnostic method wherein the primers or probes of the invention are used, by adding at the end of the claim the passage "for the purpose of detecting *Salmonella enterica* subspecies I". A basis for this amendment may be found in the description, e.g. on page 7, lines 20-22 and lines 27-29.

Stockholm, September 13, 2001
Active Biotech AB et al
by:



Harriet Allee

DR LUDWIG BRANN PATENTBYRÅ AB. Intellectual Property & Law Firm.

Stockholm Office: Box 171 92, S-104 62 Stockholm, Sweden. Visiting address: Maria Skolgata 83. Tel: +46 (0)8 429 10 00. (Non-Office hours: 429 10 99) Fax: +46 (0)8 429 10 70 (Patents). Fax: +46 (0)8 429 10 80 (Trade Marks). E-mail: brann@brann.se

Uppsala Office: Box 1344, S-751 43 Uppsala, Sweden. Visiting address: Drottninggatan 7. Tel: +46 (0)18 56 89 00. Fax: +46 (0)18 56 89 39.

Head Office and Seat of the Board: Stockholm. Reg. No. 556483-6212. Members of the Association of Swedish Patent Attorneys. Authorized representatives before the EPO and the OMV.

9. A vector vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising a host in which a recombinant vector comprising a nucleic acid sequence selected from Sequence Listing No. 2 (SEQ ID NO 2), has been inserted and, optionally, a pharmaceutically acceptable carrier.

5 •

10. A method for protection against diseases caused by *Salmonella enterica* subspecies I, comprising administering a vaccine according to any of claims 4, 6, and 8.

10 11. A method for protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising administering a vaccine according to any of claims 5, 7, and 9.

15 12. Antibodies directed against a peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2), for use in a diagnostic method.

20 13. Peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2), for use in a diagnostic method.

25 14. Primers for, or probes that hybridize with, a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2), for use in a diagnostic method for the purpose of detecting *Salmonella enterica* subspecies I.



To
THE SWEDISH PATENT OFFICE
Stockholm

International patent application no PCT/SE00/01079
Our ref: P04646PC00/HA:sd

With reference to our telephone communication of September 2, 2001, we wish to file the following pages, comprising amendments as specified herein below:

Amendments

In the description:

On page 4, under the heading "Sequence listing", the words " Sequence Listing No.1, herein referred to as" have been inserted before "SEQ ID NO 1", and the words "Sequence Listing No. 2, herein referred to as" have been inserted before "SEQ ID NO 2".

In the claims:

In new claims 1-4, 6, 8 and 12-14 the words "SEQ ID NO 1" have been put in parenthesis and the words "Sequence Listing No.1" have been inserted before the parenthesis.

In new claims 1-3, 5, 7, 9 and 12-14 the words "SEQ ID NO 2" have been put in parenthesis and the words "Sequence Listing No.2" have been inserted before the parenthesis.

Furthermore:

New claim 1

line 1: "protein" has been amended to "peptide";
lines 1-2: "the group consisting of " has been deleted;
line 2: "or parts thereof" has been deleted;

New claim 2

line 1: "the protein" has been amended to "a peptide";
line 2: "the group consisting of " has been deleted;
line 3: "or antigenic fragments thereof" has been deleted;

New claim 3

line 1: "the group consisting of " has been deleted;
line 2: "or parts thereof" has been deleted;

DR LUDWIG BRANN PATENTBYRÅ AB. Intellectual Property & Law Firm.

Stockholm Office: Box 171 92, S-104 62 Stockholm, Sweden. Visiting address: Maria Skolgata 83. Tel: +46 (0)8 429 10 00.

(Non-Office hours: 429 10 99) Fax: +46 (0)8 429 10 70 (Patents). Fax: +46 (0)8 429 10 80 (Trade Marks). E-mail: brann@brann.se

Uppsala Office: Box 1344, S-751 43 Uppsala, Sweden. Visiting address: Drottninggatan 7. Tel: +46 (0)18 56 89 00. Fax: +46 (0)18 56 89 39.

Head Office and Seat of the Board: Stockholm Reg. No. 556483-6210. Members of the Association of Swedish Patent Attorneys. Authorized representatives before the EPO and the OIM.

New claim 4

- line 2: "the protein" has been amended to "a peptide";
 "or parts thereof" has been deleted;
 "the nucleotide sequence according to" has been amended to "a nucleotide sequence selected from";
- line 4: "the protein encoded by SEQ ID NO 1" has been amended to "said peptide";
 "or antigenic fragments thereof" has been deleted;

New claim 5

- line 2: "the protein, or parts thereof," has been amended to "a peptide";
- line 3: "the nucleotide sequence according to" has been amended to "a nucleotide sequence selected from";
- lines 3-4: "the protein encoded by SEQ ID NO 2" has been amended to "said peptide";
 "or antigenic fragments thereof" has been deleted;

New claim 6

- line 2: "SEQ ID NO 1, or parts thereof" has been amended to "a nucleic acid sequence selected from Sequence Listing No. 1 (SEQ ID NO 1)";

New claim 7

- lines 2-3: "SEQ ID NO 2, or parts thereof" has been amended to "a nucleic acid sequence selected from Sequence Listing No. 2 (SEQ ID NO 2)";

New claim 8

- line 3: "SEQ ID NO 1, or parts thereof" has been amended to "a nucleic acid sequence selected from Sequence Listing No. 1 (SEQ ID NO 1)";

New claim 9

- line 3: "SEQ ID NO 2, or parts thereof" has been amended to "a nucleic acid sequence selected from Sequence Listing No. 2 (SEQ ID NO 2)";

New claim 12

- line 1: "the protein" has been amended to "a peptide";
- line 2: "the group consisting of" has been deleted;
- lines 2-3: "or antigenic fragments thereof" has been deleted;

New claim 13

- line 1: "Protein" has been amended to "Peptide";
- line 1-2: "the group consisting of" has been deleted;
- line 2: "or parts thereof" has been deleted;

New claim 14

- line 2: "the group consisting of" has been deleted.

Basis for the amendments**The description**

The insertion on page 4 in the description is for a clarifying purpose only: it makes clear that by the wording "SEQ ID NO 1" (and 2 respectively) is meant "Sequence Listing No. 1" (and 2 respectively), conforming better to the established terminology within the field.

The claims

New claim 1 refers to the use of a peptide (instead of a protein)

A basis for the use of a peptide may be found e.g. on page 6, first paragraph, where a method of obtaining a peptide according to the invention is outlined, and on page 6, third paragraph, where medical uses of such peptide are mentioned.

Similar amendments (from protein to peptide) to claims 2-5 and 12 and 13 have the same basis in the description.

All other amendments to the claims relate to linguistic improvements.

Stockholm, September 4, 2001

Active Biotech AB et al

by:


Harriet Allee

of respective phage insert is represented by horizontal bars. Name and size of the phage inserts are indicated on the left side of the figure.

Figure 2: Schematic representation of the pTY52 cosmid comprising the *tcf*-operon (SEQ ID NO 2).

5 A *tcf* specific PCR fragment of 11105 bp was cloned into the Expand vector I cosmid (Roche). The insert is represented with a thick black line while vector sequences are represented with thin lines. Relevant restriction sites sequences are indicated. The position of the *tcf*-operon, i.e. *tcfA*, *B*, *C* and *D* (SEQ ID NO 2), is represented by a shaded arrow.

10 Figure 3: The phylogenetic distribution of the identified genes on the cs7 insert was investigated using the well defined SARC collection, see Example 1.

Figure 4: A 2 kb large internal *EcoR* I fragment was used as a probe in a Southern blot of the SARC collection, see Example 2.

15 Sequence listing

Sequence Listing No. 1, herein referred to as SEQ ID NO 1, —DNA sequence of the genes encoding the precursor of the *saf* fimbriae unit of *Salmonella enterica* subspecies I.

20 Sequence Listing No. 2, herein referred to as SEQ ID NO 2, —DNA sequence of the genes which encode the precursor of the *tcf* fimbriae unit of *Salmonella enterica* subspecies I serovar Typhi.

Deposit information

25 The phages carrying the inserted SEQ ID NO 1, i.e. phages clones B1, D1, F11 and N10 (see Figure 1) have been given the ECACC Accession numbers 99051922, 99051923, 99051924, and 99051925, respectively.

The cosmids carrying the inserted SEQ ID NO 2, i.e. cosmid pTY52 (see Figure 2) has been given the ECACC Accession number 99051926.

The depositions were made May 19, 1999.

30 Detailed description of the invention

The present invention is based on the finding that two fimbrial operons, the *saf* operon and the *tcf* operon, are specific for *Salmonella enterica* subspecies I bacteria. Due to their specificity they can be used to provide vaccines against
35 *Salmonella enterica* subspecies I as well as detection methods for *Salmonella enterica* subspecies I. The *saf* operon is specific for all *Salmonella enterica*

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/73336 A1

(51) International Patent Classification⁷: C07K 14/225,
A61K 39/112

(21) International Application Number: PCT/SE00/01079

(22) International Filing Date: 26 May 2000 (26.05.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9901961-4 28 May 1999 (28.05.1999) SE

(71) Applicant (for all designated States except US): ACTIVE
BIOTECH AB [SE/SE]; P.O. Box 724, S-220 07 Lund
(SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FOLKESSON,
Anders [SE/SE]; Råsundavägen 169B, S-169 36 Solna
(SE), NORMARK, Staffan [SE/SE]; Valhallavägen 126
2tr, S-114 41 Stockholm (SE), LÖFDAHL, Sven [SE/SE];
Adolfsbergsvägen 36, S-168 66 Bromma (SE).

(74) Agents: BERGVALL EFTRING, Stina, Lena et al.; Dr
Ludwig Brann Patentbyrå AB, P.O. Box 17192, S-104 62
Stockholm (SE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: FIMBRIAL PROTEINS

(57) Abstract: The present invention is based on the finding that two fimbrial structures are specific for *Salmonella enterica* sub-
species 1 bacteria. Due to their specificity they can be used to provide vaccines against *Salmonella enterica* subspecies I as well as
for detection of *Salmonella enterica* subspecies I.

WO 00/73336 A1

FIMBRIAL PROTEINSField of the invention

The present invention is based on the finding that two fimbrial operons, the *saf* operon and the *tcf* operon, are specific for *Salmonella enterica* subspecies 1 bacteria and therefore have therapeutic use. Due to their specificity they can be used to provide vaccines against *Salmonella enterica* subspecies I as well as for detection of *Salmonella enterica* subspecies I. The *saf* operon is specific for all *Salmonella enterica* subspecies 1 bacteria and the *tcf* operon is specific for the serovar Typhi of *Salmonella enterica* subspecies 1.

All or part of the DNA-sequences of the genes encoding these proteins can be used as active agents in a vaccine against diseases caused by the *Salmonella enterica* subspecies I bacterial strains or for detection of said bacterial strains.

The present invention also relates to methods of isolating these fimbrial proteins, to antibodies directed against these proteins, and to a vaccine composition comprising these proteins or antibodies directed against these proteins for use in the treatment of infections caused by the *Salmonella spp.* The fimbrial proteins according to the invention or antibodies directed against them can be used for detection of *Salmonella spp.* bacteria.

Background of the invention

The members of genus *Salmonella spp* colonize and infect a wide range of different organisms. Many cause gastroenteritis and enteric fever in humans and domesticated animals while others are not associated with human disease (Saylers et al, 1994). The genus has been divided into two species, *Salmonella bongori* and *Salmonella enterica* where *enterica* can be further subdivided into seven subspecies, designated I, II, IIIa, IIIb, IV, VI, and VII (Reeves et al, 1989). *Salmonella enterica* subspecies I are preferentially associated with warm-blooded animals. Over 99% of all clinical *Salmonella* isolates are strains belonging to this subspecies, including serovars Typhimurium and Enteritidis, which are the major causes of *Salmonella* induced gastroenteritis in humans, and Typhi, the human specific causative organism of typhoid fever, the most severe form of human salmonellosis (Popoff et al, 1992).

Salmonella enterica subspecies I consists of over 1300 different serovars and is preferentially associated with warm-blooded animals (Bäumler, 1997). Over 99% of all clinical *Salmonella* isolates are strains belonging to this subspecies,

including serovars Typhimurium and Enteritidis, which are the major causes of *Salmonella* induced gastroenteritis in humans, and Typhi, the human specific causative organism of typhoid fever, the most severe form of human salmonellosis (Popoff and Le Minor, 1992).

5

Today gastroenteritis and enteric fever can neither be prevented nor treated with good results. Typhoid fever is a substantial public health problem in developing countries. Each year 33 million people become ill and over 500 000 people die from this infection (American Institute of Medicine, 1986). Typhoid fever can be prevented by vaccination with attenuated bacteria, such as Ty21 and Vi vaccines and whole cell vaccines. Whole cell vaccines show a high incidence of side effects (Ashcroft et al, 1964, Yugoslav Typhoid commission, 1964). The vaccines consisting of attenuated strains of *Salmonella typhi* suffer from serious drawbacks. They must be administered as three or four spaced doses in order to stimulate protective immune responses (Levine et al, 1989). The treatment of *Salmonella typhi* with antibiotics is jeopardized since there are strains of *Salmonella typhi* that are resistant to chloramphenicol, ampicillin, and trimethoprim as well as ciprofloxacin (i.e. multidrug-resistant strains) (Rowe et al, 1997).

20

Accurate detection of *Salmonella enterica* subspecies I is today not possible. *Salmonella enterica* subspecies I can today only be detected by antibodies directed against surface proteins of *Salmonella enterica* subspecies I. The use of the sequences according to the invention makes it for the first time possible to rapidly and accurately determine the presence of *Salmonella enterica* subspecies I.

25

For many pathogenic bacteria, there is evidence that the filamentous surface protein structures called pili (fimbriae) are connected to the adhesion of the bacteria to the host cells. Pili proteins are very antigenic and are easily purified. Therefore pili preparations have been used as antigens for vaccination.

30

Summary of the invention

35

The invention relates to the objects as defined in the claims. The main object of the present invention is to provide two fimbrial proteins that are specific for *Salmonella enterica* subspecies I bacterial strains, the nucleotide sequences

encoding said proteins, as well as the corresponding amino acid sequences of for therapeutic and diagnostic use. Further are recombinant microorganisms provided, in which the nucleotide sequences according to the invention have been inserted.

5

An object of the present invention is to provide vaccine compositions for use in the treatment of *Salmonella enterica* infective strains, essentially pure Saf and Tcf fili protein of *Salmonella enterica* subspecies I and *Salmonella enterica* subspecies I serovar Typhi, respectively, as well as antibodies directed to these fili proteins.

10

A further object of the present invention is to provide the DNA sequences of the genes encoding the Saf and Tcf proteins. These sequences can be used for recombinant production of the proteins and for the preparations of vector vaccines against *Salmonella enterica* subspecies 1 and *Salmonella enterica* subspecies 1 serovar Typhi, respectively, as well as for diagnostic purposes.

15

Yet another object of the present invention to use purified Saf and Tcf protein from *Salmonella enterica* subspecies 1 bacteria for active or passive immunization of mammals, i.e. the proteins according to the invention can be comprised in a vaccine composition or be used to raise antibodies which can be comprised in a vaccine composition.

20

Finally, an object of the present invention is to provide a method for preventing or reducing the possibility of *Salmonella* infection of a mammal by administering the vaccines according to the invention. The invention may be more fully understood by reference to the following drawings and detailed description.

25

30 Brief description of the drawings

Figure 1.

Schematic representation of phage clones (named N10, D1, B1, F11) covering the entire cs7 insert of *Salmonella enterica* serovar Typhimurium strain SR χ 3181, i.e. comprising the *saf* fimbrial operon, i.e. *safA*, *B*, *C* and *D* (SEQ ID NO 1).

35

The clones were selected from partial *Eco* RI and *Bam*HI libraries in the Lambda Dash II vector. The cs7 insert is represented by a bold line. The extent

of respective phage insert is represented by horizontal bars. Name and size of the phage inserts are indicated on the left side of the figure.

Figure 2: Schematic representation of the pTY52 cosmid comprising the *tcf*-operon (SEQ ID NO 2).

5 A *tcf* specific PCR fragment of 11105 bp was cloned into the Expand vector I cosmid (Roche). The insert is represented with a thick black line while vector sequences are represented with thin lines. Relevant restriction sites sequences are indicated. The position of the *tcf*-operon, i.e. *tcfA*, *B*, *C* and *D* (SEQ ID NO 2), is represented by a shaded arrow.

10 Figure 3: The phylogenetic distribution of the identified genes on the cs7 insert was investigated using the well defined SARC collection, see Example 1.

Figure 4: A 2 kb large internal *EcoR* I fragment was used as a probe in a Southern blot of the SARC collection, see Example 2.

15 Sequence listing

Sequence Listing No. 1, herein referred to as SEQ ID NO 1, —DNA sequence of the genes encoding the precursor of the saf fimbriae unit of *Salmonella enterica* subspecies I.

20 Sequence Listing No. 2, herein referred to as SEQ ID NO 2, —DNA sequence of the genes which encode the precursor of the tcf fimbriae unit of *Salmonella enterica* subspecies I serovar Typhi.

Deposit information

25 The phages carrying the inserted SEQ ID NO 1, i.e. phages clones B1, D1, F11 and N10 (see Figure 1) have been given the ECACC Accession numbers 99051922, 99051923, 99051924, and 99051925, respectively.

The cosmids carrying the inserted SEQ ID NO 2, i.e. cosmids pTY52 (see Figure 2) has been given the ECACC Accession number 99051926.

The depositions were made May 19, 1999.

30 Detailed description of the invention

The present invention is based on the finding that two fimbrial operons, the *saf* operon and the *tcf* operon, are specific for *Salmonella enterica* subspecies I bacteria. Due to their specificity they can be used to provide vaccines against

35 *Salmonella enterica* subspecies I as well as detection methods for *Salmonella enterica* subspecies I. The *saf* operon is specific for all *Salmonella enterica*

subspecies 1 bacteria and the *tcf* operon is specific for the serovar typhi of *Salmonella enterica* subspecies 1, see Examples 1 & 2.

The main object of the invention relates to two fimbrial operons, the *saf* operon and the *tcf* operon, that are specific for *Salmonella enterica* subspecies 1 bacteria for therapeutic use.

Another object of the present invention is to provide vaccines against *Salmonella enterica* subspecies 1 induced gastroenteritis, enteric fever and typhoid fever.

A further object of the present invention is to provide methods to detect *Salmonella enterica* subspecies 1. The nucleotide sequences according to the invention are useful for constructing vectors for use as vaccines for insertion into attenuated bacteria in constructing a recombinant vaccine, for insertion into a viral vector in constructing a recombinant viral vaccine, or for direct inoculation as a nucleic acid vaccine. The pili proteins according to the invention, or antigenic fragments thereof, can be used for active immunization and antibodies directed against them can be used for passive immunization. All these applications of the sequences according to the invention are obtained by applying standard techniques known to the man ordinary skilled in the art.

Vaccines against *Salmonella enterica* subspecies 1.

The genes encoding the *saf* and *tcf* fimbrial structures, or fragments thereof, may be incorporated into a bacterial or viral vaccine comprising recombinant bacteria, virus or fungi which are engineered to produce one or more immunogenic epitopes of the *saf* or *tcf* fimbrial structures. In addition, the genes encoding the *saf* and *tcf* fimbrial structures, or part thereof, operatively linked to regulatory elements, can be introduced directly as a nucleic acid vaccine, to elicit a protective immune response.

The proteins or antigenic fragment thereof, deduced from the nucleic acid sequences of the present invention are useful alone or in conventional vaccine mixtures in the vaccine compositions according to the invention. The proteins could be produced by chemical synthesis or recombinant expression according to conventional methods.

The proteins and peptides according to the invention can be obtained by using a host organism transformed or transfected with an expression vector obtained by insertion of a gene according to the invention, or part thereof, into a vector in a conventional manner. The vector which is used to construct the expression
5 vector is not particularly limited, but specific examples include plasmids such as pET (Stratagen) and the like; and phages such as M13 (NEB), phage display libraries and the like. As expression regulatory sequence can among others T7 promoters and lac promoters be used.

10 An appropriate host to be transformed or transfected with the expression vector can be chosen among for example *E.-coli*, *Salmonella* or *Bacillus subtilus*. The transformed or transfected host is cultured and proliferated under suitable conditions.

15 After culturing, the peptides of the present invention may be purified by, for example, chromatography, precipitation, and/or density gradient centrifugation. The thus obtained peptides can be used as a vaccine or for the production of antibodies directed against said peptides, which can be used for passive immunization.

20 The purified preparation containing one or several proteins according to the invention, or parts thereof, is then formulated as a pharmaceutical composition, as for example a vaccine, or in a mixture with adjuvants. If desired the proteins are fragmented by standard chemical or enzymatic
25 techniques to produce antigenic segments.

In formulating the vaccine compositions with the peptide or protein, alone or in various combinations, the immunogen is adjusted to an appropriate concentration and formulated with any suitable vaccine adjuvant. The
30 immunogen may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers for use in a vaccine formulation.

The different vaccines according to the present invention are administered to mammals in many different ways. These include intradermal, intramuscular,
35 intraperitoneal, intravenous, subcutaneous, oral, and intranasal routes of administration. The vaccine doses will differ depending on circumstances such

as body weight, interferences with other administered medicaments etc. The upper limit is not critical unless the dose shows toxicity.

The peptides and proteins of the present invention are also useful to produce
5 monoclonal or polyclonal antibodies for use in passive immunotherapy against
Salmonella enterica subspecies 1. Human immunoglobulin is preferred.
Antisera is obtained from individuals immunized with proteins or peptides
according to the invention. The immunoglobulin fraction is then enriched, for
example by immunoaffinity or affinity chromatography. Antibodies raised in
10 a suitable mammal or in the patient to be treated, can subsequently be
administered locally or topically, e.g. orally to the patient.

Detection of *Salmonella enterica* subspecies I in general.

The sequences according to the invention, or part thereof, or fragments
15 hybridizing therewith, as well as the proteins according to the invention, or part
thereof, and antibodies directed to said proteins, or antigenic fragments
thereof, can be used in molecular diagnostic assays for the detection of
Salmonell enterica subspecies I.

20 Nucleic acids having the nucleotide sequence according to the invention, or any
nucleotide sequence hybridizing therewith can be used as a probe in nucleic
acid hybridization assays for the detection of *Salmonella spp* in various tissues
and body fluids of patients. The hybridization assay may be of any type
including; Southern blots, Northern blots, colony blots.

25 PCR technology is the most preferred technology for detection according to the
invention of *Salmonella enterica* subspecies 1. Primers of at least one selected
from the 5' end and one from the 3' end can be used in PCR and other known
tests to rapidly identify the presence of *Salmonella enterica* subspecies 1. This is
30 according to conventional techniques.

The isolated and purified proteins and peptides of the invention can be used as
diagnostics to measure an increase in serum titer of *Salmonella enterica*
subspecies I-specific antibody since they bind strongly to these antibodies. A
35 serum test sample can be screened for *Salmonella enterica* subspecies I by
methods such as for example ELISA.

The invention further comprises the use of antibodies directed against the *saf* and *tcf* fimbriae structures for quantitative or qualitative determinations of the pili proteins of the invention, or fractions thereof, in cells, tissues or body fluids.

5

Detection of *Salmonella enterica* subspecies I by using nucleic acid hybridization technology

10

Nucleic acid hybridization technology can also be used to detect *Salmonella enterica* subspecies I according to the invention. The nucleic acid probes chosen from parts of the sequences according to the invention can be either DNA or RNA. DNA sequences complementary to the sequences according to the invention can also be used. The binding of the probe to the target sequence, i.e. the hybridization, must not be perfect. Variations and mutations of the sequences according to the invention can be used as long as they hybridize good enough to detect *Salmonella enterica* subspecies I. The preferred length of the nucleic acid probes is about 10 to 400 nucleotides, most preferred not longer than 100 nucleotides.

15

The nucleotide probe is preferably chosen from the parts of the sequences that have the least variation. In the most preferred embodiments when screening for SEQ ID NO 1 (the *saf* operon, specific for *Salmonella enterica* subspecies I) a nucleotide probe or PCR primer selected from nucleotides 37 368-37 868 should be avoided since this region is hypervariable.

20

The nucleic acid probes according to the invention are prepared by any conventional method such as organic synthesis, recombinant techniques, or isolation from genomic DNA.

25

The nucleic acid probes of the invention are labeled in a conventional manner to signal hybridization to target nucleic acid from *Salmonella enterica* subspecies I. The labeling may comprise a radiolabel, an enzyme, a bacterial label, a fluorescent label, an antibody, an antigen, a latex particle, an electron dense compound, or a light scattering particle.

30

The probes may be provided in a lyophilized form, to be reconstituted in a buffer appropriate for hybridization, or the probes may already be present in

35

such a buffer. The buffer may contain a suitable hybridization enhancer, detergent, carrier DNA, and a compound to increase the specificity.

Any conventional hybridization assay technique, such as dot blot hybridization, Southern blotting, sandwich hybridization, displacement hybridization and the like, can be used.

The target analyte polynucleotide of a microorganism may be in various media, most often in a biological, or physiological specimen. In most cases it is preferred to subject the specimen containing the target polynucleotide to any conventional extraction, purification, and/or isolation before conducting the analysis.

The sample containing the target analyte nucleotide sequence must often be treated to convert the DNA to a single-stranded form, which may be accomplished by a variety of conventional techniques, such as thermal or chemical techniques.

The following examples describe the isolation and specificity of the sequences according to the invention.

EXAMPLE 1

Identification and characterization of the *saf* operon.

The present inventors found, upon investigation of a 7 kb chromosomal region on centisome 7 originally isolated from the *S. typhimurium* strain SR-11_k3181, a region that exhibits many of the traits that define a pathogenicity island. It has a lower G+C composition than the average composition of the *Salmonella* genome and includes many sequences related to different mobile genetic elements. The region is not present in *E.coli* K12, and the *Salmonella* specific DNA is inserted between the tRNA gene *aspV* and the stop codon of *yafV*, a hypothetical protein upstream of the *yafH* gene at 5 min in the *E.coli* chromosome. This *Salmonella* specific insert encodes proteins creating adhesive structures and other virulence factors. Sequencing revealed genes encoding a new fimbrial operon that they designated *Salmonella* Atypical Fimbriae (*saf*), due to its relatedness to a subgroup of adhesive structures forming thin atypical fimbriae or non-fimbrial adhesins.

The *saf* operon consists of four contiguous genes, *safA*, *safB*, *safC* and *safD* that encode fimbrial subunit, periplasmic chaperone, outer membrane usher protein and alternative fimbrial subunit, respectively. The genes *safA*, *B*, *C* and *safD* encode putative proteins of 166, 244, 836 and 156 amino acids, respectively. Analyzes of clinical *Salmonella* isolates showed that DNA of 195 out of 198 clinical isolates belonging to *S. enterica* subspecies I hybridized with *safB* and *safC*, i.e. these sequences are common to more than 99% of the known *Salmonella enterica* subspecies 1 bacteria. The inventors showed that 58% of these clinical isolates carry the *safA*, see Table 1.

Table 1. The prevalence of the *saf* genes in clinical *Salmonella* isolates.

Serovar	<i>safA</i>	<i>safB</i>	<i>safC</i>	# isolates
<i>S. adelaide</i>	-	+	+	1
<i>S. agona</i>	+	+	+	6
<i>S. anatum</i>	-	+	+	3
<i>S. bareilly</i>	+	+	+	3
<i>S. blockley</i>	+	+	+	3
<i>S. bovismorbificans</i>	-	+	+	5
<i>S. braenderup</i>	-	+	+	4
<i>S. brandenburg</i>	+	+	+	1
<i>S. bredeney</i>	+/-	+	+	15
<i>S. chester</i>	+	+	+	1
<i>S. colindale</i>	-	+	+	1
<i>S. derby</i>	-	+	+	1
<i>S. dublin</i>	-	+	+	1
<i>S. eastbourne</i>	+	+	+	2
<i>S. emek</i>	+	+	+	1
<i>S. enteritidis</i>	-	+	+	8
<i>S. give</i>	-	+	+	1
<i>S. goettingen</i>	+	+	+	1
<i>S. haardt</i>	-	+	+	1
<i>S. hadar</i>	+	+	+	16
<i>S. heidelberg</i>	-	+	+	1
<i>S. huttingfoss</i>	+	+	+	5
<i>S. infantis</i>	-/+	+	+	6
<i>S. java</i>	-	+	+	1
<i>S. javiana</i>	-	+	+	1
<i>S. kottbus</i>	-	+	+	1
<i>S. livingstone</i>	-	+	+	1
<i>S. london</i>	+	+	+	1
<i>S. maastricht</i>	+	+	+	2
<i>S. mbandaka</i>	-	-	-	3
<i>S. montevideo</i>	+	+	+	1
<i>S. muenster</i>	-	+	+	1
<i>S. newport</i>	+	+	+	2
<i>S. ohio</i>	+	+	+	1
<i>S. oranienburg</i>	+	+	+	2
<i>S. panama</i>	+	+	+	3
<i>S. potsdam</i>	+	+	+	1
<i>S. rissen</i>	-	-	-	1
<i>S. saarbrücken</i>	-	+	+	1
<i>S. saint paul</i>	+	+	+	3
<i>S. schwartzengrund</i>	-	+	+	1
<i>S. singapore</i>	+	+	+	1
<i>S. stanley</i>	+	+	+	5
<i>S. subsp I 4.5,12:-</i>	+	+	+	2
<i>S. subsp I 4.5,12:b:-</i>	-	+	+	1
<i>S. subsp I 4.5,12:i:-</i>	+	+	+	1
<i>S. subsp I spont</i>	-	+	+	1
<i>S. tennessee</i>	+	+	+	2
<i>S. thompson</i>	-	+	+	1
<i>S. typhi</i>	-	+	+	1
<i>S. typhimurium</i>	+	+	+	27
<i>S. virchow</i>	+	+	+	7
<i>S. weltevreden</i>	-	+	+	1
<i>S. worthington</i>	-	-	-	2
<i>S. subsp III</i>	-	-	-	1

The phylogenetic distribution of the identified genes on the cs7 insert was investigated using the well defined SARC collection, which showed that the presence of the *safA*, *safB*, *safC* and *safD* genes is restricted to *S. enterica* subspecies I (Fig. 3). This region is hence the first subspecies I specific genetic region to be identified with a broad distribution within the subspecies. Since the serovars of subspecies I constitute over 99% of human salmonellosis and are preferentially associated with warm blooded animals, it implicates a role for the *saf* adhesive organelle in the colonization of these organisms.

EXAMPLE 2

Identification and characterization of the *tcf* operon.

The present inventors found that *Salmonella enterica* subspecies I serovar Typhi contains DNA encoding an additional fimbrial operon, the *tcf* operon, in the *sinR-pagN* intergenic region. Southern blot analysis revealed a markedly different restriction pattern in *S. enterica* serovar Typhi than the other subspecies I isolates, suggesting that the *saf-sin* region in serovar Typhi might carry additional DNA relative to serovar Typhimurium strains. A PCR reaction (using a kit from Roche) was therefore performed using a *sinR* (5'-GTA AAT CGC TTA GTC GCC-3') specific forward primer and a *pagN* (5'-TCA ACT CAA CCT TCA GCC-3') specific reverse primer.

This primer pair produced, as expected, a product of 2 kb in serovar Typhimurium from the SARC collection, while from serovar Typhi the product was 10 kb. Thus, the neighboring *sinR* and *pagN* genes in serovar Typhimurium strains are separated by approximately 8 kb in serovar Typhi.

The Typhi specific PCR product was purified, digested partially with *EcoRI* and sub-cloned into pUC18 forming a set of overlapping clones. Sequencing of the clones revealed a putative fimbrial operon designated *tcf* for Typhi Colonizing Factor. Four ORFs, *tcfA,B,C,D*, have been identified with putative proteins having significant homology to CooB (38% identical over 192 aa), CooA (37% identical over 170 aa), CooC (34% identical over 872 aa) and CooD (31% identical over 272 aa), respectively. The Coo proteins are involved in the biosynthesis of the CS1 colonizing factor antigens of enterotoxigenic *E.coli* (Fig. 4) (Froehlich et al., 1994). The peptide of the *tcfB* ORF is also homologous to the CblA major fimbrial subunit protein (45% identical over 154 aa) of the cable

type II pili of the cystic fibrosis-associated *Burkholderia cepacia* (Sajjan et al., 1995). Down-stream of the *tcf*-operon two ORFs were identified with the same transcriptional orientation as the *tcf* genes. The first was designated *tinR* for Typhi insert regulator because it is homologous (33% identical over 144 aa) to
5 *AzlB* of *Bacillus subtilis*, a member of the Lrp/AsnC family of transcriptional regulators (Belitsky et al., 1997). *tinR* is followed by an ORF (*tioA* for Typhi insert orf) encoding a putative protein of 205 amino acids with no significant homologies to anything in the DDBJ/EMBL/GenBank databases. The above
10 sequence from *Salmonella enterica* serovar Typhi strain RKS 3333 and the *tcf* region of the incomplete genome sequence from serovar Typhi strain CT18 ([http:// www.sanger.ac.uk](http://www.sanger.ac.uk)) are 99% identical over the total length of the investigated region in concordance with the clonal nature of the serovar .

A 2 kb large internal *EcoR* I fragment was used as a probe in a Southern blot of
15 the SARC collection. This blot shows that *Salmonella enterica* subspecies I serovar Typhi (SARC2) is the only strain in the collection possessing DNA hybridizing to this fragment (Fig. 4).

References:

American Institute of Medicine. (1986) New vaccine development: establishing priorities. Washington, DC: National Academy Press.

5

Ashcroft, M. T., Ritchie, J. M., Nicholson, C. C. (1964) *Am. J. Hyg.* 79:196-206.

Levine, M. M., Taylor, D. N., Ferreccio, C. (1989) *Pediat. Infect. Dis. J.*, 8:374.

- 10 Popoff, M. Y. & Le Minor, L. (1992) *Antigenic formulas of the Salmonella serovars* (WHO Collaborating Center for Reference and Research on *Salmonella*, Institute Pasteur, Paris).

- 15 Reeves, M. W., Evins, G. M., Heiba, A. A., Plikaytis, B. D. & Farmer III, J. J. (1989) *J. Clin. Microbiol.* **27**, 313-320.

Rowe, B., Ward, L.R., and Threlfall, E.J. (1997) *Clinical Infectious Disease* 24:(Suppl 1) S106-9

- 20 Salyers, A. A. & Whitt, D. D. (1994) *Bacterial Pathogenesis: A molecular approach*. (ASM Press, Washington D.C.).

Yugoslav Typhoid Comission. (1964) *Bull. WHO* 30:623-30.

Claims:

- Sub B4
1. Peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2) for use in medicine.
 2. Antibodies directed against a peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2) for use in medicine.
 3. Nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2) for use in medicine.
 4. A vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I, comprising a peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1), or antibodies directed against said peptide and, optionally, a pharmaceutically acceptable carrier.
 5. A vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising a peptide encoded by a nucleotide sequence selected from Sequence Listing No. 2 (SEQ ID NO 2), or antibodies directed against said peptide and, optionally, a pharmaceutically acceptable carrier.
 6. A nucleic acid vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I, comprising a nucleic acid sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and, optionally, a pharmaceutically acceptable carrier.
 7. A nucleic acid vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising a nucleic acid sequence selected from Sequence Listing No. 2 (SEQ ID NO 2) and, optionally, a pharmaceutically acceptable carrier.
 8. A vector vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I, comprising a host in which a recombinant vector comprising a nucleic acid sequence selected from Sequence Listing No. 1 (SEQ ID NO 1), has been inserted and, optionally, a pharmaceutically acceptable carrier.

14-09-2001

16

Sub B4
APT 34 AMDT
5 9. A vector vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising a host in which a recombinant vector comprising a nucleic acid sequence selected from Sequence Listing No. 2 (SEQ ID NO 2), has been inserted and, optionally, a pharmaceutically acceptable carrier.

Sub A1
10 10. A method for protection against diseases caused by *Salmonella enterica* subspecies I, comprising administering a vaccine according to any of claims 4, 6, and 8.

10 11. A method for protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising administering a vaccine according to any of claims 5, 7, and 9.

Sub B5
15 12. Antibodies directed against a peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2), for use in a diagnostic method.

20 13. Peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2), for use in a diagnostic method.

25 14. Primers for, or probes that hybridize with, a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2), for use in a diagnostic method for the purpose of detecting *Salmonella enterica* subspecies I.

Claims:

1. Peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2) for use in medicine.
5
2. Antibodies directed against a peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2) for use in medicine.
- 10 3. Nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2) for use in medicine.
4. A vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I, comprising a peptide encoded by a nucleotide sequence selected from
15 Sequence Listing No. 1 (SEQ ID NO 1), or antibodies directed against said peptide and, optionally, a pharmaceutically acceptable carrier.
5. A vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising a peptide encoded by a nucleotide sequence
20 selected from Sequence Listing No. 2 (SEQ ID NO 2), or antibodies directed against said peptide and, optionally, a pharmaceutically acceptable carrier.
6. A nucleic acid vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I, comprising a nucleic acid sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and, optionally, a pharmaceutically acceptable
25 carrier.
7. A nucleic acid vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising a nucleic acid sequence selected from Sequence Listing No. 2 (SEQ ID NO 2) and, optionally, a pharmaceutically acceptable carrier.
30
8. A vector vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I, comprising a host in which a recombinant vector comprising a
35 nucleic acid sequence selected from Sequence Listing No. 1 (SEQ ID NO 1), has been inserted and, optionally, a pharmaceutically acceptable carrier.

9. A vector vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising a host in which a recombinant vector comprising a nucleic acid sequence selected from Sequence Listing No. 2 (SEQ ID NO 2), has been inserted and, optionally, a pharmaceutically acceptable carrier.

10. A method for protection against diseases caused by *Salmonella enterica* subspecies I, comprising administering a vaccine according to any of claims 4, 6, and 8.

11. A method for protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising administering a vaccine according to any of claims 5, 7, and 9.


12. Antibodies directed against a peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2), for use in a diagnostic method.

13. Peptide encoded by a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2), for use in a diagnostic method.

14. Primers for, or probes that hybridize with, a nucleotide sequence selected from Sequence Listing No. 1 (SEQ ID NO 1) and Sequence Listing No. 2 (SEQ ID NO 2), for use in a diagnostic method.


1/4

Fig. 1



2/4

Fig. 2



3/4

A
Fig. 3
E. coli

Subspecies	I	II	IIIa	IIIb	IV	bongori	VI	VII								
SARC #.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16

23.1 —
9.4 —
6.6 —
4.4 —





Fig. 4



of respective phage insert is represented by horizontal bars. Name and size of the phage inserts are indicated on the left side of the figure.

Figure 2.

Schematic representation of the pTY52 cosmid comprising the *tcf*-operon (SEQ ID NO 2).

A *tcf* specific PCR fragment of 11105 bp was cloned into the Expand vector I cosmid (Roche). The insert is represented with a thick black line while vector sequences are represented with thin lines. Relevant restriction sites sequences are indicated. The position of the *tcf*-operon, i.e. *tcfA*, *B*, *C* and *D* (SEQ ID NO 2), is represented by a shaded arrow.

Figure 3.

The phylogenetic distribution of the identified genes on the *cs7* insert was investigated using the well defined SARC collection, see Example 1.

Figure 4.

A 2 kb large internal *EcoR* I fragment was used as a probe in a Southern blot of the SARC collection, see Example 2.

Sequence listing

SEQ ID NO 1—DNA sequence of the genes encoding the precursor of the *saf* fimbriae unit of *Salmonella enterica* subspecies I.

SEQ ID NO 2—DNA sequence of the genes which encode the precursor of the *tcf* fimbriae unit of *Salmonella enterica* subspecies I serovar Typhi.

Deposit information

The phages carrying the inserted SEQ ID NO 1, i.e. phages clones B1, D1, F11 and N10 (see Figure 1) have been given the ECACC Accession numbers 99051922, 99051923, 99051924, and 99051925, respectively.

The cosmids carrying the inserted SEQ ID NO 2, i.e. cosmids pTY52 (see Figure 2) has been given the ECACC Accession number 99051926.

The depositions were made May 19, 1999.

Detailed description of the invention

The present invention is based on the finding that two fimbrial operons, the *saf* operon and the *tcf* operon, are specific for *Salmonella enterica* subspecies I bacteria. Due to their specificity they can be used to provide vaccines against *Salmonella enterica* subspecies I as well as detection methods for *Salmonella enterica* subspecies I. The *saf* operon is specific for all *Salmonella enterica*

Claims:

1. Protein encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO 1 and SEQ ID NO 2, or parts thereof, for use in
5 medicine.
2. Antibodies directed against the protein encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO 1 and SEQ ID NO 2, or antigenic fragments thereof for use in medicine.
10
3. Nucleotide sequence selected from the group consisting of SEQ ID NO 1 and SEQ ID NO 2, or parts thereof, for use in medicine.
4. A vaccine for the protection against diseases caused by *Salmonella enterica*
15 subspecies I, comprising the protein, or parts thereof, encoded by the nucleotide sequence according to SEQ ID NO 1 or antibodies directed against the protein encoded by SEQ ID NO 1, or antigenic fragments thereof and, optionally, a pharmaceutically acceptable carrier.
- 20 5. A vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising the protein, or parts thereof, encoded by the nucleotide sequence according to SEQ ID NO 2 or antibodies directed against the protein encoded by SEQ ID NO 2, or antigenic fragments thereof and, optionally, a pharmaceutically acceptable carrier.
25
6. A nucleic acid vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I, comprising SEQ ID NO 1, or parts thereof and, optionally, a pharmaceutically acceptable carrier.
- 30 7. A nucleic acid vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising SEQ ID NO 2, or parts thereof and, optionally, a pharmaceutically acceptable carrier.
8. A vector vaccine for the protection against diseases caused by *Salmonella*
35 *enterica* subspecies I, comprising a host in which a recombinant vector comprising SEQ ID NO 1, or parts thereof, has been inserted and, optionally, a pharmaceutically acceptable carrier.

9. A vector vaccine for the protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising a host in which a recombinant vector comprising SEQ ID NO 2, or parts thereof, has been inserted and,
5 optionally, a pharmaceutically acceptable carrier.
10. A method for protection against diseases caused by *Salmonella enterica* subspecies I, comprising administering a vaccine according to any of claims 4, 6, and 8.
10
11. A method for protection against diseases caused by *Salmonella enterica* subspecies I serovar Typhi, comprising administering a vaccine according to any of claims 5, 7, and 9.
12. Antibodies directed against the protein encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO 1 and SEQ ID NO 2, or antigenic fragments thereof, for use in a diagnostic method.
15
13. Protein encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO 1 and SEQ ID NO 2, or parts thereof, for use in a diagnostic method.
20
14. Primers for or, probes that hybridize with a nucleotide sequence selected from the group consisting of SEQ ID NO 1 and SEQ ID NO 2, for use in a
25 diagnostic method.

SEQUENCE LISTING NO. 1

<110> Folkesson, Anders

<120> The complete sequence of the cs7 insert in Salmonella enteric serovar Typhimurium

<130> Complete sequence of the cs7 insert

<140>

<141>

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 46870

<212> DNA

<213> Salmonella typhimurium

<220>

<221> CDS

<222> (37368)..(37868)

<223> safA putative fimbrial subunit

<220>

<221> CDS

<222> (37952)..(38689)

<223> safB putative periplasmic chaperone

<220>

<221> CDS

<222> (38713)..(41223)

<223> safC putative outer membrane usher

<220>

<221> CDS

<222> (41245)..(41715)

<223> safD putative fimbrial subunit

<400> 1

gatacaaatc tcagggtggt tttatacatc ctgtgaagta aaaaaaaccc tatcactgta 60
aaagggatac ggtttttttt cgtcttcaag aagttccacc gtctatcgtg gaatctggcg 120
caaatgggcc tacgcctgga tgacgaacag gatattaccg ccacttcttt cactgtcatg 180
gctattttga tcccactgac atttaaggcg cggcctcatg gcggtgctta accgggatcg 240
ggacatgttc agcgcagaag cagactgcgt aatgttgata tcactcagat aattacggag 300
aaccgccaga catgcgcac atcactccag ggcattccac ttctccagca actccaccgg 360
gatctcattg atcacctccg agaaccgttt tcccaccagt ctttcagcct ggcgtaacag 420
tgggatggtc gggctactgg gttcactgct ctcaaaccag cgacgaatgc accgcaggcg 480
ttccagcgca tcattacgat cgcgaattgg ccccggttca gcattgtgtg ggagggatat 540
accgggtggc gcgttgacag gcggcacatc ctctgcccgt gccggaacgg cattatccat 600

aaccgtgccc gcgggggtctg gcactggcgc tggcgacgga gggatttccg gtgtggttgt 660
ctgtaccacg tcaggcagca gcgctaacaa ctgccgcagg cgtgaaaaat ctggagccag 720
atcgccaat gtctcacgcg cccacacttg caggcgctct gcgctttcct gcgcttcgcg 780
aaacgccgcc agcggtaatg cccacggggc ttcgaggtcg gccagttgct ggcggacgga 840
ttcggggggcc agcgcacag ccggggcgggg agcggataac gcgcgctcca catcccgtac 900
ctgtaggcgc agggcggcac tgtttgacag cgtaataccg cgaatgtccg ccatacgcgc 960
ttcgtgatcc agcagcgccg ccagggcatt actgcgcgc agcgacgcat cttcaataga 1020
ttctgcggat gcgccttcgc cggtaagcag ctgtggatgg agtgcacag accagattac 1080
gtcagttct gccagttgtg tgagcatttc cgccagtccc tgtgcgccag cctgctggat 1140
gcgactgcgc agcagcagga tcaacacccg gatatcctta ctgcgcgtga gcagacggcg 1200
cgcatcacgt tcaatttccg gccagttcac ggcttccggc gtactgacaa aatcaccata 1260
ttgcgcctcc gcctgggggg cggcgcggt gaacagcagc aggtattccg gatcgactc 1320
cggatcgggg ccgcagggtt gttccgcgct taccggttta gtcagggaca tgtccatata 1380
attactctca gtgggttaag ccgtgttcag gttcaaaaat catgccggtc accggacggc 1440
catgcatggc ttacctgcc caggccgtcc agccaagccg ctgcgcgccg ccgataccg 1500
caggcggtgc ggcagagggc ttcaactgca gctcaatttc ccagcaatat tcaaaaccga 1560
tgaacgtacg caccagttct gtcagcacgg gcagattgtt gccgccgggc agaaaacgca 1620
ggtaatcctc cagcgtgagc gggccgataa ttagccggaa tttgtactgc atatccggta 1680
cggcctggcc gataagcgcc ccgttgccca gcaccgaaga ctgcgcgggc gtgcccagac 1740
gggtgatttc atcgttcgcc accgttatcc agtgcagggc gaattctttc accgcaaaag 1800
gtacgctgaa atagtgcgc agcgtggcgg ccagcccgtc aggattgcgc gattcgcgta 1860
ccagatgggc ggaggctgcc aggcgaacat gatctgacag cgggctttcg gcgctttccc 1920
gtagatcctg cccgctgaga ctggcgatat aaaacgcaaa acggtcgtgt tccggtttgt 1980
ccagcccgc accagcggac tgggcgctgc gccatgcctg ccagaactgc gtcagccagc 2040
ggtaggtgaaa aatattggaa aaatgaacca gcgtcggatc gtgacgactc tctgagcggc 2100
tcagtgccag ctcggtatag tgcagcggca acgggccgtt tggcccccat agtccgaggc 2160
tgtacaggct cagggtcagg cgtccatcct gccagctgac ctgggcgatt tcccgtggcg 2220
caaaggctcat cgtcggcgtc tgtcccagac ggaatttttc catccgtggc ttgccagata 2280
cttgcctgcc ggagtatcac agagctgggc atccacgcgc cgcatacagg tcaggaatcc 2340
gtaacgccag ggggttttct gcgcctgggt gagagcgccg gtcatacgtt ccccgttgc 2400

ccggttctga ccggccaggt catgacatgc ccgcgttgca tcgagtgcag cgtcatctgc 2460
gagaaggtat taatggaaac atggcgggca atatagtgtt ccagcaccag accgaacagg 2520
taaggactga taccggaaaa tccttcttcg tccacgggtca gttcgcaact gacgccccgg 2580
ccatagacca acaggccgga gccgggcagg cggcgggtca ccgggggtgtt tttgcagcca 2640
atcaggctgc gcacctggcg cgactgcggg ctgtcgtgag ccgggataaa cagattcagc 2700
agatcgcgca gcgcctggcc gccggtgcgg tgatccagat cggccagcgg cagataatta 2760
aacgacaact gccggatcag ccgccaggcc atttcgcggt cagccagcgg cggctgcggc 2820
gggcgcggcg gtctgataag acccacgccc gccaccggaa tcgccgcac tacggtcaga 2880
tcatcccggc cattacgtgg aataaggcag ggcagatcgc ggtagtcac cattgccgtg 2940
acggtgatat ggcgagatt ttccgggtag ggcgcttcat gctgatcaac cagcgagagg 3000
aagacttccg agccggtata ggggggttcgg gtgccatagc ggccggcggt ttctgacgag 3060
cggcgcggtt cagcagcag tgaaaaataa cggccggtgt tgcccttcgtc attattacgg 3120
gtgtgatata gcggacgaaa aatcatcttc cgtgtgggtt ccgcttcag gccttcgact 3180
tcctgaacag aaaacacctc gtaatccagc ggacgggtac gatccaccac cagatgctgt 3240
tccgtcacgc tgtgagtgc ttcaatccgg gtggtgggtg gaggaagcag gttgatcacc 3300
ggcgtacaga acaggctgaa ctgtgcagcg tccgtctgat gaatcagcca gtccggcggc 3360
aggcgggttaa gcagtatgac aatttccgcc acattgccct gcaccttttg taaccggca 3420
gacaatccgg tcggggtgaa gaagtaaaac cgttccggac aggcgaaaaa ttcatgcagc 3480
agattatggc cgtgaaacac gttccaggcg agcggtagca gccctgccc tggctccagc 3540
ccttcgtgcg ccaccgggtg ttgaagattc acattcagtt cggcgtcaaa gtgaccgggt 3600
tcaccggcca gtgtggcgac ggcgctggta tgtagcagct caaacagggtg tgacgcaatg 3660
cgttcttcgc cgcagaggta aaagggcagc cgtgccggac cggccagctc gctgaaagtc 3720
agttccccga aggttcgcag ggtgatgcgc aatgccccgg cgacatgaat attaggcggc 3780
agatagcggg gcagggcggg catatccggc ggcgcgggcg tcaggcgtag ctctcgtatg 3840
gacagcggcc acagcgtgac gtcctggctg ctgcgaaact ggcaggcggg attttcgcct 3900
tccgggatgg gggaaacgaa cgcggtatcg cgcggcacgg tgaccccttt cggcaggctc 3960
ccttctcgtg tatcgggata cagctttacc actgccatcg atggcgtggg ggtgacgtaa 4020
ttggggctga cgacttccag taaccgctgt gtgaagcggg gaaactcggc gtcaattttt 4080
agctgagtgc gggcgctcag aaagctgaac gcctcgatca tgcgttccac atacgggtcg 4140
gcaatatcgg ttccctgcat cccagtcgg gcggcaattt tgggatggag ggtggcgaac 4200
tcagcaccgg tctcccgag gtagctcagt tcgcgggtgt aatactccag tagccgtgga 4260

tccatgaata atgccctgta ttaaaagaac gtaatgcggc tcagctccat atccagcgcg 4320
ctgcgtacca gaaactccgt gggatacggc tgcgtcagaa tttgtccgcg aatttcaaac 4380
tgtagcgtgt tatagetacc ctgccgggtt ttatcgagca agggcgtgac cctgagtgtg 4440
gcggcggttca gccgggggttc gaaacggata atggcgcgcc ggatcgccctc gctgatatcg 4500
tcccacttat gctcatacat aaagctgccc gccagcgggc gcaggccata gttgagcact 4560
gacgcgcgcg cctgcggata gcgccggggc tcgatgtcac cctcgtggct aatgggtattg 4620
agcaaaaagg agagatcccc gcgaatgac tccttcagtt gtaccggcgt gacgctgata 4680
tcccgggtcaa ttttctgata cggagcattg tcacacagcc gatcaaacag cgtgggcagc 4740
aggtgggttag cgggtgtaaa acgagacgtg ctcatgcgcc atcgttttcc tgagcatgaa 4800
aggtacaatg ggccatgtcc agcaggctga tategccgtg gctggtcagc cacactttct 4860
gccccagcgc ccgcacgggtg gtttcgccgg ggccgtcctg ccaggcgggt tccctgcaca 4920
gacgcagggc gtcggatgca ctttccgaac cgctgtaacg ggtaaagagc caggcgccgt 4980
gcgtatcgcc attcaccagg gtgatattaa cgggtttcca cagcagatca gtcaggcgcg 5040
tcggttgcgg cgattccagc gagcgtattt gcgaaaacgg cagccagata tacacgccgc 5100
cggtgactag ctcaagtacc gggccaaggc gggaatcgct gtcgctcgcc cagtcaaattg 5160
cgccgcggtt ccactgcccc cccgtgtctg ttatggcttc cagtgcggta ttacgggtgt 5220
tatcaacctc accggtatcg tcatgacagg cgagtgcgc cagcagtgac tccacccaaa 5280
cgggctgcgg cagaagaaaa ccgggtcgtt gttcaccttg aaaaacgggtg tggcggaaca 5340
tttcgcagcg aaccagctcc cggtacagcc gggcctcctg ggtataattg gcctccatcc 5400
tggcgcatag ctgaagctgg tgtagcgccc gcgaccagtc tccggccaca cacagcaact 5460
gaaacaggct gtggcggcag agcgctttcg ccggattttc ccgaacctgc tgctccgcca 5520
tctgaatccc ctccgcaata gagtatctct gtatcagcgc ggacagggtg gcaggaagcg 5580
tgtcagtttt tttcatgggc ggtatttcca ttttctgtg tcggagtgat tcggtagtgg 5640
ctatcgatgc caataatacg atgctcgcg cgggtcagat cgggcagtat ctcgctatgt 5700
gcggttttcc cccccagttc cggcgagagc agttgcagga tatcgggcat tgattccatc 5760
gccagccagt gcatttcacc ctcaccggtc gtgtccagcg tatccagaat ggcatcaata 5820
ccgggcgcgc ctgccaccat atcctgtaac gtgtcgggtg cggccttttt atcgtataac 5880
gacgtcaaat cctgggtgac agcgtcttca tttcggggaa acggttttagc acggaggggc 5940
ttttcctgcc cggaggggccc caatgcctgc tgatattcct ggtaaagctg gtgtagtgtg 6000
ctatccgctt catggccagt gtaagaggat gcggtttccc ggacgggaat aatatcgaac 6060

gggttctgcg	gattgagctg	ttgttgttta	aaccagtcca	gatccaggta	ctcagcaacg	6120
gattcagatg	actgaaccaa	ctgaggaaac	gaaacatcgg	gacgggactc	atcattgggtg	6180
cgggcaaggc	accaggatga	cagaccccat	tcaatcgat	ctccatcatt	cagccgcata	6240
cggtgatgag	gttccatcac	ctgctcattg	acggcacagc	acagttcacc	agagtgatta	6300
acaatccacc	acgcctcttc	gtggcgaaca	agactgagcg	cgatatcgtc	tttcccatgt	6360
tgctcaaaaa	gcggaatgta	gggggcggcg	gcagtaaata	cgatgtatgt	ccctgcggga	6420
tactgtgcgt	tatccgttat	accctgcgac	tgtattttcc	gtaattccca	catgtcttgt	6480
ttcattatgt	cccttaaagt	tatttatatt	tctggaggaa	acgtttaggg	agttttaatt	6540
cataaataat	tttaactaaa	tttataggga	gtcattattg	atgacaccct	ttttattatt	6600
ttcgtcgtga	atgcattggt	gtatgcatag	atgtcttttt	tgaaatatta	tttcttttaa	6660
ttctgcaatt	gcgattttta	tcttgctggt	cattgattat	ttaatatata	cggcttaggt	6720
gctaattagt	ccctgatctg	tatcattggt	ttgtttcgat	attttttcga	ggctatcaat	6780
aaagaattgt	ttatatattt	atatgcattg	atgcattatt	tttatgaatt	tttatgtcac	6840
aaggcataac	acatggaaac	tcctgtttca	cgcagtgcgt	tgtatggaaa	actggccggc	6900
ccactattcc	ggtcgctgga	atcggcaacg	gcattttgca	aactacgctc	taatccctgg	6960
gttgagctga	ctcactgggt	gcaccagtta	acacagcagc	ccgataacga	tattctccac	7020
gttcttcggc	attaccagat	ccctctttct	gatgtggaga	aagcgttact	ccggcaactg	7080
gatatgctgc	ccgccggggc	cagcgccatt	agtgattttt	ctcaccatat	cgatctcagc	7140
gttgaaaagg	cctggatgct	ggcgagcgtc	cgttacggcg	ataacaaaat	tcgcagcggc	7200
tggttgctgc	tggccttggt	gaccacgcca	gaactgcgtc	gggtactgag	cagtatctgc	7260
gcgccgctgg	ccacgcttcc	ggttgatgaa	ctgacggaaa	tactgccctc	gttgatcgaa	7320
acatcgccgg	aagcgcagga	gcgcccttac	gacgggtccg	gcctggcacc	agccattccc	7380
ggtgaaagca	gtcaggcgat	tcccaacggc	gggcaggacg	gtaaatccgc	gctggcaaaa	7440
tactgtcagg	acatgacggc	acaggcgcg	gacggcaaaa	tcgacccggg	gacggggcgt	7500
gagcatgaaa	tccgcaccat	gacggatatt	ctgctgcgcc	gtcgccagaa	taatccacta	7560
ctgactgggt	aggcggggcgt	cgggaaaacg	gcggtcgctg	aagggttttg	cctcgcgatt	7620
gcgcaggggg	aagtgcgcgc	cgcgctgcgg	gaagtacggc	tactggcgct	ggacgttggc	7680
gctctgttgg	ccggagccag	catgaaaggc	gagtttgaat	cgcgtctgaa	agggttactg	7740
gaagaggccg	ggcgctcgcc	gcagccgggt	attctgtttg	ttgatgaagt	tcacactctg	7800
gtgggcgcgg	gcggcgcatc	cggcacgggc	gatgcgcgta	acctgctgaa	accggcgctg	7860
gcgcgcggca	ccctgcggac	tatcggcgcc	accacctgga	gcgaatacaa	gcgccatatt	7920

gagaaagatc cggcgctgac ccgctcgtttt caggtggtgc agattgccga accggaagag 7980
atccccgcaa tggaaatggc gcgtgggtctg gtggatacgc tggaaaaaca ccataacgta 8040
ctgattctgg atgaggcggt acgtgcggcg gtacagcttt ctcaccgcta cattccccgcc 8100
cggcagttgc cggataaggg catcagcctg ctggataccg ccgcggccccg cgtggcgctg 8160
acgctgcaca cgccgcctgc cagcgtacag ttcctgcgcc agcagctaaa agcggcgga 8220
atggaacggc cgctggtgca gaagcaggaa aaaatgggga ttcagtcaga tgagcggcg 8280
gatgcgctga tggcgcgaaat tttctcgctc aacaatgaac tgactgcac cgaatccccg 8340
tggcagcggg agctggaact ggtacatacg ttgcaggaa tgcgtctcg agagtctgat 8400
gctgatgaca aaaccacgct gcaacaggcc gaaacggcg taaggagtg gcaggcgac 8460
gcgccggtgg tgttccccga agtcagcgcg gcggttgctg cggcgattgt cgccgactgg 8520
accggtattc ctgctggggc catggtgaaa gatgaggcca gccagggtgt ggaactgcct 8580
gcccgactgg cgcaacgcgt taccgggcaa gacggcgcg tggcgagat tggtgaaact 8640
attcagaccg ccaggcgggg actgggagat ccacgcaaac cggtgggcg gtttatgctg 8700
gccgggcccgt ccggtgtcgg taaaaccgaa accgcgctgg cgctggcgga ggctatctac 8760
ggcgcgagc agaacctgg aaccatcaat atgagcgagt tccaggaggc tcacaccgtt 8820
tccacgctga aaggcgcgcc gcccggtat gtgggctatg gcgagggtgg tgtgctgacg 8880
gaagcgggtg gtcgccacc ctggagcgta gtgctgctcg acgagatcga aaaagcgcac 8940
catgacgtcc acgaactctt ctatcagggtg ttgacaagg gtgggatgga ggacggcgag 9000
ggtacacatg tcgatttcaa aaacaccacg ctattactca ccaccaacgt gggttccgac 9060
ctcatcagcc agatgtgtga agatccggcc ttaatgccc atgctacggg gcttaaagag 9120
gcgctaatac cggaattgag caagcatttc ccggcggcgt ttctggggcg cgtgacgggtg 9180
atcccttacc tgccgctgga cgaaacgtcg cgtggcggtg ttgcccgtct gcaccttgac 9240
cggctgggtg cgcggatgag tgaacagcac ggcgtgacgc tgacgtatag cgaggaaactg 9300
gtcgcacata ttgtggcggt ctgtccaatg catgaaacgg gcgcgcgggt gctgattggc 9360
tacatcgaac agcacattct gccacgactg tcgcgctact ggttgaggc catgacggaa 9420
aaagccgcga tcaggcagat tgatatcggc gttaatgggt atgagcagat tgtttttgag 9480
atcgtttgct gaaaccggcc gttcgaagtg tccgtagtgc gattttaaaa actgtaccgg 9540
tataccgctc cccttgcgcc aaccagttga ctaaaaagga aatgaaggat tatggctatc 9600
aacaatagcg cgagaaatt catcgcgcg aaccgcgcgc gcgcgctgca gattgaatat 9660
gacgtagaga ttacgggttc cgagaaaaaa atcgagctgc cgttcgtgat ggcgggtgctg 9720

gcgcatctgg ccgggaaacc gcgtgaagaa ctgccgccgg tgacggatcg caaatctctc 9780
gatattgata ttgataactt caatgagcgc atgaaagcca ttgccgccgg cgtggcgctc 9840
gctgtgccga atacgctgac ggggtgaaggc cagttgatgg tcgatatcac gctggaaaat 9900
atggacgact tttcgccggc acagattgcc cgcaagggtgg acgccctgaa ccagttactg 9960
gaagcccgcga ctcaactggc gaacctccag acctacatgg atggcaaggc gggggcggaa 10020
aatctgggtca ataaactggt gcaggacccg actctgctga aaacgctggc gaatgcgccg 10080
aaatcggccg ctaccagca agatgtgtca gcggataatg aatcagcggga ataacgtcga 10140
atTTTTaagg aatTTTcatg gcaaacagta atatgcaggc aaccgacgcg gttgctcagg 10200
ataccgctc cgcattccggg gaatttgatg cgttgctgaa tcaggccttc cgaccaaga 10260
ctaccaggc ggcaaaagcc gtggaagccg cgggtgcagac gctggcgaac acgatcaccg 10320
tcagcgatga cgctataaa agcatcagcg ctattattgc gcagatcgac tTaaactga 10380
ccgaacagat caaactgatc ctgcaacatc ccgactggca gaagctggaa tcttcgtggc 10440
gcggtatgga gcatctggtt tacaacaccg agaccgacga aaagctgaaa attcgcttca 10500
tgaatctgtc aaaagatgaa ttgccggcgca acatgaagcg ttacaagggc atcgctggg 10560
atcaaagccc gatgttcaag aaactgtatg aagccgaata cggccagtta ggtggcgaac 10620
cttatggctg tatcattgcg gattactact tcgaccatac accgcccgat gtggatctgc 10680
ttggctctat cgccaaagtc gccgcgtcgg cccatgcgcc gtttattgcc ggggcttccc 10740
cctcgggtact gcaaattggac tcttggcagg aactggcgaa tccccgcgac ctgacaaaaa 10800
tcgtcaccga gaacctggaa tatgcgccgt ggaactcgct gcgggctagc gaagactccc 10860
gttatattgg cctgacgatg ccgcgttttc ttgcccgctt gccgtatggc gcaaaaacca 10920
accggtgga cgagtttgat tttgaagaag atgcggatgg ttctgaccat accaaatacg 10980
tctggagcaa cgcggcctac gcgatgggcg taaacatcaa ccgttccttc aaacactacg 11040
gctgggtgtac gttgattcgc ggtgtggaat caggcggtgc ggtggaaaat cttccctgcc 11100
ataccttccc gactgacgat ggcggcgtgg acatgaaatg cccgaccgaa atcgccatct 11160
ctgaccgccg cgaggctgaa ctggcgaaaa acggttttat ccggttgatc caccgtaaaa 11220
actcagacta tgccgccttt atcggcgcac agtcgctgca aaaaccacag gaatactacg 11280
atccggacgc gacggccaac gctaacctgt ctgcccgctt accgtacctg ttcgcctgct 11340
cgcgcttcgc tcacttcctc aaatgtatcg tccgcgacaa aatcggttcc tTaaagagc 11400
gtgaggatat gcagcgctgg ctaaatgaat ggattatgaa ttatgtcgac gccgatccgg 11460
tgaactcctc gcaagaaact aaagcccgtc gtccgctggc tgccgctgaa gtagtggtgg 11520
aagaggtcga aggcaatcca ggttattacg acgcgaaatt cttcctgcgt ccgcatttcc 11580

agcttgaagg gctgacggga tcgctgcgcc tggcgacaaa actgccgtca gtgaagcagg 11640
gcaatgcctg atatatatatt tgtgaatggt taagcgagt aagtcagaga agatagagaa 11700
tataaagagg gatatgaaga aaagaatttc gtctcgccca cggctctcgt aagggtggggt 11760
acgtaatgat gacacatatc cgaatgccag taacaatgcc gaagcttttt atatcattga 11820
gtaggaaata catattatga ccataagccc aacttttcat ctgttacctg gtattgttct 11880
gctcttttca caatatgctg tagcctggga agtcagttgc ccggctgta ttgatactca 11940
gtcttctgct gtgagcctga agtctgatgt cccagcggcg tggcagcttt cttcccgata 12000
tatgtcgcgt ttatggttaa gtagtattgg ggtaacgcag ggtaaacctg aaaacctgat 12060
ggatctcaaa ccagagacta aaaaagtaaa cggcgaaaat tggctctgtat gggaaacaga 12120
acgtggtagc gataaagaaa ccgacgccta ttgggttttcg tgtatttatg gtcataaaca 12180
gatatgggtg acgcaaccaa tacctgcttc ttctactcgc tgtaagactc gtaattttga 12240
gggacgcga gaagaccagt ctgtatcttt tatctgtaat tagcgatttg agacgtgaaa 12300
atttcagtac aggttatggt ttttattatc ggaagttatg aagcattatt tatatgcatt 12360
aaataatgca aattcataaa ataactaaat acattatcgg taccggaaaa atatacagtc 12420
ctctgttctc ctgaagttat tggagaagga ttctgtacgg caatgattta tctataaaca 12480
aaaagatata gataaaatca ggtttatttt aagtaaaaact taataaggat ataaaaatgg 12540
cttatgacat ttttttgaaa attgacggca ttgatggcga gtcaatggat gacaaacaca 12600
aaaatgaaat tgaagtactg agctggcgct ggaatattca tcaggaatcc accatgcacg 12660
ccggtagcgg cctcggctcc ggtaagggtc ccgtcaccaa cctggatttt gatcactata 12720
tcgaccgcgc cagcccgaac ctgttcaaact actgcgcctc cggcaagcac attccgcagg 12780
ccattctggt tatgcgtaag gctggcggca atccgctgga gtacctcaag tataccttca 12840
ccgacctgat tgcgcgctg gtttccccga gcggcagcca cgatggtgaa atcgctccc 12900
gtgaaacggt ggagctctcc ttcagcaccg tgaagcagga atacgtgggt cagaaccagc 12960
agggcggcag cggcggcacc atcaccgcag gctacgactt caaggccaac aaagaaattt 13020
aacggctggt tttccggcca gatgttatgt ctggctgggt ttattgtttt gattttaaag 13080
gaatttacag tgaataaatg gcgtaacccc actgggtgggt tatgtgcggt agctatgcct 13140
tttgactgc tctgctttc cggatgcggc agtagcgatt cgctacttga cccctaateg 13200
cagcggcctg gcctgagcgt gaaagcggtt tacaagggtga attctgacaa tcagaagaaa 13260
gcggcgctca tgaagatacg tggtgagaat taatgacctt cacagaattt ttagagggtta 13320
agcaaaatga acagaccttc attcaatgaa gcgtgggttag cttttaggaa ggtgaatcat 13380

tccgtcgtg atgtgggtag cattattggt ggaaacgttg ggaaaaatat aactggtggt 13440
tattttcaaa atgcctgccc tattcgaatg agctatgttt tgaatgcgac agggttccca 13500
atagcccgtg actctccgtg tgcaaagggt agtgggtgccg ataataaatt ctatatattat 13560
cgcgatgaatg atatgattga ttatcttact catactatgg gcaagcctga tcttattgtt 13620
aataatccga aacagagtga ctttatcggg aagaaaggaa ttatcgtagt aaaagggcat 13680
ggctggagca atgccagagg acacggtaca ttatggaatg gcagtatctg ttcagatcag 13740
tgccacttat taaatgaccc agataatgga ccatttggtc ctgaagttgg gacactgtgg 13800
atactgccgt gaaatgggtta atattagttta ctttcagcat aagtggaaatg ctggtatggc 13860
agccatcctt tgcacaagaa gcattgacca cacaatattc acagtcggaa ctcttaaaaa 13920
attgggcgtt gagtcattgt ctggcattag tatacaaaga tgatgtcgtt aaaaacgatg 13980
ccagagctac ggccagtgtt taccttgaat atggtaaaca atctgtggag atttaccatg 14040
aaattgatga gattgcgaaa aaatattcag ggttgaaata taacggttctg atatcatcag 14100
attttaatac catgaagtgc atagatttta tccatgacag ggaattaaat gaattaatta 14160
aaaggcgtgt cgagaagtaa aattcaaaga tattaaaagc atacgttctc ttgctctgat 14220
gaatttatgg gtaagaaaga gctgtacagg aatagttaat ctgttcacct aataaagcag 14280
ataaatcagg gcttaattta ggtagttaaa aggatagtag atatgtctta tgacattttt 14340
ctgaaaattg acggcattga cggcgagtca atggatgaca aacacaaaaa tgaaattgaa 14400
gtactgagct ggcgctggaa tattcatcag gaatccacca tgcacgccgg tagcggctct 14460
ggttccggta aggtctccgt cactaatctt tcatttgaac attacatcga tcgcgccagc 14520
ccgaacctgt tcaaatactg ctcttccggc aagcacattc cgcaggccat tctggttatg 14580
cgtaaggctg gcggcaatcc gctggagtac ctcaagtaca ctttcacaga tctgattatt 14640
gcaatgggat cgcccagcgg aagccaggga ggggaaattg cgtctcgcga atcaattgaa 14700
ctctccttca gcaccgtgaa gcaggaatac gtgggtgcaga accagcaggg tggcagcggc 14760
ggcaccatca ccgcaggcta cgacttcaag gccaaacaaag aaatttaacg gctgtttttc 14820
cggccagatt tatatctggc cggatttatt attttgattt taaaggaatt tacagtgaat 14880
gaatggcgta accccactcg gtgggttatgt gcggtagcta tgccttttgc actgctcctg 14940
ctttccggat gcggcagtag cgatgcgtta cctgacctcg aatcacagcg actcgacctg 15000
agcgtgaaag cctccgataa ggtgaatcct gacaatcaga agaaggccgc gccattgag 15060
atacgtgttt atgaactgaa aaatgacgcc gctttcacga cagctgatta ctggtcgctc 15120
catgacaacg acaaatccgt ccttaccgac gatttagtgc gtcgcgacag ctttatatttg 15180
cgtcccggcg aagagaaaaa actgcgtcgc ccgctgaatg cgcagaccac ggcaatcggc 15240

gtactggccg gataccgtaa cctggccaaa tcggtctggc gggtaacctt caaaatcccg 15300
gaagcccccg aaaaagcctg gtacagcagc ttcatatcgg ggaaaggaaa agtgcagttg 15360
gaggcggaac tggaacaaaag cgccattgta attacggaac gggataaatg aattatgagc 15420
tggaatgacc gcgtagtctg gagtgaagga caatttttac tgccgcagat gtttcagcag 15480
caagagcggt atctggaaca cgtcatgcat taccgcagcc tgccgctgac cccctttttc 15540
tggggattca gccactacaa tattgatggc gaagcgctga acatcggtta actgatactg 15600
aaagaggcat cagggatttt tcttgacggc acgccgttta acgcaccgga ccacaccccg 15660
ctgccgccgc cactgaccat tctgccggag cacctgaacc agcagatttg tctggcggtta 15720
ccggtacgcg cgccgaacag cgaagaaacc acgtttgaca ataaccgga atcattggcg 15780
cgtttctcgg tacatgaaca cgacatccgc gacgccaaact cgctgggacg tggcgcgag 15840
ttattacagc tcagtcattt gcgcctgcgg ctgctgccgg aaaaggcggt gacgggcgcc 15900
tggtattggc tgccgttgac ccgcattacc ggggtgaacc ctgacgggag gatagatatc 15960
gaccacgacc tgatcccgcc catcattaat tatcaggcca gttcactgat gtgtacctgg 16020
ctgtcgtgga tcaacgatct catccggatg cgggcccatt cgctggcgga acggctgacc 16080
ggcagcgaca accacggcca tgaagcagcg gaggtctccg attacctgct gctgcaaatt 16140
ctcaatcgct ttgagccgct gctgactcac ctggcgaaaa ccccgctggc cccggagggtg 16200
ctgtaccgct acctgtccga actggccggg gaactctcca cctatgtgag tccacaaacg 16260
cgacggcccc ctgaatacaa agagtacaaa cacctgacgc cctatgccgg gttgaaatcg 16320
ctggttgatg aggtgcagtt cctgctgaac gcggtactga tccggggcgc gcagcgcatt 16380
gagctgaaag aggggactta cggcatcctg aatgcgggtg tggccccctc cgatcttgcc 16440
gatttcagca cgctgggtact ggcgataaag gcttcaatgc cgaccgatgt gctactgcaa 16500
cattttgccg ccagaccaa aatcgggcca tccgatcgcc tgccggaact gatccgctcg 16560
catctgccgg ggctggcttt gcagggttctg cctgtaccac cgcgccaaat cccgtttcag 16620
gccggataca tctattacga catccgcgcg gagggagcat tgtgggaaca cattgcccgt 16680
tacggcgggg tggccatgca taccgccggg gaatttccgg ggctggagac agaactgtgg 16740
ggagtgcgcg ataaatgaca gacagtacc tgacgccgcc agcggcggtat atgatgtcct 16800
ttttgtccac cacgccgga cataaggaca gtgaatatga aacgccggtta cacaccagcc 16860
agcgcacgga actcaatgtc atcgttgaag acggtccgga cagcaaaact cggctggctg 16920
aaatcagcgc ggcggttaac ccgttgctcg ccgctgcccg gcctttattg tgcgctctcg 16980
cagccatgcc cgctaaactg gatgcggccc tggtagagcc ttaccgtaat ctgctggtac 17040

gcgagatgca tctgtaccag acattatgcg atcaggcgaa cctgcggcgc gagcacgtac 17100
tggcgggtacg ttactgcctg tgtacggcgc ttgatgaagc cgccaataac acaacctggg 17160
gacggcgcgg cgtctgggccc ggaaaaagcc tgctggtaac atttcatggg gaaagcgaag 17220
gcgggataaaa acttttccag atcatcgggc gtctggcggc cagcttccag gagcatggca 17280
acgtactgga ggttatctac cacctgctgg gggtgggatt tgaaggccgc tacagcgtgc 17340
agccagacgg gcgtaagcaa ctggacaata ttcgccagca actgctgaca cagctttcac 17400
agcgtcgcga tccggttatg cccgcgctct cgectgactt tcagggggcg ataagcggac 17460
gactgcggcg gatgcgcggg gtgccggctt ggctgagcgc cgggatagcc ctggtggcga 17520
tgctgacgct gtttggcctt tacagccacc ggatggatgt gcagaccgtc accgtacaac 17580
agcatattga tgcgattggg ataaaactgc cgccgcgcgc tgtgccgggt cataagctgc 17640
ggctgaaaat cctgctggca aacgaaatcg cccgtggcct gctgaccgtg gacgaagatg 17700
accagcacag taggggtggc ttcggtggcg acgccatgtt tgtgccggga cagaaaacgg 17760
tgagtgacgc aatccggcca gtgattaaca aagcggcgcg ggaaatcgcc cgcgtgggcg 17820
gcgcagtcac tgtaacgggt cacactgaca gccagcccat tcattcgggt gaattcccat 17880
ccaacctggg actgtcggaa aaacgggcgg cggaagtgtc ggcgttgctg acctccggcg 17940
gcgtacctgc cggacgggta catatcgctc gcaagggcga tacgggtgccg gtggcggata 18000
acggcagtaa agccgggcgg gcgaaaaacc gtcgggtgga aattctggta gtggagtga 18060
tgaatgatga aaaaatcaac ctatgatgtg tctcatcatt cggcagtatg tggcgtgacg 18120
ggggattatt atcggatctc agcgacatat cacataacac gatctgttcg tgtttttttg 18180
atcatcttat gttgcctgtt atccgggtggc gcttttgccg gatccccgat taacgcagga 18240
ttcatttccc ccgataatgt caacctcagt actcaggatt tcctgaaatt ttatgccact 18300
gacaacgtac agaaaaaaga caatgcactg atgtatatgc tgggggtgga ggatgcgaca 18360
gaaggtaaag cctgggtgtg atatgggtcag gttgacagta taacaataaa ccatactgtg 18420
ctgacctggg ttgaacagca cgcagtgaaa aagcctgatg taagggttc aatactaata 18480
gaggaagcat tagttaaaaa ttttccctgt cagaggacag actcctccat aaaaattgct 18540
tcccgggtcat ctcccatttt atccctgacg ccggatgcgc ttaatctttc aggtaatgac 18600
ttttttaaat tttgggtgtc tggtaatcaa cgggataaac tcagggcggg tgtctatctg 18660
ctcggcgtgg aggatgcgac agagaacaaa ctgtgggtgtg gatacgcttt atttaagacg 18720
ctaacattaa atgaattagt ctatgtttct cttaaaaata aaaccaatga ggaactgaat 18780
tctcgcgcgg ctgaacttat cataaataaa ttaatagagt atccctgtaa tatataaaat 18840
cattcaagtt gcatcaaggc ggcaaggag tgaatccccg ggagcgtaca ttagttcgtg 18900

actgggggtga gcgaggaaag ccaacgcaca tgcagcctga agtatgacag gtataccctg 18960
tgataatgtt atcgctgcca gtccagataa agtcttggtg gtaaagtctt ggtggtaaga 19020
tattgatatg ttttaaggtaa tggctctgtct gttgggtgggt gttcctgcca tttcttatgc 19080
gcacgattat ggggtgtgcta cgggttgagc atcaatggag tcatcattat ttgatgccat 19140
aaaaaatgac ctgaatatag atgtcgctac tattataaag gataaaacaa aggtagagat 19200
tcttgatata tcacctgtat ctaaggctta tgcagaatct ctggccagga tggattatga 19260
aaaagataag gccaaaaata aagtggcaat attagataaa aaatcctatt tcgatagtta 19320
ctatgaaaat cagggttaaat ctatcgctggc aaaatatacc tatattaaca aagataaaga 19380
aaaagatatt ttcattgcat ccagcttcat gaatgctgat gagtgctctg taagatttaa 19440
tggcttatatt actttatcca gggaatttta aaatattgat tattgggtgg cgagtcgaaa 19500
tataatgcaa aaatttctta gtctgctttt ttcccggcgc gcgctggcag ttgtgggcgt 19560
tctgggtctg gcgctgctgg tctgggtttgt cgggcccgtg gtgtcatttg ataccctgcg 19620
cccgtgggc tccgtgggta gccgggtagt gaccattgcc ctgttgctga tgctgctggt 19680
actgtggctg gtcaactggt cgatgagtat catcggcac agtgcctgt gcctggcgat 19740
tggcttcgtc acaccgctgc tggccctggg cgatgtccat ccgtttgcgc cgctgtgggt 19800
ccgcctgacc ctgattggtt tcatcctgct gatgtacgc ctgtacggcc tgtaccggct 19860
gtggcgctgc ctgcgtatgg atgaacaact gctgcgtcgc ttccctgcac cgcgcgggga 19920
agaggtaccg gtggcaggcg agatcaaagc cgacctgcgc accgtcaacc atattgtcac 19980
gcaggccatc cggcagctgc ggcagttgcg ggtggatatg cctggctggc gtaaaatctt 20040
cgagggaaaa cgctttctgt atgagctgcc gtggttcatg gtggctggca gtcccggcga 20100
cggcaaaacc acggccctgc tgaacaccgg attgcagttc ccgctggcgg agcaaatgga 20160
gcagacttcg cgcacctga cagtaccggg tggcggcacg ctacactgcg actggtggtt 20220
taccaacgaa gcggtgttga ttgataccgc cggacgctac gcccgccacg atgacgggtg 20280
tgaagcgagc gccgcgcagc gtaacgccgg agagtggcag ggctttctcg gtctgctgcg 20340
taaacatcgc cccggcgcgc cgcttaacgg cgtgatcctg acgctaaacg tggcggattt 20400
aaccgcacag tcaccggcgg aacgcctggc ggctgcgcg gctctgcggg cgcgactggc 20460
agaactgcgc gagaccctgg ggattcgctt tccggtctat ctggtggtca ccaaaatgga 20520
tttgttgccg ggggttcagcg aatatttttcg cacgctgacc agccatcttc gtgcacaaat 20580
ctggggcttc acgttgccgt acagccgcag gcgaaaagcg ggcgaccgc aggcgctgca 20640
cgccgcctgc gcgcaggagc tggcgcgcct gacgctgcgg ttggatcagg gactggatac 20700

ccggttacag gaagagtacg accttaaaaag ccgccagcgg ctgtatacct tcccgcgtga 20760
gttcgccgcc ctccggcgagc cgttgctgga ggctattgaa cagatcttcc tcgattcaaa 20820
attcgatgcc acgcaactga ataacacgct gcgcgggggtg tttttcacca gcgccgcgca 20880
ggcgcaggcc gacgccgtgg ccgaccagtt gagtatctgg cagcgctttg tccggggcgat 20940
aaaaaccgcc cgtggcggaat cctccgcctc tctccacac gctctgccgg acggcaaccg 21000
cagctacttc ctgcatgacc tgctgacaca gtttattttt cgtgaagcgc acctgggtgga 21060
gccaaacctc cagtgggcct ggcgttaccg cctgctgcgc ctccggcgggc acctgctggt 21120
actgggtgctg gcattcctgt tgtggcaggg gatgcagacc agccagcaga ccaacggcga 21180
ctatctgaat gaaatcagcg cccgcgcgac ccggctggac ggtgatgtga aagcctacac 21240
cggtaaaccg gcgatggctc ccgtcccggc actgctggac agcgcaaggg aactgtccgc 21300
ctggccggaa ctggaccggg acgcgccgcc gctggcctgg cgtacggtc tgtacagcgt 21360
accgccggta accgacagcg tggcgctcgt gtacaaccgt ctgctggatc aactgctgct 21420
gccgccgctg gtgaaacgga tggagtatgt gctggcggac gccattgccc gtcaggatag 21480
taaagcggcc tacgatgccc tgcgcactca tctgctactg aatctggata aagatcacga 21540
agataaatac aacgcggcgg agatccagtc gtgggtgatt aacgatctgg ggaacagcga 21600
cagcgtggcc gggttcggcg ggccgcgccg cgtgctgacg catatcgaag cgctgtttga 21660
cggcagccgg gtgggtgcatt caccgtatga gaaagatgag gcgctgatcc gccaggcgcg 21720
ggcattcctc gacggtcaca ccagtaccga gcgtatctac gcgcggggcg tggcggcaat 21780
ggagagcgaa gcgccgcagg agttcacgct ggtacgcgcc gtcggcgcgg atgcgggaac 21840
ggctcttctg cgtagcaacg gcgcgccgct ggatcggggc gtgccgggta tttttacccg 21900
tgaaggatac cgggagctgt tcgacaaaacg attaccggaa tttgtggcgg cggcgacggc 21960
gaacgatggc tgggtgatgg gccgggagag tacgccaaaa aagctgactg acagcctgcg 22020
cagccagata ccggggcagg agcagtctgt cggccgcgaa gtccgccgtt tgtacctgac 22080
ggaatatgcc cgcgcgtggc aggattttct ggacagtatc catagtatca acagtgccgg 22140
ggaagagggc agttccggcc tggcctatga ttacaggtg ctgcgcaccc tggcgtcgcc 22200
ggactcaccg ctgatgcggc tgggaaaagc ggtgggtggag cagaccacgc tggtgccgcc 22260
gccggacccg caggccagac agaaacaact ggccgacgcg gcatccggta acgcggggaa 22320
agtgggtacag acggcaaaac tgttccagga tattcaccgg gaagaacggc tggaaaaaac 22380
gctgggtggat gatcgtttcg ccgcgctgcg cgaggtcatt gccggggcga cggacggcgg 22440
acagagcggc ggtgggacga tgcagatcgc ttcgctgctg accatgctca acgagtatta 22500
caccctaactg accattgctg atagcgcgct ggccggcggg acgttgccag cgcgcattac 22560

tgccgcagac aagttgcaac tggaggcggc gaaactgccc gcgccgctga aaaacatcct 22620
gctggatctg acgaagcagg gaacgcgcaa aatcaacgcc gggaccggcg acgtgctgaa 22680
caccagatg gaggcgatga tgggcgacga ctgccgtgac gccatcgacg ggcgctatcc 22740
gttcgcegac agtccgcagg aggtcagcgc cgaggacttt aaccgcatct tcgccagecg 22800
cggcgtactg gatgctttct ggagcaaaca actggctccg ctggcggaca ccgccagcga 22860
cccgtggcgc tacaaaccga ccgaaggcaa catgacattg cagggggccg atctgacgcc 22920
gtttcagcag gcgaagcaga tccgcagcgt attttttaac agcgagggcg ggaaaaaatt 22980
ttcctggtcg atgcagatta gcgtggtgga tatggaccgc gccatcacgg aactggtgat 23040
tgatatcgac ggccagggtgc tgcgctacgc ccatggctcg gaccgtcccc tgaaagtaac 23100
gtggccggga ccgcgcaacg gctcgatggc ggaaatcacc gccagcccgc gtattcgcca 23160
ggacacctca acgctactga ccggcggggc gtggggcgctg tttcatctgc tggacgccgg 23220
aatggtacag gaaacggcgg tgcggggggcg tcaactggtg gaatatgatt ttgacggtcg 23280
ccgggtggtg ctggaaatca ccgccgggcg ggattttaac ccggtcagcc gggagctgtt 23340
gcagaacttc agttgcccgg cgagggcgct gtaatgcgcc ggccagcagt ggtatcagcc 23400
ccggcgatgt tcggcaggct gccggaccag cgcgactatg tgcgctggcg agtgggcgct 23460
gaagaggggac gaatatggca ggactggctg aaccgccaga cgtgggtggg cagcggggcg 23520
catatcgtgt tgccgggagg ccagacgacc gatgaagagc gtgacggctg gatgcacctg 23580
tcgccgcgtg gcgaacatga tatgccgcg ccggaacacc atccgctgcc gtggagcttt 23640
gtgatgtcgc cgggatTTTT gccgatgggt gggacgactg actggctgac cggagtgcctg 23700
atggcgtcac gggatagcgt gggacgcccg tggccgctgg tgatttacca gcgctgcggt 23760
cgggagtggc tggacgagag tttgcaggag acgcagggct ggctgtactg gctggcgagg 23820
ctggcggcgc agcatatcac gccggacacg atgcggcgcg ggcggctgac cgagcaggctg 23880
gaccagctat gggcgatgtg gcagccgggg ccgtgggtggg cgcagtggct gcgtgggtta 23940
cgacgtacat cgcaacgcag ccgggaactg accgggctgc cggatgaagc accggtagta 24000
gaactgcggg gcgtgcgtta tctgccgtgg ccgggctggc cgggtaagac gctggggcag 24060
gcaacaccgg ggcaaggctg gttctggcag cagaacagtg aaggggcggt tgtggatgcg 24120
ctggggttgg tggatgaaaa aaatagaggc cagatgctgt gaaaaagtac gctgtagagg 24180
ttctgtttat gtctgcctgt gcaggaatgt tcctgcccgt atttgcctgg ggcggaacag 24240
atgtaaacat tgataacccg ctggcggagt gtgtggatat ccatcccgtt catcgtcagg 24300
aaatggataa ccttaccatt ctgaaaacaa cggtcacact gaaaaaaagc accggtgaat 24360

gtggctgttt ctcaacatta atcaactata ccagcttact ggcgcaggat gttgaggggt 24420
acggacgcgg aagtgcatat tcccttcagg aggggaatat ctactggcg aagatgcagg 24480
gacgttatcc tttcagcttt gtattatcgg tggataacca gtctgtacgg gatcagaagc 24540
tggcgctaata gatacgttgt acaccaccgc tgtaatacac agaatagtca gggagaagat 24600
gatggcagta agactgactt ttgacgggca aaagctgaca tggcctggta tcgggatatt 24660
taaggcgacc acgggggttac cggatttaca gtggccagat aaacagtgtg tgccggatgc 24720
ggcgataccg gaagggaatt ataaattgtt tattcagttt cagggggagg caccgataag 24780
aaatgctgcg gattgtgatc tgggaccatc atggggctgg agtaccattc cgcgaggcca 24840
ggctgccgga acatgtgaga tatactgggc gaactgggga tataatcgta tccggctgga 24900
atcagcggat gagaagaccc gaaaagcctg tgggggcaag cggggtgggt tttatatcca 24960
tgattccacc aaagggttaca gtcattggtg tattgaagtg gaaccgggtg tttccgtat 25020
tctgaaacag gagacggaaa aagaaaatgg tgaaaagaca tttacggtta atgttaagta 25080
tgtttctggg cagcaaacga atgggtggaac aaaacaataa taccgttaaa accggatgaa 25140
attatcgtgt ctggacgtgc tgtggttgac aatgattaca atgggtggcca gataagtaat 25200
gagcaccaat gataaagtat atgactggcg gtgtgctggg tattaatcaa atttctataa 25260
aatgcaatgc gaatctggta agcgtaataa aaataaaatc ataattattg tatgttcatt 25320
tccttattta tgtaattcag tatttatgtt atgtgctaata ttttgtgttt ttattttcat 25380
ggctcttgtc agcaatatac cctgttcttc tggtaaatat ttaaatataa caggctgggt 25440
gcattataaa gtgcggggca ctgtttcctg acggtgagtc tatttatttt aatccggtat 25500
taaaggagtc actaccatga gttttgtatc cacaataat aaatccggtg tgggaggggt 25560
gacgacaacc acgcccgcga taaccggaga aagtggcggg gtcaccgcag attcagtcgc 25620
cggaagcgtg gcagatgcgg cggaatccgc cgtggaacag gctgcgggat cgctatttgg 25680
cgcattgccg gagccatcag gactggtgaa agccgcggta gcagcggcgc aggctgccgc 25740
cgccgcagggt atggcgcagg atgcggtatc ggccatcgtc tctgctgttg caggcgggccc 25800
gggggcgcat aatgtgacgg tcagcggcag cgccgtaccg ccgggcgcat tactgttcgc 25860
cagcctggac ggcggcgaaa cattaagtga actgttcagc tatgtggtac agctaaaaac 25920
gcccgcaccc ctgaatctgg gctatgtctc cccggcgggc aacctgccgc tcaaaccgat 25980
ggcgggcaaa gatctgtgcg tcaacatcga actggatggg ggcggtaaac gacatattcag 26040
cgggctggtc acggcggcgc ggggtgggtgg ccatgaaggg cgttcgggta cctatgagct 26100
gcgtatggag ccgtgggtaa aactgctgac ccataccagc gactacaaag cattccagaa 26160
taaaaccgtg gtggatatcc tggatgaggt tctggcgga tatccctacc cgggtggaaaa 26220

gggaaaacgg aagtgtacca gcgtcaggcc gggttttattg caacccttgg caagggtactg 28080
gtcttcaccc tgaccagtcc ccgtcctttt gatgataaag cagacctact ctggaacacc 28140
tggtctggcag gcttttcagcc ggataaaaaac gaataatcac acggagggtgt gaccatgtat 28200
gaagcagccc gtgtggatga tcctatctac cacaccagcg cgctcgccgg gtttcttattc 28260
ggcgctatca tcggcatcgc cattatcgcg cttgcgcgct ttgccttctt tagctgcgggt 28320
tttcttgccg ggctgattct gggttttatg gccgatcaaa tagcctccgg ggtattgcaa 28380
ctgggcgagg ccatcgggcg ctccatccac cacacggcag gaaaaatcct caccggtttcg 28440
gagaatgtca gcaccaacag tcgcccggcg gcgcgcgcgg tactgagtac ggtgaaatgc 28500
gataaccata tcgcagaaaa acgcatcgcc caagggtcgg aaaatatcta catcaacagc 28560
cagcccgccg cccgtaagga tgaccacacc gaatgcgacg cggtgattga agacggtttcg 28620
ccgaatgtgt ttctcggcgg cggcacacag acgggtactgg aaatcagttc tgaaattccg 28680
gactggctgc gcaagggtgg ggatgtattg ttgtcgtgg cgagtctgct cggcgggctg 28740
gccggggcgt ggccggcaggc ggcaaagctg gggacgaaat ttggcactaa atgtgccgct 28800
aagtttatcg gcggggagct tgtcgggatg gccgtgggtg aggctatcag cgggctgttc 28860
agcaatccgg tggatgtgac caccgggcag aaaatcctgc tgccggaaac ggacttcacc 28920
ctgcccggtc gcctgccggg cacctgctcg cgtttttacg ccagccacct ggaaactgtg 28980
ggactgttgg gacggggctg gcggctgaac tgggaaacca gcctgcgcga tgacgatgaa 29040
cacatcacgc tgaccggcgt acagggggcg gaactgcgtt acccgaaaac gatgctgacg 29100
cccggccacc agatatttga cccggaagaa cagttatacc tcagccgcct gcatgacggg 29160
cgttacgtgc tgcattacac cgatcgcagc tattacgtat ttgggtgattt tgacagtgac 29220
ggcatggcat acctgctgtt tatggagacg ccgcaccgcc agcgcattgt cttcgggcac 29280
gaaggaggca gactggtacg gatagcctcc agcagcgggc atcacctgtt actgcaccgc 29340
acacagaccc cggcagggga gcggctgtcg cgaattgaac tgggtgcaggg cggcaccctg 29400
ggcaatctgg tggagtaccg gtatgacgat aacgggtcaac tgaccggcgt ggtgaaccgg 29460
gcgggaacgc aggtgcgtca gtttgcttat gaaaacgggc tgatgacggc gcacagcaat 29520
gcgacggggg tcacctgccg ctaccgctgg caggaaactcg acggcgcgcc gcgcgtgacg 29580
gagcacgaca ccagtgaagg cgaacattac cgctttgact atgattttgc cgcaggcacc 29640
accaccgtca ccggcaggca gggggagaca tggcagtggt ggtacgacag ggaaacgtat 29700
atcaccgcgc accggacgcc gggcggtgga atgtaccgct tcacgtacaa cgaagaccac 29760
ttccctgtca acattgagct gcccgggcgg cgcacgggtg cgatatgaata tgacatccag 29820
aaccgggtgg tgaagacgac agatccggaa ggccgggtga cgcagacgca gtggaacggc 29880

gaagggcgat tagctaaacg caaagggttg cctgttcctg aaatgccaac agcagaaaac 31740
ataactgtaa ggggcgagaa aattaatggg gaagttgaag caaaatgcta aataaattta 31800
aattgtgggt gagcaaacat actgattata cggtaattca taatgaaaat gatttatctt 31860
acagtattat tatagatttt gaagatgacc ggtatatatc aagatttact gtatgggatg 31920
acctaagctg tatgtcagaa gtaatggatg tggatactgg tttatataaa ttaaacaaga 31980
gaaacgaatt ttctacattt gatgaacttc tggatatatt tgatgatttt atgataagta 32040
ttaaataata gttggccggg taagaagtta actcttcccg gctgttttat tatctaacc 32100
ccatcaatcc ggagacgcgc taccggtagc atgcgctggg caggcgggtg agcaaggcga 32160
cgtacgggcg gcacacgggc catacggcgc ggagccggac ggactttgtg tgggaggggt 32220
tcaggctgtt gcaggagaac gtgcagcagc agggctggcg gacatatctg tacgatgcgg 32280
aacagccgta cacgccgggtg gcgagcgtga cgggaaaggg agaaagcagg cagggtgtgg 32340
attaccacac ggacgtgacg ggcacgccgc aggaggtgac ggcggcggac ggaacgctgg 32400
tgtgggcggg gtatatcagg gggtttgag aaaatgcggc ggacatcagc aacagcggg 32460
cgtactttca ccagccgctg cggctgccgg ggcagratct tgacgacgag acagggctgc 32520
attacaatct gttcagatat tatgcaccgg agtgtggacg gttcgtcagt caggatccga 32580
ttgggctggc ggggggggct gaatctttac cagtatgcgc ctaatccgat tagatggatc 32640
gatectttag gacttgctat cctggagcat caatctaatt ttgatgcggc aaggagaacc 32700
ggatttgaaa atgcgggtat gacaaaccct gaggatgtca ctttctcgaa agtcgatccc 32760
aaaactggta ctgttggtga gtttaaaggc ccaaagggg cttaaagttgc ttatgatgca 32820
cctcatgcag atatggatgt gacagcaggc catgataaac cacatgcttg ttggcaatcc 32880
gcaggaaaaa gaggttccgg aggagctaata agaggtaata ttacttatga tggcccacaa 32940
catccgcac gctctgactc taaggagat gataaatgtt aaattcaaata atgtctgaac 33000
ttagaatcga actggagaat gcgattaaaa atctcgggtat tcatgattat cgtgtcgata 33060
aaccggaaca aatcgtttct gagataaaaag agatatatgt taatggtaata cctagaacct 33120
gggtggttatc attaaaacat agacaatatg tcttttctta taccgataat tctggatata 33180
aaaacatatc acaaatagta agtaaacaac tcaatgaaag caatgtaatc aacaaacata 33240
tatttttgat tgctgatgaa gataatgagc aaatatatgt atataacgtt cctcttaact 33300
ccctgcctga aattatagaa aattgcagat attttgaata ttatgttgca gatcatgaac 33360
tatcttggct tatatgtgaa aatgatcatg gtgatttgat tgtatgctca accattaagt 33420
aaagcgcgag tgctcttttag cgatatagtt gcccatatct aggcgttact agccgaagat 33480
ggcgcgattg tctggcaggg gaaacagcaa ttctgaggtc aggaagatag cataaccat 33540

taaccgggat agatccgcta gacctgaatc cagttgatgc gacaggttat agggtttatg 33600
gttatttgct cctggagcaa ataaacctta ttacattggt attactaatg atatggtttg 33660
acgaagggcc gagcattaaa gcactggcag gttatcaaaa gaaaatggaa ggatgctgcc 33720
atttgatgaa aatgtaatct aatggaaagt cagaggttac gagaaatatt atatagagaa 33780
atataaaacc agaaccggaa ccatagggtga aaaaattccc tcaacaaata gagagaataa 33840
atataattca tttgatcatg ggcgaacaga tcccagcgca caagcattta aagactctta 33900
aaatagtaag ggagttgggt ccggtggagg aaaatgcgga tgagtgatta agaatttttg 33960
ggctgtgata agaagtcgag aacaatgctg cgttttgtga agcccggaga catattttgt 34020
tttaaattag atgaagatag atattgtttt gggcgaatta taacactaat gactgtcgga 34080
catctttctg aattatttga tataattaaa aaacccctg gaataacaga gttagaaatt 34140
agtaatgcaa ggcgaattat tgaaccaatt atagtggata catattcttt atttgataag 34200
aaattagaaa atggaagtga ctggagaatt attggtcac aggttaatta caatccaaaa 34260
aatttagatg gtatctattt tgcacttggga atagggtgatt cctgtaaaaa gaaagactgt 34320
tacggaaatg attttctcat ttcagaaagt gagtggaaaa cacttcctaa attatctcct 34380
aaaggggggt ttgatatcaa aaaacggctt gaaattgcct gaaaatgaaa ataaaaagcc 34440
gggaaagatc ttttgtcttc ccggatttta ttatttaatc cccgttcacc acattattta 34500
ccccgcctt aatatgcttc atcgactttt tcacctgata aagctccttc cgtagatccc 34560
tcacttcgtc cgtctctgca atcaggatca aacaccctc ggagatcttc acggtgacgc 34620
cgtgcccggc ctcaaattcc gcttcttccct gccagtcacc ctttaagggtgc tggctgggga 34680
tttgtgagta acaggcggtc atgcaggttt cgctgttgat atggcggacg ctgacgccgg 34740
aggcattcat atttgctgac taaataaatt cttatttatt cgccggatgc tggctgattg 34800
tggagctcag ggtgagtga tggggcgcg acatcctggc accgcgcctc cctctccccg 34860
gccagccccg gccggtgatg agcagccggc tgccggggcc gtattttgac gatgaaacgg 34920
gcctgcatta aaatctgttc agatattatg taccggagtg tggctgggtc gtcagtcagg 34980
atccaatagg gctgaaaggg ggatggaacc gatatcattc tccgctgaat cctattacag 35040
atagtgatcc tcttggcctt attacttgtg gtgctgatag aggtgattct ggcaagttat 35100
taagatgaaa aatgggtgaa aataattgcg ttagtgaatg ctcatattatg cctttaccta 35160
caaaaagtaa cggatttgct tgctggaatt gtgttaacga atgcaaataa aatcaatgct 35220
gttgatgttt ttactacagg aataagtatg gttaacgata aggatacagc tatattaatt 35280
agtaatttaa tggtgagatt cggtaaggag cttgatgaat ctgttgctgt tgttcagtc 35340

cgctgtgatg aggatgaatt taatgtatat cgagaaacgg ttggttttat catgggtgaa 35400
atgcttatta aaataatgaa tccattatat gaaaaacatc cagaaataaa accaaaagga 35460
ttgaaacaaa acatctggaa ccggatgaat aatgtgtaaa agccggaggg gttatctttt 35520
cccggctttt tattatcaat tactcattaa ctctgttcc gttcttttgc gtttaatcac 35580
cggaatatct ccggtattgt tcagcgcgcc ggaaatgttt ttaaccactg ttctgcactc 35640
cgtttattaa tgcgggttac gcccatccct tcaatacagc caaagagtcc gtgggtatgc 35700
tgcggcgtga tcacgatgca atccctcatt acccgcacct tgacgggcat cccgttaata 35760
aaccgccct gcggcatcca ttcaccgtac aaacgaactg aaagtctctc aacgcgtgag 35820
tatgtaagta tcccgcataa tcgagccatt cacatttaga gatcatccga cataatcaat 35880
ctgccaacgc aggagatcgc tatgcgtaaa gcccgattta ctgcgcacca gatcatcgct 35940
gtgattagat cagtcgaatc cggacggact gttaaagatg tctaccggga gcccggtatt 36000
tctgaagcca ccagggacaa ctggaggtct ggatacggcg gcagggatac gcgtggaatc 36060
acaaaaggct ccaccgtatt tactgtctgc tcaagctgaa ttttcgccgt aagggtaaac 36120
aacggctgcc ggtacgcaat cctcgcacc tggtcacgcc ggaagcgctg aaccagagct 36180
ggctctgtgg cgctgttttc gcacgttcaa tgttggtgat gactgtaatc gtgaagcgtt 36240
gtcgattgaa atcgatctga atctgccagc tctgcgagtg gtccgtgtac tcgacaggat 36300
tacagcaacc gcggttatct ggccatgctg cgtatggata agggaccgga atttatctcg 36360
ctggcactgg ctgaatgggc aaagaaacat gcagtaaagc tggcgtttat ccagccgggt 36420
aagccgaaga aaaacgtttt catcacgcgc ttaaccgga cataccgtac agaaatactc 36480
aattcttatc tgttcagaac gctgaatgag gtgtgggaaa ttaccgataa agggttatca 36540
gaatataact gcgaacgtcc acatgaatcg cggaaacaata tgataccgaa ggaataccgc 36600
caataacggt atctggccgg aatcttaaaa atgcatggaa ctaaaacggg tctatttaca 36660
ggggcacctg cgatgaattt cgctgcactg aaaagcgata ccggatgaga gctgcttcaa 36720
attaatgtgc catgttcacg gggagggtgt gcgacgtttg cataatccag caagaactga 36780
aaggaagggg agagcttttt catgcctgta taatcagtct ggcctgtgtc agtcagctct 36840
tagtggtgag actctcgttg gagcgttata attgcttttc tgtttcggaa aacaagattt 36900
tccattaaag atcttccctg cgaggaaaag ttaactaata atcttaccgt cgagttagga 36960
gatgtatgtt taaatataaa caatgttgca acgatgcctg ataattatcc tctcttcgaa 37020
gataagtttc ccacaccag tgtagtaggt gtcatggtaa tgttatcact tgaatgtaaa 37080
tggaaggat aattgctttt tgactggcat tctattccac cctgacaaca cgatgttaac 37140
atcaacactg tttatattgg caataacgca atttttttca gattaagagg tgctctgata 37200

tatagatttt tatgacatta cttatttgaa ttggtaacaa ataccaataa gtacaagctg 37260

ttattaccag ccacggattt ttacatacg gtaagatttg gstatggcggtt atgtattctg 37320

gatgtgctgg attatttttaa tttggtttaa aaaagggtggt tattcaa atg aaa agc 37376

Met Lys Ser

1

ata aaa aaa ttg att atc gca agt gcg ttg agc atg atg gct gct agt 37424

Ile Lys Lys Leu Ile Ile Ala Ser Ala Leu Ser Met Met Ala Ala Ser

5

10

15

tgt tat gct ggc tca ttt ttg ccg aac tca gag caa caa aaa tca gtg 37472

Cys Tyr Ala Gly Ser Phe Leu Pro Asn Ser Glu Gln Gln Lys Ser Val

20

25

30

35

gat att gtg ttt tcc tct ccc caa gat tta acc gta tcg ctt att cca 37520

Asp Ile Val Phe Ser Ser Pro Gln Asp Leu Thr Val Ser Leu Ile Pro

40

45

50

gtg tcg ggc tta aag gct ggg aaa aat gct cct agc gcg aaa att gcg 37568

Val Ser Gly Leu Lys Ala Gly Lys Asn Ala Pro Ser Ala Lys Ile Ala

55

60

65

aag ctt gta gtt aat tct act act ctt aaa gaa ttc ggg gtc agg ggg 37616

Lys Leu Val Val Asn Ser Thr Thr Leu Lys Glu Phe Gly Val Arg Gly

70

75

80

att tct aac aac gtg gta gac agt act ggc act gca tgg cgt gta gct 37664

Ile Ser Asn Asn Val Val Asp Ser Thr Gly Thr Ala Trp Arg Val Ala

85

90

95

ggg aaa aat act ggt aaa gag atc ggt gtg ggc tta tca agt gac agt 37712

Gly Lys Asn Thr Gly Lys Glu Ile Gly Val Gly Leu Ser Ser Asp Ser

100

105

110

115

ctt aga aga tct gat agc acg gaa aaa tgg aat ggg gtg aac tgg atg 37760

Leu Arg Arg Ser Asp Ser Thr Glu Lys Trp Asn Gly Val Asn Trp Met

120

125

130

acc ttt aat agc aat gac aca ctt gat att gtc ctg aca gga ccg gcg 37808

Thr Phe Asn Ser Asn Asp Thr Leu Asp Ile Val Leu Thr Gly Pro Ala

135

140

145

cag aat gtc aca gct gac acg tac cca ata act tta gac gta gtg gga 37856

Gln Asn Val Thr Ala Asp Thr Tyr Pro Ile Thr Leu Asp Val Val Gly

150

155

160

tat caa cct taa tagtaaacaa ctattagtgt attgtgcctt gtttaaggcg 37908

Tyr Gln Pro

165

caatacacat caaatcatct atttttcttt tacaattttt gat atg aaa ata gtt 37963

Met Lys Ile Val

170

aat ttt gct gta atg gcg gta gct ttg ttc gcc act aat tct atg gtt 38011

Asn Phe Ala Val Met Ala Val Ala Leu Phe Ala Thr Asn Ser Met Val

175

180

185

WO 00/73336

PCT/SE00/01079

23

tca gta tat gcc gtc aac cag caa tta aat tca gcc act aaa tta ttc	38059
Ser Val Tyr Ala Val Asn Gln Gln Leu Asn Ser Ala Thr Lys Leu Phe	
190 195 200	
agc gtg aag ctg ggg gct aca cga gtg att tat cac gct ggt acg gct	38107
Ser Val Lys Leu Gly Ala Thr Arg Val Ile Tyr His Ala Gly Thr Ala	
205 210 215	
gga gcg acg ctc tcg gtg agc aac ccg cag aat tac cct att ttg gtt	38155
Gly Ala Thr Leu Ser Val Ser Asn Pro Gln Asn Tyr Pro Ile Leu Val	
220 225 230 235	
cag tct tca gtc aaa gca gca gac aaa agt tcg cct gct ccc ttt ttg	38203
Gln Ser Ser Val Lys Ala Ala Asp Lys Ser Ser Pro Ala Pro Phe Leu	
240 245 250	
gtg atg ccg cct cta ttt cgt tta gaa gca aac cag cag agt caa ctg	38251
Val Met Pro Pro Leu Phe Arg Leu Glu Ala Asn Gln Gln Ser Gln Leu	
255 260 265	
cgt att gtc cgt act ggt ggt gac atg cca acg gat cgt gag act tta	38299
Arg Ile Val Arg Thr Gly Gly Asp Met Pro Thr Asp Arg Glu Thr Leu	
270 275 280	
cag tgg gtc tgt ata aag gcg gta cca ccc gaa aat gaa ccg tcg gat	38347
Gln Trp Val Cys Ile Lys Ala Val Pro Pro Glu Asn Glu Pro Ser Asp	
285 290 295	
aca cag gct aag ggc gcg acc ctt gac ctc aat ttg tcc atc aac gcc	38395
Thr Gln Ala Lys Gly Ala Thr Leu Asp Leu Asn Leu Ser Ile Asn Ala	
300 305 310 315	
tgt gat aag ctg att ttc cgc ccg gat gcc gtg aag ggg acg ccg gaa	38443
Cys Asp Lys Leu Ile Phe Arg Pro Asp Ala Val Lys Gly Thr Pro Glu	
320 325 330	
gat gtt gca gga aat tta aga tgg gtg gag acg ggc aac aaa ctt aag	38491
Asp Val Ala Gly Asn Leu Arg Trp Val Glu Thr Gly Asn Lys Leu Lys	
335 340 345	
gtg gag aac ccc acc ccg ttt tac atg aat tta gcc tct gtc aca gta	38539
Val Glu Asn Pro Thr Pro Phe Tyr Met Asn Leu Ala Ser Val Thr Val	
350 355 360	
ggg gga aag ccc att aca ggg ctt gag tat gtc ccc ccc ttt gct gac	38587
Gly Gly Lys Pro Ile Thr Gly Leu Glu Tyr Val Pro Pro Phe Ala Asp	
365 370 375	
aaa aca cta aat atg cca ggt agt gcc cat ggt gat atc gag tgg aga	38635
Lys Thr Leu Asn Met Pro Gly Ser Ala His Gly Asp Ile Glu Trp Arg	
380 385 390 395	
gtt att aca gac ttt ggt ggt gaa agt cat ccg ttc cac tac gtt ctt	38683
Val Ile Thr Asp Phe Gly Gly Glu Ser His Pro Phe His Tyr Val Leu	
400 405 410	
aaa taa atccaggggc ttagcggcag aaa atg aag ttc aaa caa cct gcc ttg	38736
Lys Met Lys Phe Lys Gln Pro Ala Leu	
415 420	
cta ctg ttc atc gcg gga gtg gtt cat tgc gca aat gcg cac act tac	38784

WO 00/73336

PCT/SE00/01079

24

Leu	Leu	Phe	Ile	Ala	Gly	Val	Val	His	Cys	Ala	Asn	Ala	His	Thr	Tyr		
			425					430					435				
aca	ttc	gat	gca	tca	atg	ttg	ggc	gat	gca	gcg	aaa	ggg	gtt	gat	atg	38832	
Thr	Phe	Asp	Ala	Ser	Met	Leu	Gly	Asp	Ala	Ala	Lys	Gly	Val	Asp	Met		
			440				445					450					
tcg	ctc	ttt	aac	cag	ggg	tta	caa	cag	cca	ggg	act	tat	cgc	gtg	gac	38880	
Ser	Leu	Phe	Asn	Gln	Gly	Leu	Gln	Gln	Pro	Gly	Thr	Tyr	Arg	Val	Asp		
			455				460				465						
gtg	atg	gtg	aac	ggg	aaa	cgt	gtc	gac	acc	cgt	gat	gtg	gtg	ttc	aaa	38928	
Val	Met	Val	Asn	Gly	Lys	Arg	Val	Asp	Thr	Arg	Asp	Val	Val	Phe	Lys		
					475					480					485		
ttg	gaa	aag	gat	ggg	caa	gga	acg	cct	gtt	ctg	gct	cct	tgt	ttg	acg	38976	
Leu	Glu	Lys	Asp	Gly	Gln	Gly	Thr	Pro	Val	Leu	Ala	Pro	Cys	Leu	Thr		
				490				495						500			
gtc	agt	cag	ctt	tca	cgc	tac	ggc	gta	aaa	acg	gaa	gat	tac	cct	cag	39024	
Val	Ser	Gln	Leu	Ser	Arg	Tyr	Gly	Val	Lys	Thr	Glu	Asp	Tyr	Pro	Gln		
			505					510					515				
ttg	tgg	aaa	gca	gca	aag	ccc	cca	gat	gag	tgt	gcg	gat	ctg	acc	gcc	39072	
Leu	Trp	Lys	Ala	Ala	Lys	Pro	Pro	Asp	Glu	Cys	Ala	Asp	Leu	Thr	Ala		
		520					525					530					
att	cca	cag	gct	aaa	gcg	gta	ctg	gat	atc	aat	aat	cag	caa	ctg	caa	39120	
Ile	Pro	Gln	Ala	Lys	Ala	Val	Leu	Asp	Ile	Asn	Asn	Gln	Gln	Leu	Gln		
		535				540					545						
ctg	agt	att	ccg	cag	ttg	gcg	ttg	cgt	ccg	gaa	ttt	aag	ggg	atc	gct	39168	
Leu	Ser	Ile	Pro	Gln	Leu	Ala	Leu	Arg	Pro	Glu	Phe	Lys	Gly	Ile	Ala		
					555				560					565			
cca	gaa	gat	ctt	tgg	gat	gat	ggg	att	ccg	gcg	ttt	ctg	atg	aac	tac	39216	
Pro	Glu	Asp	Leu	Trp	Asp	Asp	Gly	Ile	Pro	Ala	Phe	Leu	Met	Asn	Tyr		
				570				575						580			
agt	gcg	agg	aca	acg	cag	acg	gat	tac	aaa	atg	gat	atg	gtg	ggg	cgt	39264	
Ser	Ala	Arg	Thr	Thr	Gln	Thr	Asp	Tyr	Lys	Met	Asp	Met	Val	Gly	Arg		
			585					590					595				
gac	aac	tct	tcc	tgg	gta	caa	ctg	caa	ccg	gga	atc	aat	ata	ggg	gcg	39312	
Asp	Asn	Ser	Ser	Trp	Val	Gln	Leu	Gln	Pro	Gly	Ile	Asn	Ile	Gly	Ala		
			600				605					610					
tgg	cgt	gtc	cgc	aac	gcg	acc	agc	tgg	cag	cgg	agt	agt	caa	ctg	tcg	39360	
Trp	Arg	Val	Arg	Asn	Ala	Thr	Ser	Trp	Gln	Arg	Ser	Ser	Gln	Leu	Ser		
		615				620					625						
ggg	aag	tgg	cag	gca	gca	tat	acc	tat	gct	gag	cgt	gga	ctg	tac	tca	39408	
Gly	Lys	Trp	Gln	Ala	Ala	Tyr	Thr	Tyr	Ala	Glu	Arg	Gly	Leu	Tyr	Ser		
					635				640					645			
cta	aaa	agt	cgt	ctg	act	ctg	ggg	caa	aag	act	tcg	cag	ggg	gag	ata	39456	
Leu	Lys	Ser	Arg	Leu	Thr	Leu	Gly	Gln	Lys	Thr	Ser	Gln	Gly	Glu	Ile		
				650				655						660			
ttt	gat	agt	gtg	cca	ttt	acc	ggg	gtg	atg	ttg	gca	tcg	gat	gac	aac	39504	
Phe	Asp	Ser	Val	Pro	Phe	Thr	Gly	Val	Met	Leu	Ala	Ser	Asp	Asp	Asn		

PCT/SE00/01079

25

			665				670				675							
atg	gtg	ccc	tac	agt	gag	cgg	cag	ttt	gct	ccg	gta	gtg	cgt	ggg	att	39552		
Met	Val	Pro	Tyr	Ser	Glu	Arg	Gln	Phe	Ala	Pro	Val	Val	Arg	Gly	Ile			
			680				685				690							
gcc	cgc	acg	cag	gct	cgg	gtg	gag	gtc	aaa	cag	aat	ggg	tac	acc	att	39600		
Ala	Arg	Thr	Gln	Ala	Arg	Val	Glu	Val	Lys	Gln	Asn	Gly	Tyr	Thr	Ile			
			695				700				705							
tac	aac	acc	act	gtg	gcg	ccc	gga	ccg	ttt	gca	ctg	cgg	gat	ctg	tcg	39648		
Tyr	Asn	Thr	Thr	Val	Ala	Pro	Gly	Pro	Phe	Ala	Leu	Arg	Asp	Leu	Ser			
			710				715				720				725			
gta	aca	gac	agt	agt	ggg	gat	ctg	cat	gtc	acc	gtg	tgg	gag	gcc	gat	39696		
Val	Thr	Asp	Ser	Ser	Gly	Asp	Leu	His	Val	Thr	Val	Trp	Glu	Ala	Asp			
			730				735				740							
ggc	agt	aca	caa	atg	ttt	gtg	gtg	ccg	tat	cag	acc	ccg	gcg	ata	gca	39744		
Gly	Ser	Thr	Gln	Met	Phe	Val	Val	Pro	Tyr	Gln	Thr	Pro	Ala	Ile	Ala			
			745				750				755							
ctg	cac	cag	gga	tat	ttg	aag	tac	agc	ctg	ttg	gcg	ggc	cga	tac	cga	39792		
Leu	His	Gln	Gly	Tyr	Leu	Lys	Tyr	Ser	Leu	Leu	Ala	Gly	Arg	Tyr	Arg			
			760				765				770							
tcg	tca	gac	tct	gca	acg	gat	aag	cgg	cag	atc	gcg	cag	gct	acg	ttg	39840		
Ser	Ser	Asp	Ser	Ala	Thr	Asp	Lys	Arg	Gln	Ile	Ala	Gln	Ala	Thr	Leu			
			775				780				785							
atg	tat	ggg	ctg	ccg	tgg	aat	ctc	act	gca	tac	ggc	ggg	ata	cag	agt	39888		
Met	Tyr	Gly	Leu	Pro	Trp	Asn	Leu	Thr	Ala	Tyr	Gly	Gly	Ile	Gln	Ser			
			790				795				800				805			
gca	acg	cat	aat	caa	gct	gca	ttg	ctt	ggg	ttg	ggg	gga	tct	ctc	ggg	39936		
Ala	Thr	His	Asn	Gln	Ala	Ala	Leu	Leu	Gly	Leu	Gly	Gly	Ser	Leu	Gly			
			810				815				820							
cgg	tgg	ggg	agt	tta	tct	gtc	gat	gga	agc	gac	aca	cac	agt	cag	cgt	39984		
Arg	Trp	Gly	Ser	Leu	Ser	Val	Asp	Gly	Ser	Asp	Thr	His	Ser	Gln	Arg			
			825				830				835							
cag	ggg	gag	gcg	gta	cag	caa	gga	gcc	tcc	tgg	cga	ctg	cgt	tac	agc	40032		
Gln	Gly	Glu	Ala	Val	Gln	Gln	Gly	Ala	Ser	Trp	Arg	Leu	Arg	Tyr	Ser			
			840				845				850							
aac	cag	ctg	act	gcg	acg	ggg	aca	aat	ttt	ttt	ctg	acg	aga	tgg	cag	40080		
Asn	Gln	Leu	Thr	Ala	Thr	Gly	Thr	Asn	Phe	Phe	Leu	Thr	Arg	Trp	Gln			
			855				860				865							
tat	gcc	tcg	cag	ggc	tat	aac	acc	cta	tcc	gat	gtg	ctc	gac	agt	tat	40128		
Tyr	Ala	Ser	Gln	Gly	Tyr	Asn	Thr	Leu	Ser	Asp	Val	Leu	Asp	Ser	Tyr			
			870				875				880				885			
cga	cat	aat	ggc	aac	cgt	cta	tgg	tcg	tgg	cgg	gaa	aat	ttg	cag	ccg	40176		
Arg	His	Asn	Gly	Asn	Arg	Leu	Trp	Ser	Trp	Arg	Glu	Asn	Leu	Gln	Pro			
			890				895				900							
agc	tcg	cgt	act	acc	ctg	atg	ttg	agt	cag	tca	tgg	ggg						

ggc aat ctg agt tta acc ggt tcc cgt acc gac tgg cgt aat cgc ccc	40272
Gly Asn Leu Ser Leu Thr Gly Ser Arg Thr Asp Trp Arg Asn Arg Pro	
920 925 930	
ggc cat gat gac agc tac gga ctg agt tgg gga acc tct atc gga ggg	40320
Gly His Asp Asp Ser Tyr Gly Leu Ser Trp Gly Thr Ser Ile Gly Gly	
935 940 945	
ggc tcg ctg tca ttg aac tgg aat caa aac aga acg ctg tgg cgc aat	40368
Gly Ser Leu Ser Leu Asn Trp Asn Gln Asn Arg Thr Leu Trp Arg Asn	
950 955 960 965	
ggc gcg cac cgt aaa gag aac ata acc agc ctg tgg ttc agt atg cca	40416
Gly Ala His Arg Lys Glu Asn Ile Thr Ser Leu Trp Phe Ser Met Pro	
970 975 980	
tta agc cgc tgg acg ggg aat aat gta agt gct agt tgg cag atg act	40464
Leu Ser Arg Trp Thr Gly Asn Asn Val Ser Ala Ser Trp Gln Met Thr	
985 990 995	
tca cca tca cac ggt ggt cag acg caa caa gtg ggg gtc aac gga gag	40512
Ser Pro Ser His Gly Gly Gln Thr Gln Gln Val Gly Val Asn Gly Glu	
1000 1005 1010	
gca ttc agt cag caa ctg gat tgg gag gtg cgt cag agt tac cgt gcc	40560
Ala Phe Ser Gln Gln Leu Asp Trp Glu Val Arg Gln Ser Tyr Arg Ala	
1015 1020 1025	
gat gcc ccg cca ggt ggt ggt aat aac agc gca ttg cac ttg gca tgg	40608
Asp Ala Pro Pro Gly Gly Gly Asn Asn Ser Ala Leu His Leu Ala Trp	
1030 1035 1040 1045	
aat ggg gat tac ggc ctg tta ggt ggt gac tat agc tac agc cgg gcg	40656
Asn Gly Asp Tyr Gly Leu Leu Gly Gly Asp Tyr Ser Tyr Ser Arg Ala	
1050 1055 1060	
atg cgc cag atg gga gtc aat atc gcg gga ggt ata gtt atc cac cat	40704
Met Arg Gln Met Gly Val Asn Ile Ala Gly Gly Ile Val Ile His His	
1065 1070 1075	
cat ggt gtg acg ctg ggg caa cct ttg caa ggc tca gtg gcg ctg gtt	40752
His Gly Val Thr Leu Gly Gln Pro Leu Gln Gly Ser Val Ala Leu Val	
1080 1085 1090	
gaa gcg cca ggg gcc tcg ggg gtg cca gtt ggc ggc tgg cct ggc gtt	40800
Glu Ala Pro Gly Ala Ser Gly Val Pro Val Gly Gly Trp Pro Gly Val	
1095 1100 1105	
aag acg gat ttt cgt ggc gac acc aca gtg ggc aac ctg aac gtc tat	40848
Lys Thr Asp Phe Arg Gly Asp Thr Thr Val Gly Asn Leu Asn Val Tyr	
1110 1115 1120 1125	
cag gag aat aca gtc agc ctc gat ccg tcg cga cta ccg gat gac gca	40896
Gln Glu Asn Thr Val Ser Leu Asp Pro Ser Arg Leu Pro Asp Asp Ala	
1130 1135 1140	
gag gtc aca caa acc gat gtg cgc gtg gtg cca acc gaa ggg gcg gtg	40944
Glu Val Thr Gln Thr Asp Val Arg Val Val Pro Thr Glu Gly Ala Val	
1145 1150 1155	

WO 00/73336

PCT/SE00/01079

27

gtg gaa gcg aag ttt cac act cgc atc ggg gcc agg gca ctg atg acg	40992
Val Glu Ala Lys Phe His Thr Arg Ile Gly Ala Arg Ala Leu Met Thr	
1160 1165 1170	
ctg aaa cgg gaa gat ggt agc gcc att cct ttc ggg gcg cag gtt aca	41040
Leu Lys Arg Glu Asp Gly Ser Ala Ile Pro Phe Gly Ala Gln Val Thr	
1175 1180 1185	
gtc aat ggg cag gat ggc agt gct gct ctg gtg gat act gat agc cag	41088
Val Asn Gly Gln Asp Gly Ser Ala Ala Leu Val Asp Thr Asp Ser Gln	
1190 1195 1200 1205	
gtt tat ctc act ggt ttg gcg gat aag ggc gaa ctg acg gtg aaa tgg	41136
Val Tyr Leu Thr Gly Leu Ala Asp Lys Gly Glu Leu Thr Val Lys Trp	
1210 1215 1220	
gga gca cag caa tgt cgg gtt aac tac cgc cta cct gcc cac aag gga	41184
Gly Ala Gln Gln Cys Arg Val Asn Tyr Arg Leu Pro Ala His Lys Gly	
1225 1230 1235	
atc gcg ggc ttg tat caa atg agc ggt ctc tgc aga tag ccgattctga	41233
Ile Ala Gly Leu Tyr Gln Met Ser Gly Leu Cys Arg	
1240 1245 1250	
aggagagaat a atg tgg atg aaa ata cag cga gtg aaa acg gtt atc tat	41283
Met Trp Met Lys Ile Gln Arg Val Lys Thr Val Ile Tyr	
1255 1260	
agc gta agc tta ctg gtc gct gcc agt agc ttg gtg ccg ata gcg aac	41331
Ser Val Ser Leu Leu Val Ala Ala Ser Ser Leu Val Pro Ile Ala Asn	
1265 1270 1275	
gcc gca gaa aaa ctt cag aca acg cta cgt gta ggt act tac ttt cgg	41379
Ala Ala Glu Lys Leu Gln Thr Thr Leu Arg Val Gly Thr Tyr Phe Arg	
1280 1285 1290 1295	
gct ggg cac gtg cca gat ggg atg gtg ctt gcg caa gcc tgg gtg act	41427
Ala Gly His Val Pro Asp Gly Met Val Leu Ala Gln Gly Trp Val Thr	
1300 1305 1310	
tat cac ggc agt cac agc ggg ttt cgg gta tgg agc gat gag caa aag	41475
Tyr His Gly Ser His Ser Gly Phe Arg Val Trp Ser Asp Glu Gln Lys	
1315 1320 1325	
gcg ggt aac acg cct acc gta ttg ctg ctg agc ggg caa cag gat cct	41523
Ala Gly Asn Thr Pro Thr Val Leu Leu Leu Ser Gly Gln Gln Asp Pro	
1330 1335 1340	
cgc cat cac att cag gtt cgc ctg gag ggc gag ggg tgg caa cca gat	41571
Arg His His Ile Gln Val Arg Leu Glu Gly Glu Gly Trp Gln Pro Asp	
1345 1350 1355	
acg gtg agt ggt cgt ggc gcc att tta aga acc gct gca gat aac gcc	41619
Thr Val Ser Gly Arg Gly Ala Ile Leu Arg Thr Ala Ala Asp Asn Ala	
1360 1365 1370 1375	
agt ttc agt gtg gtc gtt gat ggc aat cag gaa gtg cct gcg gac acc	41667
Ser Phe Ser Val Val Val Asp Gly Asn Gln Glu Val Pro Ala Asp Thr	
1380 1385 1390	
tgg acg ctg gat ttt aag gcc tgt gca ttg gcg cag gag gat acg tag	41715

Trp Thr Leu Asp Phe Lys Ala Cys Ala Leu Ala Gln Glu Asp Thr
 1395 1400 1405

ccgtctgttc cactcactact tcctgtatca gtgaataagg cgaatactgt atatcaggtt 41775
 cgaggatgta ttgaaaattt actcaaggca aatatgggta gcaatcttca ttgcagaaaa 41835
 atcaattgct gattgatttt aaaatctgaa attcatcttt ttgtaggga gaggaatatt 41895
 atgtttcgta aaataattta acggacactg atgcctttat tatttctgtt ttgtggattt 41955
 gtttgattca ctcttttgtg agcgggggctt tataagcccc tgggtataagg tttgtttatc 42015
 tgtcagggtat tcatatgtga tatttaagat tttatgttta gggggctttt tcttgteccc 42075
 tcaggcgtaa aaataattta ttttttacat aaaggaataa agcatatgtc ttatgcacga 42135
 catttaccgg tattaatgta tcaccatgtc agtgataaac ccggacagat aaccttatct 42195
 ccccgtagct tccgggcgca gatgaaatgg ctggccgaat ctggctggaa aaccgttact 42255
 gcctgcagag gtggaagctt tttatcatgg tgcaagattg cctcgtaaaa gcgtcatgct 42315
 gacctttgat ggcggctggc tggataactg gttgcagggt tttccgggtgc tgcaggagtt 42375
 taatctgcat gcgcactctt ttcttgtgac cagtttgatc agtgacggac cggtcctgat 42435
 tcctgcaggc gaaccggtgt acttcatga tgagtgtcaa atgctgggta aacaaggccg 42495
 ggctgatgag gtcattgtgc gctgggtcaga ggtccgggag atgcacctca gtggccttgt 42555
 tgagtttcac tcgcacacgc acaccaccg acgctgggac cagaagcctg tgtcccgtaa 42615
 tccgtcggat ttgcttcgtg tcgatattct tcttagtcgt aagcggatga gggagatgct 42675
 gggttattgc agtcagcatc tgtgctggcc tgagggctgg tattgttctg actatattca 42735
 tgtggctgaa gagttggggg tcacataacct gtataccaca gaaaggcgta tgaacaatcc 42795
 agtcacgggt tcacagcgta ttggtcgtat caacgcaaag gagcgaaaga atgtgggctg 42855
 gctgaaacgt cgtctgtttt atcacaccac gcccggattt tcttcgctgc tggcccggca 42915
 taagggggca cgtcggatag ctgactgagc cagagaccag gatgaaagtg ctgcataccg 42975
 aatcctcccc catcatcggc gggcaggggt tgtaggctat atcccaaagt atggtgctga 43035
 ttttgagcag aaataagata acaccggagg ccgtgataga cccggttgcg cagaatctgg 43095
 aggcagcagg tcaactggcg agggcttcta cccgctggct tttggttatg ggagattttg 43155
 aatgtacaga ggcccagcgg gagtggttgt tgttgcgccg gaattattgc cttgcgcaga 43215
 tatcttcccc tggcgccagt aaagctggat atcagcgacg tgacgaaatg agaggagcct 43275
 gcacataggt ttgtgttttg agtaagtgtc ttatttaaac cgtctgttct gtttcctccg 43335
 ctttcacaaa taatgtcgag ccgggtgggg gactcaagta agaataatct ggcgatgttt 43395
 tgcttgtttc cacgggatac tttgttaggt gaacgataca attaatgcgc tccagactgc 43455

gtcacagaaa aggagaatgc ctttgcagaa cgggcgcacg acaatgaacc actttattat 43515
tggtatctgg ttcggcgaca accttgacga tcacgtctga gataggggtat ttacactgag 43575
tggtaaacag gttcaattag taaccggaga tggatgcaaa atcatgatcg attcagatgc 43635
tattttgcag ccaatagatt ttttattaag atgatatcaa ggacattgag gcacacaatg 43695
acgtatcagt aagtcgttga tagctcatct gatataagaa tttcttttat caacggaaga 43755
taatgatgga actgatcaat aatcgtggta tgcgagactg gatgatattt attaaagtgg 43815
cggaagtagg gaatctttcc cgggctgcgc gggaattaga tattagcatt tctgctgtca 43875
gtaaatcgct tagtcgcctt gagaattcta ttgagggtac tttacttcgg cgcgattcac 43935
atcacttaga actgactgga gctggtcaga cagcctatgc aagcatgaaa aggataacat 43995
cttcctttca gtccttgctg gatgaattgc gaaatccgga taaaattatc agagggagta 44055
taaaattttc ggctccggct attgtctgtg agtttcttgc caataagtgg atatgggaat 44115
ttacagctag ctatccggat acaaaaatct acctggattc acgagagcgt agcgattttt 44175
ttagtaaate cctggagttt gatgagctgg tttttaaaag tggcataatc gaaagtgagg 44235
atctcgtgta tcgaaagata agccctttta agttgggttct ttgtgagagt ccgaaatata 44295
tcagaaaata tggcaggatc tcacaccctg gcgatttgga aaatcacatt attgtgggtc 44355
ttcacaacca tggcttttcc ggacctctta ctcttttccg tcaggatgaa tcatacacta 44415
ttagtggcgc tgttaatgtt catttatctt ccaataatct tttgagtgtt ctttaatttg 44475
ttttagaagg aaaggggtatc aacctcatga ctccggcctg gcttgccacc aaatacttaa 44535
aaaataatga acttgaaatt atacttcctg aatggagggt tccagatctc cccatttatc 44595
ttgtatggcg tcatcgtcag tattattctc ctctatttca acgctttctg tcttttattg 44655
aagataaatg gaataatcgc ccacaaattg attttctgaa tgatgattaa cccgtttgga 44715
atggttttga tacgttcctg acttaaacc acatgatgac tgaattgagg catcgagata 44775
tgcgactggt cagccagtcg tcttttgacg atgccaata caaaacatga tgccgactga 44835
cggaatgat aatacgcgga aacaggacgg ggcgtgtttt gggcagccgg aagttaagcc 44895
cataccagaa acgttgcagt gtactgaaaa atggcgccag gttgcacctg ttcaaagatt 44955
ttctgaaggc gcaggagtat tcattactga tatcctccat tgcgccttcg ggaaccacac 45015
ggaccagcta ttttaccgat agtgttttaa aggcgtaagt aatgccgagc atgaagtcac 45075
tggaggcagc ctttgtgtct gcatcataag cggtatgttc atcaccagca tagtgatttt 45135
ttgaaatgct tactttgcca gcattaatgt atttataact ggcgtcaatc ataattatt 45195
ctgttacagc atattttgca ccgatacctg cgccccaggc aaagttattt tttgaagcag 45255
acagagtttc attaatacca aaaccaacag gaatgggtgtt attacttagc ttcacatgag 45315

cgaggccaac gcctgcgctg atatagggag taaatgccgt actattgtga aaatcataat 45375
 agccattaac catgtaagtg gtcattcgga cctgattttt tacatttatg tgtactggat 45435
 caccaaatgc aataatatcc tgcccgctt tagcatccgt ctcacctctg aaagtggat 45495
 ccagtttctaa acgtactgga agctggaatg gatcataaaa gtcataaccg atagcaacc 45555
 cgccgcaaaa aacgcctttg gtacggtcag gtaacgttgc atgaccatta actatctcat 45615
 cctggctgaa ggttgagttg attccataga cattgactac ggatgtcccc gctttcccgg 45675
 tgatatagat cccttctttt gctgatgcag tagcggacca ggctaccaca aggggaatga 45735
 tgcagactgc gaaaaagttt ttcatttcag aacctgcctt aatattgggc taaaagacaa 45795
 gtttcacggg ataggggtgtg atataacgat tacataaacg aagcccaaaa aacggctctat 45855
 tgtaacgctg ggttttctgt aagcgggtaa aaaatgagat gaagatttta aataacaata 45915
 cgataatcgt cggtatggaa atccatctcc tcgccaatt gccccacgta cggtttcact 45975
 tctacgttat gtaacgggta gtgtgagatg gagcgatgct gtaagaaaaa gatgaagatg 46035
 aatttgtacc cgacctggat aaagcccggt atcccggat aacgggcaaa aatatttact 46095
 caagtgcctg ggcgagatct tgttgtacct gttgacgctg ttctgggtgtt aagactttgc 46155
 ttaaatacaa ataataattta acccgataat agcgagcctg ttgttctatg ttactgaagg 46215
 ctgcaagctg ctgttttacg gcggcgctcat cccatttacc ggatttaatc acctctatca 46275
 gcgcaccgtc ttttaattccc ttcatagaaa tctgactgac gtcgggttcc agttgttggg 46335
 gaagtttttt gatccgggta atctgatcgt ttgtcagctt cagatgctgg acaataggat 46395
 cctggggcggg caggggagga ttggggacag cgggtggcgaa agcgccaaaa gaaacgccc 46455
 ccagagtcgc tgccagtaaa gttgtgcgta caaagttttt catgaagata tcctgataag 46515
 ggagtgatta accgtttttt ttaccacga atggcgagca attatcttag agcctatccc 46575
 agtagggcta ttttacttgc cattttggac ctgggcagtg ctcgcaaaa cgcgttagcg 46635
 ttttgaacgc cgctagcggc ggcccgaagg gcgagcgtag cgagtcaaac ctcacgtact 46695
 acgtgtacgc tccggttttt gcgcgctgtc cgtgtccaaa ctggctgcgc caataacgcc 46755
 tgggtgggata ggctcttagt cagaatacgt tgectgccac attacgccac gcgaatttgt 46815
 tttacggaga gttacggagt gaaacaatcc cgccgcggtg agcggcaggt tgctt 46870

<210> 2

<211> 166

<212> PRT

<213> Salmonella typhimurium

<400> 2

Met Lys Ser Ile Lys Lys Leu Ile Ile Ala Ser Ala Leu Ser Met Met

WO 00/73336

PCT/SE00/01079

31

1	5	10	15
Ala Ala Ser Cys Tyr Ala Gly Ser Phe Leu Pro Asn Ser Glu Gln Gln	20	25	30
Lys Ser Val Asp Ile Val Phe Ser Ser Pro Gln Asp Leu Thr Val Ser	35	40	45
Leu Ile Pro Val Ser Gly Leu Lys Ala Gly Lys Asn Ala Pro Ser Ala	50	55	60
Lys Ile Ala Lys Leu Val Val Asn Ser Thr Thr Leu Lys Glu Phe Gly	65	70	75
Val Arg Gly Ile Ser Asn Asn Val Val Asp Ser Thr Gly Thr Ala Trp	85	90	95
Arg Val Ala Gly Lys Asn Thr Gly Lys Glu Ile Gly Val Gly Leu Ser	100	105	110
Ser Asp Ser Leu Arg Arg Ser Asp Ser Thr Glu Lys Trp Asn Gly Val	115	120	125
Asn Trp Met Thr Phe Asn Ser Asn Asp Thr Leu Asp Ile Val Leu Thr	130	135	140
Gly Pro Ala Gln Asn Val Thr Ala Asp Thr Tyr Pro Ile Thr Leu Asp	145	150	155
Val Val Gly Tyr Gln Pro	165		

<210> 3
 <211> 245
 <212> PRT
 <213> Salmonella typhimurium

<400> 3
 Met Lys Ile Val Asn Phe Ala Val Met Ala Val Ala Leu Phe Ala Thr
 1 5 10 15
 Asn Ser Met Val Ser Val Tyr Ala Val Asn Gln Gln Leu Asn Ser Ala
 20 25 30
 Thr Lys Leu Phe Ser Val Lys Leu Gly Ala Thr Arg Val Ile Tyr His
 35 40 45
 Ala Gly Thr Ala Gly Ala Thr Leu Ser Val Ser Asn Pro Gln Asn Tyr
 50 55 60
 Pro Ile Leu Val Gln Ser Ser Val Lys Ala Ala Asp Lys Ser Ser Pro
 65 70 75 80
 Ala Pro Phe Leu Val Met Pro Pro Leu Phe Arg Leu Glu Ala Asn Gln
 85 90 95
 Gln Ser Gln Leu Arg Ile Val Arg Thr Gly Gly Asp Met Pro Thr Asp
 100 105 110
 Arg Glu Thr Leu Gln Trp Val Cys Ile Lys Ala Val Pro Pro Glu Asn

WO 00/73336

PCT/SE00/01079

32

115	120	125
Glu Pro Ser Asp Thr Gln Ala Lys Gly Ala Thr Leu Asp Leu Asn Leu		
130	135	140
Ser Ile Asn Ala Cys Asp Lys Leu Ile Phe Arg Pro Asp Ala Val Lys		
145	150	155
Gly Thr Pro Glu Asp Val Ala Gly Asn Leu Arg Trp Val Glu Thr Gly		
165	170	175
Asn Lys Leu Lys Val Glu Asn Pro Thr Pro Phe Tyr Met Asn Leu Ala		
180	185	190
Ser Val Thr Val Gly Gly Lys Pro Ile Thr Gly Leu Glu Tyr Val Pro		
195	200	205
Pro Phe Ala Asp Lys Thr Leu Asn Met Pro Gly Ser Ala His Gly Asp		
210	215	220
Ile Glu Trp Arg Val Ile Thr Asp Phe Gly Gly Glu Ser His Pro Phe		
225	230	235
His Tyr Val Leu Lys		
245		

<210> 4
 <211> 836
 <212> PRT
 <213> Salmonella typhimurium

<400> 4

Met Lys Phe Lys Gln Pro Ala Leu Leu Leu Phe Ile Ala Gly Val Val		
1	5	10
His Cys Ala Asn Ala His Thr Tyr Thr Phe Asp Ala Ser Met Leu Gly		
20	25	30
Asp Ala Ala Lys Gly Val Asp Met Ser Leu Phe Asn Gln Gly Leu Gln		
35	40	45
Gln Pro Gly Thr Tyr Arg Val Asp Val Met Val Asn Gly Lys Arg Val		
50	55	60
Asp Thr Arg Asp Val Val Phe Lys Leu Glu Lys Asp Gly Gln Gly Thr		
65	70	75
Pro Val Leu Ala Pro Cys Leu Thr Val Ser Gln Leu Ser Arg Tyr Gly		
85	90	95
Val Lys Thr Glu Asp Tyr Pro Gln Leu Trp Lys Ala Ala Lys Pro Pro		
100	105	110
Asp Glu Cys Ala Asp Leu Thr Ala Ile Pro Gln Ala Lys Ala Val Leu		
115	120	125
Asp Ile Asn Asn Gln Gln Leu Gln Leu Ser Ile Pro Gln Leu Ala Leu		
130	135	140
Arg Pro Glu Phe Lys Gly Ile Ala Pro Glu Asp Leu Trp Asp Asp Gly		

WO 00/73336

PCT/SE00/01079

33

145						150						155						160
Ile	Pro	Ala	Phe	Leu	Met	Asn	Tyr	Ser	Ala	Arg	Thr	Thr	Gln	Thr	Asp			
				165					170					175				
Tyr	Lys	Met	Asp	Met	Val	Gly	Arg	Asp	Asn	Ser	Ser	Trp	Val	Gln	Leu			
			180					185					190					
Gln	Pro	Gly	Ile	Asn	Ile	Gly	Ala	Trp	Arg	Val	Arg	Asn	Ala	Thr	Ser			
		195					200					205						
Trp	Gln	Arg	Ser	Ser	Gln	Leu	Ser	Gly	Lys	Trp	Gln	Ala	Ala	Tyr	Thr			
	210					215					220							
Tyr	Ala	Glu	Arg	Gly	Leu	Tyr	Ser	Leu	Lys	Ser	Arg	Leu	Thr	Leu	Gly			
225					230					235					240			
Gln	Lys	Thr	Ser	Gln	Gly	Glu	Ile	Phe	Asp	Ser	Val	Pro	Phe	Thr	Gly			
				245					250					255				
Val	Met	Leu	Ala	Ser	Asp	Asp	Asn	Met	Val	Pro	Tyr	Ser	Glu	Arg	Gln			
		260						265					270					
Phe	Ala	Pro	Val	Val	Arg	Gly	Ile	Ala	Arg	Thr	Gln	Ala	Arg	Val	Glu			
	275						280					285						
Val	Lys	Gln	Asn	Gly	Tyr	Thr	Ile	Tyr	Asn	Thr	Thr	Val	Ala	Pro	Gly			
	290					295					300							
Pro	Phe	Ala	Leu	Arg	Asp	Leu	Ser	Val	Thr	Asp	Ser	Ser	Gly	Asp	Leu			
305					310					315					320			
His	Val	Thr	Val	Trp	Glu	Ala	Asp	Gly	Ser	Thr	Gln	Met	Phe	Val	Val			
				325					330				335					
Pro	Tyr	Gln	Thr	Pro	Ala	Ile	Ala	Leu	His	Gln	Gly	Tyr	Leu	Lys	Tyr			
		340					345						350					
Ser	Leu	Leu	Ala	Gly	Arg	Tyr	Arg	Ser	Ser	Asp	Ser	Ala	Thr	Asp	Lys			
	355						360					365						
Arg	Gln	Ile	Ala	Gln	Ala	Thr	Leu	Met	Tyr	Gly	Leu	Pro	Trp	Asn	Leu			
	370					375					380							
Thr	Ala	Tyr	Gly	Gly	Ile	Gln	Ser	Ala	Thr	His	Asn	Gln	Ala	Ala	Leu			
385					390					395					400			
Leu	Gly	Leu	Gly	Gly	Ser	Leu	Gly	Arg	Trp	Gly	Ser	Leu	Ser	Val	Asp			
			405						410					415				
Gly	Ser	Asp	Thr	His	Ser	Gln	Arg	Gln	Gly	Glu	Ala	Val	Gln	Gln	Gly			
		420						425					430					
Ala	Ser	Trp	Arg	Leu	Arg	Tyr	Ser	Asn	Gln	Leu	Thr	Ala	Thr	Gly	Thr			
	435						440					445						
Asn	Phe	Phe	Leu	Thr	Arg	Trp	Gln	Tyr	Ala	Ser	Gln	Gly	Tyr	Asn	Thr			
	450					455					460							
Leu	Ser	Asp	Val	Leu	Asp	Ser	Tyr	Arg	His	Asn	Gly	Asn	Arg	Leu	Trp			
465					470					475					480			

WO 00/73336

PCT/SE00/01079

34

Ser	Trp	Arg	Glu	Asn	Leu	Gln	Pro	Ser	Ser	Arg	Thr	Thr	Leu	Met	Leu	485	490	495
Ser	Gln	Ser	Trp	Gly	Arg	His	Leu	Gly	Asn	Leu	Ser	Leu	Thr	Gly	Ser	500	505	510
Arg	Thr	Asp	Trp	Arg	Asn	Arg	Pro	Gly	His	Asp	Asp	Ser	Tyr	Gly	Leu	515	520	525
Ser	Trp	Gly	Thr	Ser	Ile	Gly	Gly	Gly	Ser	Leu	Ser	Leu	Asn	Trp	Asn	530	535	540
Gln	Asn	Arg	Thr	Leu	Trp	Arg	Asn	Gly	Ala	His	Arg	Lys	Glu	Asn	Ile	545	550	555
Thr	Ser	Leu	Trp	Phe	Ser	Met	Pro	Leu	Ser	Arg	Trp	Thr	Gly	Asn	Asn	565	570	575
Val	Ser	Ala	Ser	Trp	Gln	Met	Thr	Ser	Pro	Ser	His	Gly	Gly	Gln	Thr	580	585	590
Gln	Gln	Val	Gly	Val	Asn	Gly	Glu	Ala	Phe	Ser	Gln	Gln	Leu	Asp	Trp	595	600	605
Glu	Val	Arg	Gln	Ser	Tyr	Arg	Ala	Asp	Ala	Pro	Pro	Gly	Gly	Gly	Asn	610	615	620
Asn	Ser	Ala	Leu	His	Leu	Ala	Trp	Asn	Gly	Asp	Tyr	Gly	Leu	Leu	Gly	625	630	635
Gly	Asp	Tyr	Ser	Tyr	Ser	Arg	Ala	Met	Arg	Gln	Met	Gly	Val	Asn	Ile	645	650	655
Ala	Gly	Gly	Ile	Val	Ile	His	His	His	Gly	Val	Thr	Leu	Gly	Gln	Pro	660	665	670
Leu	Gln	Gly	Ser	Val	Ala	Leu	Val	Glu	Ala	Pro	Gly	Ala	Ser	Gly	Val	675	680	685
Pro	Val	Gly	Gly	Trp	Pro	Gly	Val	Lys	Thr	Asp	Phe	Arg	Gly	Asp	Thr	690	695	700
Thr	Val	Gly	Asn	Leu	Asn	Val	Tyr	Gln	Glu	Asn	Thr	Val	Ser	Leu	Asp	705	710	715
Pro	Ser	Arg	Leu	Pro	Asp	Asp	Ala	Glu	Val	Thr	Gln	Thr	Asp	Val	Arg	725	730	735
Val	Val	Pro	Thr	Glu	Gly	Ala	Val	Val	Glu	Ala	Lys	Phe	His	Thr	Arg	740	745	750
Ile	Gly	Ala	Arg	Ala	Leu	Met	Thr	Leu	Lys	Arg	Glu	Asp	Gly	Ser	Ala	755	760	765
Ile	Pro	Phe	Gly	Ala	Gln	Val	Thr	Val	Asn	Gly	Gln	Asp	Gly	Ser	Ala	770	775	780
Ala	Leu	Val	Asp	Thr	Asp	Ser	Gln	Val	Tyr	Leu	Thr	Gly	Leu	Ala	Asp	785	790	795

WO 00/73336

PCT/SE00/01079

35

Lys Gly Glu Leu Thr Val Lys Trp Gly Ala Gln Gln Cys Arg Val Asn
 805 810 815

Tyr Arg Leu Pro Ala His Lys Gly Ile Ala Gly Leu Tyr Gln Met Ser
 820 825 830

Gly Leu Cys Arg
 835

<210> 5

<211> 156

<212> PRT

<213> Salmonella typhimurium

<400> 5

Met Trp Met Lys Ile Gln Arg Val Lys Thr Val Ile Tyr Ser Val Ser
 1 5 10 15

Leu Leu Val Ala Ala Ser Ser Leu Val Pro Ile Ala Asn Ala Ala Glu
 20 25 30

Lys Leu Gln Thr Thr Leu Arg Val Gly Thr Tyr Phe Arg Ala Gly His
 35 40 45

Val Pro Asp Gly Met Val Leu Ala Gln Gly Trp Val Thr Tyr His Gly
 50 55 60

Ser His Ser Gly Phe Arg Val Trp Ser Asp Glu Gln Lys Ala Gly Asn
 65 70 75 80

Thr Pro Thr Val Leu Leu Leu Ser Gly Gln Gln Asp Pro Arg His His
 85 90 95

Ile Gln Val Arg Leu Glu Gly Glu Gly Trp Gln Pro Asp Thr Val Ser
 100 105 110

Gly Arg Gly Ala Ile Leu Arg Thr Ala Ala Asp Asn Ala Ser Phe Ser
 115 120 125

Val Val Val Asp Gly Asn Gln Glu Val Pro Ala Asp Thr Trp Thr Leu
 130 135 140

Asp Phe Lys Ala Cys Ala Leu Ala Gln Glu Asp Thr
 145 150 155

SEQUENCE LISTING NO. 2

<110> Folkesson, Anders

<120> The complete sequence of the tcf insert of Salmonella enterica serovar Typhi.

<130> The tcf insert in Salmonella typhi

<140>

<141>

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 9253

<212> DNA

<213> Salmonella typhi

<220>

<221> CDS

<222> (1898)..(2608)

<223> tcfA putative fimbrial subunit

<220>

<221> CDS

<222> (2659)..(3234)

<223> tcfB putative fimbrial subunit

<220>

<221> CDS

<222> (3360)..(6029)

<223> tcfC putative fimbrial subunit

<220>

<221> CDS

<222> (6052)..(7131)

<223> tcfD putative fimbrial subunit

<220>

<221> CDS

<222> (7264)..(7719)

<223> tinR putative transcriptional regulator

<400> 1

```

tgtaagtcac ccgcataatc gagccattca catttagaga tcatccggca taatcaatct 60
gccaacgcag gagatcgctg tgcgtaaagc ccgtattact gcgcaccaga tcatcgctgt 120
gattagatca gttgaatccg gacggactgt taaagatgtc taccgggagg ccggtatttc 180
tgaagccacc agggacaact ggaagtctgg atacggcggc atggaagctt ctgatattaa 240
atcttgagga tgtcaacgcc aggatttatg gtcgtttttc gctattttta atatccgctg 300
tttgatcact tctgctgtcc gctttccgcc atttcattct cactgattgg cgttgcgctt 360
ttggtcagcg ccccgacttt gcgtttttcc ttcagttggt aactttctcc tttgatattc 420

```

agtgtggttg	agtgatgcag	tagccgatcc	aggatcgcctg	ttgcccagcac	gttatcaccg	480
aacatctctc	cccagttctgc	gaagcctttg	tttgacgtca	ggataatgct	cgttttttca	540
taccgtcggc	tcagcagtcg	gaagaacaga	ctggcttctt	cactgggtcat	tggcaggtaa	600
cctatttcgt	ccaggatcag	ccccgcgcga	tagctcagtt	gttgtagctg	gcgctccagg	660
cggttttcca	gtttcgcttt	catcagcgtc	taccaacctg	tcctgcggca	tgaacaacac	720
ccgatggccc	acatctgccc	ctttcacacc	gggggcagcg	gccagggtggg	ttttctccac	780
tccggggggc	ccagcaggat	cacattctcg	cagcgcctcca	cgaacgccag	accggccaac	840
ccccggacga	ccttacgata	gatgcctggc	tsgaagctga	agtcgaactg	ctccagcgtt	900
ttgactcatg	gcagacgagc	ctgtttcagc	cgggattcca	ttccgcgctg	atgtctgccg	960
ttctattctt	gctgcagcgc	catgcacagg	aatgtcgact	tattttgggc	tgacagaggc	1020
attgggtcgt	aagacttgta	tattcatgtt	gcttactcgc	acaaaagggg	gaaaggaacc	1080
gtaaacaaca	ttgacaggta	agggactggc	atcaatttga	atgggtatttt	ttataacatt	1140
atgtttttaa	agggtgaattg	tattttcatg	gtgagttcgt	ctgttttata	ttgttgtttg	1200
tggaatattt	agctaataatt	taatctaaaa	atagtgtatt	atattgatra	cactttgctg	1260
gagagggtgta	aacatcaagc	gtaaccatat	gatgtatata	agttttttgtt	tgctgatata	1320
atatttttaa	cagatattga	gcaagtaaat	ctgatctaac	tgtaacttta	gttttctaaa	1380
ttaattactt	tgcttacttt	tttttacctg	gttttgtaaa	acctcatgat	gatcagtcct	1440
tttgtggctt	tgtttaaggc	ttatttggtt	ttgtagtcctg	aattgtatct	ccctcctgga	1500
gggctttctt	tagattctct	gtctcctacg	ttgttatgtt	acgtattttgt	tgctttgaag	1560
gagggggaaa	tacagttcca	tttatctgag	taagtcaggc	acacagtaac	aactttctta	1620
tgaagaattt	ccaaaatttt	tactgcggcg	ttattaattg	ttcagcgaatt	cttacagata	1680
tgtcgttcgc	ttttgggtgaa	tgaaatccgt	ggacttttat	ttactaattt	tttctttctt	1740
gaaaaaaaca	gagggtattga	gcgaaaaatt	ttattccgta	tgatgccctc	cacacaaaat	1800
gtattaacac	tgaatcgtaa	tttgcttctt	tatgctgata	actttctgtc	tatgctaata	1860
ctaaaattta	gatgactttt	atacggtaaa	atctgggt	atg	aat ttt aaa gat act	1915
				Met	Asn Phe Lys Asp Thr	

ctt	ccc	ggg	gtg	ttt	ctc	tgt	gtc	gct	atg	ttt	gca	tgt	ggt	cat	gcc	1963
Leu	Pro	Gly	Val	Phe	Leu	Cys	Val	Ala	Met	Phe	Ala	Cys	Gly	His	Ala	
			10					15					20			
agg	gcg	aat	atg	ctc	gtt	tat	ccc	atg	gcg	gca	gaa	att	aat	agt	agc	2011
Arg	Ala	Asn	Met	Leu	Val	Tyr	Pro	Met	Ala	Ala	Glu	Ile	Asn	Ser	Ser	
		25					30					35				

cgc gaa gag gcc acc tcg ctg ttc gtc tat tct aaa tca gat cat gtg 2059
 Arg Glu Glu Ala Thr Ser Leu Phe Val Tyr Ser Lys Ser Asp His Val
 40 45 50

caa tat att cga aca aga atc atg cgt att gaa cac ccc ggt atg cca 2107
 Gln Tyr Ile Arg Thr Arg Ile Met Arg Ile Glu His Pro Gly Met Pro
 55 60 65 70

cag gag aag gag gta cca gca ggg aat gat ata gag aca gga ctt gtt 2155
 Gln Glu Lys Glu Val Pro Ala Gly Asn Asp Ile Glu Thr Gly Leu Val
 75 80 85

gtc tcc ccg gag aaa ttt gct ctt tcc ccg gga aca aaa aaa aca ata 2203
 Val Ser Pro Glu Lys Phe Ala Leu Ser Pro Gly Thr Lys Lys Thr Ile
 90 95 100

cgt gtt atc agt act cag gca ccg gaa aga gag gaa gcc tgg cgg gta 2251
 Arg Val Ile Ser Thr Gln Ala Pro Glu Arg Glu Glu Ala Trp Arg Val
 105 110 115

tac ttc gag gct gtt cct gaa ctg gaa gat gat cca cag gca ggc gga 2299
 Tyr Phe Glu Ala Val Pro Glu Leu Glu Asp Asp Pro Gln Ala Gly Gly
 120 125 130

aag caa aat tca tcc gta agt gtg aat ctt gtc tgg ggg gtg ttg ctg 2347
 Lys Gln Asn Ser Ser Val Ser Val Asn Leu Val Trp Gly Val Leu Leu
 135 140 145 150

cgt gtt tct ccg tca gac ccc agg cct gcg ctg gta acg gac ggt cac 2395
 Arg Val Ser Pro Ser Asp Pro Arg Pro Ala Leu Val Thr Asp Gly His
 155 160 165

cac ctg ctg aat acg gga aac aca cgg ctt tct ctt att cgg gct ggc 2443
 His Leu Leu Asn Thr Gly Asn Thr Arg Leu Ser Leu Ile Arg Ala Gly
 170 175 180

aac tgc gac acc aca tgc cac tgg cag aat ata ggc aaa agt att tat 2491
 Asn Cys Asp Thr Thr Cys His Trp Gln Asn Ile Gly Lys Ser Ile Tyr
 185 190 195

ccc ggc ggg agt gct gat att ccg gcc gga ata aaa agt aat gca ttt 2539
 Pro Gly Gly Ser Ala Asp Ile Pro Ala Gly Ile Lys Ser Asn Ala Phe
 200 205 210

cgt gtg gaa tat cgt acg ggt gca aat tca ccg gta atc tct gct gat 2587
 Arg Val Glu Tyr Arg Thr Gly Ala Asn Ser Pro Val Ile Ser Ala Asp
 215 220 225 230

tta aca gca gcc gga aag taa aaacacacgg agcgtacgct ataccctaca 2638
 Leu Thr Ala Ala Gly Lys
 235

tttattctca gggggagcgg atg tat acc gag tgt aca tat atc act gta ata 2691
 Met Tyr Thr Glu Cys Thr Tyr Ile Thr Val Ile
 240 245

aac aac aaa gca agg tta ttt ttt atg aac atg aaa aca tct ttt att 2739
 Asn Asn Lys Ala Arg Leu Phe Phe Met Asn Met Lys Thr Ser Phe Ile

WO 00/73336

PCT/SE00/01079

39

250	255	260	
gcc gca gct gtg gca ttg gcc acc gtt tat tct ttt tct gtt tct gcg			2787
Ala Ala Ala Val Ala Leu Ala Thr Val Tyr Ser Phe Ser Val Ser Ala			
265	270	275	280
gtc cag aag gat att acc gtc act gcc aat att gac agt aca ctt gaa			2835
Val Gln Lys Asp Ile Thr Val Thr Ala Asn Ile Asp Ser Thr Leu Glu			
	285	290	295
ctg ctg cag gcc gat ggt tca tcc ctc ccg tcg act atg aag ctg gat			2883
Leu Leu Gln Ala Asp Gly Ser Ser Leu Pro Ser Thr Met Lys Leu Asp			
	300	305	310
ttc atg ccg ggt aag ggc ctg gtc cat aaa tca ctc cag acc cgc ctt			2931
Phe Met Pro Gly Lys Gly Leu Val His Lys Ser Leu Gln Thr Arg Leu			
	315	320	325
tac agc aac gat cag acc aag tcg gtc aat gta aaa ctg ttg aat gct			2979
Tyr Ser Asn Asp Gln Thr Lys Ser Val Asn Val Lys Leu Leu Asn Ala			
	330	335	340
cca caa ctc atc aac gtc ctg gat ccc acc aaa acc att gat atg gaa			3027
Pro Gln Leu Ile Asn Val Leu Asp Pro Thr Lys Thr Ile Asp Met Glu			
	345	350	355
gtg act ctg gga gga cgg tca ctg acc acc acc aat tct gta ctg gaa			3075
Val Thr Leu Gly Gly Arg Ser Leu Thr Thr Thr Asn Ser Val Leu Glu			
	365	370	375
gct aaa acc ctg ttc ccg gac gga aaa act ggc gat gct tca gct ctg			3123
Ala Lys Thr Leu Phe Pro Asp Gly Lys Thr Gly Asp Ala Ser Ala Leu			
	380	385	390
ctg aac ctg gat att ggt cag aag gct gga gca gcc tta caa aac ctg			3171
Leu Asn Leu Asp Ile Gly Gln Lys Ala Gly Ala Ala Leu Gln Asn Leu			
	395	400	405
cct gcc ggt gaa tac agc gga ttg gtc agt ctg gtg att tca cag gct			3219
Pro Ala Gly Glu Tyr Ser Gly Leu Val Ser Leu Val Ile Ser Gln Ala			
	410	415	420
gtc act gcc ggc taa taactgggta ttagctcttc atctgatccg gttttggggg			3274
Val Thr Ala Gly			
425			
gcaccgttcg tacctgaacc ggatccggta ttgatcttat tattcattgc aattcagggtc			3334
tctttacgtg agtcgttatt tctgg atg tat tat tta ctg gga ttg tgc agt			3386
	Met Tyr Tyr Leu Leu Gly Leu Cys Ser		
	430	435	
ttt acc agc cag gca act ctt att ccc cct cct gga ttt gaa tct ctg			3434
Phe Thr Ser Gln Ala Thr Leu Ile Pro Pro Pro Gly Phe Glu Ser Leu			
	440	445	450
ctg gaa gga cag act gag caa att gaa gtg ttg cta cca ggg cat tca			3482
L u Glu Gly Gln Thr Glu Gln Ile Glu Val Leu Leu Pro Gly His Ser			
	455	460	465
			470

ctg gga tta ttt ccg gtg gtg gtt aaa ccg gac acc gtg cag ttc atg	3530
Leu Gly Leu Phe Pro Val Val Val Lys Pro Asp Thr Val Gln Phe Met	
475 480 485	
tcc cca ttg atg gta ctt gaa agc agt ggg ctt gcc gcg ttg ccg gcc	3578
Ser Pro Leu Met Val Leu Glu Ser Ser Gly Leu Ala Ala Leu Pro Ala	
490 495 500	
gca gaa cgg caa aaa gcg ctg gct gca ctc agc cgt ccg ttg cta cgt	3626
Ala Glu Arg Gln Lys Ala Leu Ala Ala Leu Ser Arg Pro Leu Leu Arg	
505 510 515	
aac agc aat ctg gtc tgt ggt gtc tca gaa gca aaa gac agc agc gag	3674
Asn Ser Asn Leu Val Cys Gly Val Ser Glu Ala Lys Asp Ser Ser Glu	
520 525 530	
tgt ggt tac gtg gca aca gat aaa gag gat gtt gcg gtt att ttt gat	3722
Cys Gly Tyr Val Ala Thr Asp Lys Glu Asp Val Ala Val Ile Phe Asp	
535 540 545 550	
gag aac aac gct cag tta tct ttg ttt ctt aac ccg gac tgg ttg ccg	3770
Glu Asn Asn Ala Gln Leu Ser Leu Phe Leu Asn Arg Asp Trp Leu Pro	
555 560 565	
gat gaa gaa cga cgt gat aaa cgc tgg ctg act ccg acc ccg gag ggt	3818
Asp Glu Glu Arg Arg Asp Lys Arg Trp Leu Thr Pro Thr Pro Glu Gly	
570 575 580	
gtc agc gca ttt att cac cgc cag acg ctg tat ctg agt gat gat ctc	3866
Val Ser Ala Phe Ile His Arg Gln Thr Leu Tyr Leu Ser Asp Asp Leu	
585 590 595	
cac agt cgt aat atg aca ctg aat ggt agc ggt gcc ctg ggg ctt ggt	3914
His Ser Arg Asn Met Thr Leu Asn Gly Ser Gly Ala Leu Gly Leu Gly	
600 605 610	
gac ggt cgt tat ctg gga ggc gac tgg gcg gct atc tgg aat cag tca	3962
Asp Gly Arg Tyr Leu Gly Gly Asp Trp Ala Ala Ile Trp Asn Gln Ser	
615 620 625 630	
gaa cat tac aat aac agt cag gcc tgg ttt gac aat ctg ttt gtc cgt	4010
Glu His Tyr Asn Asn Ser Gln Ala Trp Phe Asp Asn Leu Phe Val Arg	
635 640 645	
cag gat ctc ggc aat cag tat tat ctc cag gct ggt ccg atg gat cag	4058
Gln Asp Leu Gly Asn Gln Tyr Tyr Leu Gln Ala Gly Arg Met Asp Gln	
650 655 660	
ccg aat ctg tcc agc gcc acg ggg ggg gat ttt ggg ttc agt ctg ctt	4106
Arg Asn Leu Ser Ser Ala Thr Gly Gly Asp Phe Gly Phe Ser Leu Leu	
665 670 675	
ccc ctg agc cgg ttt gat gga tta cga acc ggg acc acc caa gct tat	4154
Pro Leu Ser Arg Phe Asp Gly Leu Arg Thr Gly Thr Thr Gln Ala Tyr	
680 685 690	
gtt aac cat gag gtg gac cat aat gcc act ccg gtt atg gtt cag gtt	4202
Val Asn His Glu Val Asp His Asn Ala Thr Pro Val Met Val Gln Val	
695 700 705 710	

PCT/SE00/01079

41

acc	cga	aat	gcc	cgt	att	gat	att	tat	cgt	ggc	agc	gag	ttg	ctg	ggg	4250
Thr	Arg	Asn	Ala	Arg	Ile	Asp	Ile	Tyr	Arg	Gly	Ser	Glu	Leu	Leu	Gly	
				715					720					725		
agt	cag	ttc	ctg	acc	ccg	gga	atg	cat	acc	ctg	gat	act	cat	tct	ctt	4298
Ser	Gln	Phe	Leu	Thr	Pro	Gly	Met	His	Thr	Leu	Asp	Thr	His	Ser	Leu	
				730					735					740		
cca	ccg	gga	agc	tat	cct	ctg	gcg	ttg	cgg	gtg	tat	gag	gat	ggg	att	4346
Pro	Pro	Gly	Ser	Tyr	Pro	Leu	Ala	Leu	Arg	Val	Tyr	Glu	Asp	Gly	Ile	
				745					750					755		
ctg	cgg	cga	acg	gag	acc	cag	ccc	ttc	agt	aag	ggg	ggc	aat	agc	ttc	4394
Leu	Arg	Arg	Thr	Glu	Thr	Gln	Pro	Phe	Ser	Lys	Gly	Gly	Asn	Ser	Phe	
				760					765					770		
agt	gca	cag	acc	cag	tgg	ttt	att	cag	ggc	ggg	ctg	gaa	gat	acc	ggg	4442
Ser	Ala	Gln	Thr	Gln	Trp	Phe	Ile	Gln	Gly	Gly	Leu	Glu	Asp	Thr	Gly	
				775					780					785		
gat	aaa	gcc	agc	cat	tat	gac	ggc	gag	act	gtc	atg	gct	gcc	gga	ttc	4490
Asp	Lys	Ala	Ser	His	Tyr	Asp	Gly	Glu	Thr	Val	Met	Ala	Ala	Gly	Phe	
				795					800					805		
caa	act	ggg	ctg	cgg	aaa	aat	atc	agt	ctg	acc	gaa	ggc	atc	tct	ctg	4538
Gln	Thr	Gly	Leu	Arg	Lys	Asn	Ile	Ser	Leu	Thr	Glu	Gly	Ile	Ser	Leu	
				810					815					820		
gca	cat	gag	gcc	tgg	tac	agt	gaa	acc	cga	ctg	aat	tca	cag	cat	gca	4586
Ala	His	Glu	Ala	Trp	Tyr	Ser	Glu	Thr	Arg	Leu	Asn	Ser	Gln	His	Ala	
				825					830					835		
gtg	ctg	gat	ggc	acg	ctg	gac	ctt	tct	gcc	ggg	ata	ctg	cat	ggg	aca	4634
Val	Leu	Asp	Gly	Thr	Leu	Asp	Leu	Ser	Ala	Gly	Ile	Leu	His	Gly	Thr	
				840					845					850		
gac	agc	acg	agc	ggc	aac	act	gag	cag	gtg	aca	tac	aac	gac	gga	ttt	4682
Asp	Ser	Thr	Ser	Gly	Asn	Thr	Glu	Gln	Val	Thr	Tyr	Asn	Asp	Gly	Phe	
				855					860					865		
tcc	gcg	agt	ctg	tgg	cgt	aac	cat	acg	gaa	agt	gat	gcc	tgt	agt	ggc	4730
Ser	Ala	Ser	Leu	Trp	Arg	Asn	His	Thr	Glu	Ser	Asp	Ala	Cys	Ser	Gly	
				875					880					885		
cgt	cat	cca	cag	tca	gtg	cat	gcc	agt	atg	acc	tgc	cag	act	tcg	atg	4778
Arg	His	Pro	Gln	Ser	Val	His	Ala	Ser	Met	Thr	Cys	Gln	Thr	Ser	Met	
				890					895					900		
aac	gcc	tcc	ctg	tcg	gtt	tcg	gtg	ggg	aac	tgg	tat	gcc	cta	ctg	gga	4826
Asn	Ala	Ser	Leu	Ser	Val	Ser	Val	Gly	Asn	Trp	Tyr	Gln	Ala	Leu	Gly	
				905					910					915		
tac	agt	acc	agc	agg	aca	gaa	ggc	cgg	ccg	gtt	tac	cgg	gga	tat	gat	4874
Tyr	Ser	Thr	Ser	Arg	Thr	Glu	Gly	Arg	Pro	Val	Tyr	Arg	Gly	Tyr	Asp	
				920					925					930		
gat	aac	agt	gac	aaa	gaa	aat	gtg	ttc	tgg	cga	cag	gca	tac	atc	cct	4922
Asp	Asn	Ser	Asp	Lys	Glu	Asn	Val	Phe								

WO 00/73336

PCT/SE00/01079

43

1175	1180	1185	1190	
tac ttc ctg aca ccc ggg cat ctg ctg gtt cac aac atc agc gcc agt				5690
Tyr Phe Leu Thr Pro Gly His Leu Leu Val His Asn Ile Ser Ala Ser				
	1195	1200	1205	
atg agc cga ctg tac gtt ggc cgc gta ctg gac aag gat ggc aga ccg				5738
Met Ser Arg Leu Tyr Val Gly Arg Val Leu Asp Lys Asp Gly Arg Pro				
	1210	1215	1220	
ctg ctg gac gca cag cca ctg aac tat cca ttt ttg tgc ttg gga cct				5786
Leu Leu Asp Ala Gln Pro Leu Asn Tyr Pro Phe Leu Ser Leu Gly Pro				
	1225	1230	1235	
tcc ggg cga ttt agc ctg cag agc gag cat aaa gaa tcc agc ctg tgg				5834
Ser Gly Arg Phe Ser Leu Gln Ser Glu His Lys Glu Ser Ser Leu Trp				
	1240	1245	1250	
ctg ctg tct aaa aac agg atc ctg cgt tgt ccg atg tca gta cat aaa				5882
Leu Leu Ser Lys Asn Arg Ile Leu Arg Cys Pro Met Ser Val His Lys				
	1255	1260	1265	1270
cgt cgg gat gtt atg cag gta gtg ggt gat gtg cgg tgt gaa tta agt				5930
Arg Arg Asp Val Met Gln Val Val Gly Asp Val Arg Cys Glu Leu Ser				
	1275	1280	1285	
gac gtg gat gcc ctg cca cag gcg ttg caa ata tgc ccg cgg gtc atc				5978
Asp Val Asp Ala Leu Pro Gln Ala Leu Gln Ile Ser Pro Arg Val Ile				
	1290	1295	1300	
cgt ttg ctg aac gtg gca ggt ttg ctg cgc cat tcc gtt cag gaa gcc				6026
Arg Leu Leu Asn Val Ala Gly Leu Leu Arg His Ser Val Gln Glu Ala				
	1305	1310	1315	
tga cgtagagata aaggcgttaa ct atg agt aat aaa atg aag tgg acg agt				6078
	Met Ser Asn Lys Met Lys Trp Thr Ser			
	1320	1325		
atg aca gcc cat tgg tca gca att att aat ttc atc cga aaa tat gtt				6126
Met Thr Ala His Trp Ser Ala Ile Ile Asn Phe Ile Arg Lys Tyr Val				
	1330	1335	1340	
tat cca gca agg ata att gcc atc ctg ctg atg gct ggc gct aca ctg				6174
Tyr Pro Ala Arg Ile Ile Ala Ile Leu Leu Met Ala Gly Ala Thr Leu				
	1345	1350	1355	1360
cca caa gtc gcc gat gcg att acc gtc gac ctg aat tac gac aag aac				6222
Pro Gln Val Ala Asp Ala Ile Thr Val Asp Leu Asn Tyr Asp Lys Asn				
	1365	1370	1375	
aat gta gcg gtc atc act cct gtc tgg tcc caa gaa tgg agt gta gca				6270
Asn Val Ala Val Ile Thr Pro Val Trp Ser Gln Glu Trp Ser Val Ala				
	1380	1385	1390	
aat gtg ttg ggg gga tgg gta tgt cgt tca aac agg aat gaa aat gag				6318
Asn Val Leu Gly Gly Trp Val Cys Arg Ser Asn Arg Asn Glu Asn Glu				
	1395	1400	1405	
ggg gcg tgt gaa gaa aca cat ttg gta tgg tgg tat gct ttt gga gct				6366
Gly Ala Cys Glu Glu Thr His Leu Val Trp Trp Tyr Ala Phe Gly Ala				

WO 00/73336

PCT/SE00/01079

44

1410	1415	1420	
tat tca aaa att cgt ctg cgt ttc aga gaa caa atc agc cat gcc gaa			6414
Tyr Ser Lys Ile Arg Leu Arg Phe Arg Glu Gln Ile Ser His Ala Glu			
1425	1430	1435	1440
att acg ctc ata ctg ctc ggc agt gtt cgt gat gcc tgt tat act ggt			6462
Ile Thr Leu Ile Leu Leu Gly Ser Val Arg Asp Ala Cys Tyr Thr Gly			
1445	1450	1455	
gtc atc aac atg aac gct gct gca tgt caa tgg ggt agg tcg ctg aaa			6510
Val Ile Asn Met Asn Ala Ala Ala Cys Gln Trp Gly Arg Ser Leu Lys			
1460	1465	1470	
ctt agg ata cct tca gaa gag ctt gcg aag ata cct aca agc gga aca			6558
Leu Arg Ile Pro Ser Glu Glu Leu Ala Lys Ile Pro Thr Ser Gly Thr			
1475	1480	1485	
tgg aaa gca acg tta gtc ctg gat tat tta caa tgg ggc gga gac gat			6606
Trp Lys Ala Thr Leu Val Leu Asp Tyr Leu Gln Trp Gly Gly Asp Asp			
1490	1495	1500	
ccc tta ggc aca tca act aca gat atc acg ctg aat gta aca gac cac			6654
Pro Leu Gly Thr Ser Thr Thr Asp Ile Thr Leu Asn Val Thr Asp His			
1505	1510	1515	1520
ttt gct gaa aat gcg gct att tac ttt ccg caa ttt ggt aca gca acg			6702
Phe Ala Glu Asn Ala Ala Ile Tyr Phe Pro Gln Phe Gly Thr Ala Thr			
1525	1530	1535	
ccc cgg gtg gac ctg aat ctt cac cgg atg aat gcc tca caa atg tcg			6750
Pro Arg Val Asp Leu Asn Leu His Arg Met Asn Ala Ser Gln Met Ser			
1540	1545	1550	
ggc agg gct aat ctg gat atg tgt ctg tat gac gga ggt gtg aaa gcc			6798
Gly Arg Ala Asn Leu Asp Met Cys Leu Tyr Asp Gly Gly Val Lys Ala			
1555	1560	1565	
cgt tca tta cag atg aag ata gaa gga agc aat aag tca ggt acg gga			6846
Arg Ser Leu Gln Met Lys Ile Glu Gly Ser Asn Lys Ser Gly Thr Gly			
1570	1575	1580	
ttt cag gtt ata aag agc gat tct gct gat acg att gat tat gcg gtc			6894
Phe Gln Val Ile Lys Ser Asp Ser Ala Asp Thr Ile Asp Tyr Ala Val			
1585	1590	1595	1600
agt atg aat tat ggg gga cga agt att cct gtc acc cgt ggc gtg gag			6942
Ser Met Asn Tyr Gly Gly Arg Ser Ile Pro Val Thr Arg Gly Val Glu			
1605	1610	1615	
ttc agt ctg gat aac gtg gat aaa gca gca acg cgt ccg gtg gta ctt			6990
Phe Ser Leu Asp Asn Val Asp Lys Ala Ala Thr Arg Pro Val Val Leu			
1620	1625	1630	
ccc ggg caa cgg cag gcg gta cgt tgt gtg cca gtg ccc ctt acc ctg			7038
Pro Gly Gln Arg Gln Ala Val Arg Cys Val Pro Val Pro Leu Thr Leu			
1635	1640	1645	

tgttttttga agagttacaa aagtcattta atttattcaa ccataaatat gggttaaata 8039
 aatataact caggatcccc tgggaatttg tgctcataca tatggaaagg atcagtaaat 8099
 taaatagcgt cgggttattt gctgtttctg ttgactttta taacaaccac aaatttctga 8159
 gcgagtacat caggagtcgc agagattatg gtatggaagt ttggtttgat ttttgtggta 8219
 aacattctta ttccagtga attaaaaacc ttggattctt ttttcaggct tgcgtagtgc 8279
 ctctgatcc taattttatt agtagtgttt atcattatca taagttccaa aagattcttg 8339
 tcggggatat aaatgatgta gaacagaggg ccgtgtacca gaacgaagtt gattacatgt 8399
 atggaatgca atggccatcg tcatatgacg gtcttttctt tcgggatcat aaaaaaatg 8459
 aaacttggtg tatataacag aaggagtga aatttgaatc aaaaatatct tatttatttt 8519
 ttgtttaatt attgttttgt tttttattac gattaaatat aaagaacatc attgttcgtg 8579
 cgggtggggag gctggaagtt taggggatga ccgtttatca acaattttat tacagccacc 8639
 atacgaatgg tttatatatg cactagatgt attattttag tttaatatat cgatggttgc 8699
 tatttgcatt gatgatgttc cgttacatta aggaatatat atctgtatct cgttatacgc 8759
 acactcacat tactaatcat tattaatatg agtgtgggtc ttgttttacg catgcatggc 8819
 tgcattgtgac gttaaattta aatgagctga ctgtatgaat tctaaatact ttagagaggt 8879
 gttttttgtc tcggtagttg ttatattatt attttatttg gtgttatttg cagccagtgc 8939
 tcatgctgaa ggcggtttca gatctggagg cattgggtta tttatgacgg gaacaagaga 8999
 gatgctactg tagagataat aaattctgct aaagattccc caattcttgt gcattgacat 9059
 cctccacgtc ctgaagggcg tgggttcctg ctccaacggg ctgcctgact gcacgctcct 9119
 tccacaggca agcacggcgt gtcccgctct aaaatgttac gcgcgccgtt tacatcggcg 9179
 ttgcgagat atcttcatac cagacacttg taagtatctc gcataatcgt gccattcaca 9239
 tttagagatc atac 9253

<210> 2
 <211> 236
 <212> PRT
 <213> Salmonella typhi

<400> 2
 Met Asn Phe Lys Asp Thr Leu Pro Gly Val Phe Leu Cys Val Ala Met
 1 5 10 15
 Phe Ala Cys Gly His Ala Arg Ala Asn Met Leu Val Tyr Pro Met Ala
 20 25 30
 Ala Glu Ile Asn Ser Ser Arg Glu Glu Ala Thr Ser Leu Phe Val Tyr
 35 40 45

Ser Lys Ser Asp His Val Gln Tyr Ile Arg Thr Arg Ile Met Arg Ile
 50 55 60
 Glu His Pro Gly Met Pro Gln Glu Lys Glu Val Pro Ala Gly Asn Asp
 65 70 75 80
 Ile Glu Thr Gly Leu Val Val Ser Pro Glu Lys Phe Ala Leu Ser Pro
 85 90 95
 Gly Thr Lys Lys Thr Ile Arg Val Ile Ser Thr Gln Ala Pro Glu Arg
 100 105 110
 Glu Glu Ala Trp Arg Val Tyr Phe Glu Ala Val Pro Glu Leu Glu Asp
 115 120 125
 Asp Pro Gln Ala Gly Gly Lys Gln Asn Ser Ser Val Ser Val Asn Leu
 130 135 140
 Val Trp Gly Val Leu Leu Arg Val Ser Pro Ser Asp Pro Arg Pro Ala
 145 150 155 160
 Leu Val Thr Asp Gly His His Leu Leu Asn Thr Gly Asn Thr Arg Leu
 165 170 175
 Ser Leu Ile Arg Ala Gly Asn Cys Asp Thr Thr Cys His Trp Gln Asn
 180 185 190
 Ile Gly Lys Ser Ile Tyr Pro Gly Gly Ser Ala Asp Ile Pro Ala Gly
 195 200 205
 Ile Lys Ser Asn Ala Phe Arg Val Glu Tyr Arg Thr Gly Ala Asn Ser
 210 215 220
 Pro Val Ile Ser Ala Asp Leu Thr Ala Ala Gly Lys
 225 230 235

<210> 3
 <211> 191
 <212> PRT
 <213> Salmonella typhi

<400> 3
 Met Tyr Thr Glu Cys Thr Tyr Ile Thr Val Ile Asn Asn Lys Ala Arg
 1 5 10 15
 Leu Phe Phe Met Asn Met Lys Thr Ser Phe Ile Ala Ala Ala Val Ala
 20 25 30
 Leu Ala Thr Val Tyr Ser Phe Ser Val Ser Ala Val Gln Lys Asp Ile
 35 40 45
 Thr Val Thr Ala Asn Ile Asp Ser Thr Leu Glu Leu Leu Gln Ala Asp
 50 55 60
 Gly Ser Ser Leu Pro Ser Thr Met Lys Leu Asp Phe Met Pro Gly Lys
 65 70 75 80
 Gly Leu Val His Lys Ser Leu Gln Thr Arg Leu Tyr Ser Asn Asp Gln
 85 90 95

WO 00/73336

PCT/SE00/01079

48

Thr Lys Ser Val Asn Val Lys Leu Leu Asn Ala Pro Gln Leu Ile Asn
 100 105 110

Val Leu Asp Pro Thr Lys Thr Ile Asp Met Glu Val Thr Leu Gly Gly
 115 120 125

Arg Ser Leu Thr Thr Thr Asn Ser Val Leu Glu Ala Lys Thr Leu Phe
 130 135 140

Pro Asp Gly Lys Thr Gly Asp Ala Ser Ala Leu Leu Asn Leu Asp Ile
 145 150 155 160

Gly Gln Lys Ala Gly Ala Ala Leu Gln Asn Leu Pro Ala Gly Glu Tyr
 165 170 175

Ser Gly Leu Val Ser Leu Val Ile Ser Gln Ala Val Thr Ala Gly
 180 185 190

<210> 4
 <211> 889
 <212> PRT
 <213> Salmonella typhi

<400> 4
 Met Tyr Tyr Leu Leu Gly Leu Cys Ser Phe Thr Ser Gln Ala Thr Leu
 1 5 10 15

Ile Pro Pro Pro Gly Phe Glu Ser Leu Leu Glu Gly Gln Thr Glu Gln
 20 25 30

Ile Glu Val Leu Leu Pro Gly His Ser Leu Gly Leu Phe Pro Val Val
 35 40 45

Val Lys Pro Asp Thr Val Gln Phe Met Ser Pro Leu Met Val Leu Glu
 50 55 60

Ser Ser Gly Leu Ala Ala Leu Pro Ala Ala Glu Arg Gln Lys Ala Leu
 65 70 75 80

Ala Ala Leu Ser Arg Pro Leu Leu Arg Asn Ser Asn Leu Val Cys Gly
 85 90 95

Val Ser Glu Ala Lys Asp Ser Ser Glu Cys Gly Tyr Val Ala Thr Asp
 100 105 110

Lys Glu Asp Val Ala Val Ile Phe Asp Glu Asn Asn Ala Gln Leu Ser
 115 120 125

Leu Phe Leu Asn Arg Asp Trp Leu Pro Asp Glu Glu Arg Arg Asp Lys
 130 135 140

Arg Trp Leu Thr Pro Thr Pro Glu Gly Val Ser Ala Phe Ile His Arg
 145 150 155 160

Gln Thr Leu Tyr Leu Ser Asp Asp Leu His Ser Arg Asn Met Thr Leu
 165 170 175

Asn Gly Ser Gly Ala Leu Gly Leu Gly Asp Gly Arg Tyr Leu Gly Gly
 180 185 190
 Asp Trp Ala Ala Ile Trp Asn Gln Ser Glu His Tyr Asn Asn Ser Gln
 195 200 205
 Ala Trp Phe Asp Asn Leu Phe Val Arg Gln Asp Leu Gly Asn Gln Tyr
 210 215 220
 Tyr Leu Gln Ala Gly Arg Met Asp Gln Arg Asn Leu Ser Ser Ala Thr
 225 230 235 240
 Gly Gly Asp Phe Gly Phe Ser Leu Leu Pro Leu Ser Arg Phe Asp Gly
 245 250 255
 Leu Arg Thr Gly Thr Thr Gln Ala Tyr Val Asn His Glu Val Asp His
 260 265 270
 Asn Ala Thr Pro Val Met Val Gln Val Thr Arg Asn Ala Arg Ile Asp
 275 280 285
 Ile Tyr Arg Gly Ser Glu Leu Leu Gly Ser Gln Phe Leu Thr Pro Gly
 290 295 300
 Met His Thr Leu Asp Thr His Ser Leu Pro Pro Gly Ser Tyr Pro Leu
 305 310 315 320
 Ala Leu Arg Val Tyr Glu Asp Gly Ile Leu Arg Arg Thr Glu Thr Gln
 325 330 335
 Pro Phe Ser Lys Gly Gly Asn Ser Phe Ser Ala Gln Thr Gln Trp Phe
 340 345 350
 Ile Gln Gly Gly Leu Glu Asp Thr Gly Asp Lys Ala Ser His Tyr Asp
 355 360 365
 Gly Glu Thr Val Met Ala Ala Gly Phe Gln Thr Gly Leu Arg Lys Asn
 370 375 380
 Ile Ser Leu Thr Glu Gly Ile Ser Leu Ala His Glu Ala Trp Tyr Ser
 385 390 395 400
 Glu Thr Arg Leu Asn Ser Gln His Ala Val Leu Asp Gly Thr Leu Asp
 405 410 415
 Leu Ser Ala Gly Ile Leu His Gly Thr Asp Ser Thr Ser Gly Asn Thr
 420 425 430
 Glu Gln Val Thr Tyr Asn Asp Gly Phe Ser Ala Ser Leu Trp Arg Asn
 435 440 445
 His Thr Glu Ser Asp Ala Cys Ser Gly Arg His Pro Gln Ser Val His
 450 455 460
 Ala Ser Met Thr Cys Gln Thr Ser Met Asn Ala Ser Leu Ser Val Ser
 465 470 475 480
 Val Gly Asn Trp Tyr Ala Leu Leu Gly Tyr Ser Thr Ser Arg Thr Glu
 485 490 495

Gly	Arg	Pro	Val	Tyr	Arg	Gly	Tyr	Asp	Asp	Asn	Ser	Asp	Lys	Glu	Asn
			500					505					510		
Val	Phe	Trp	Arg	Gln	Ala	Tyr	Ile	Pro	Ala	Ser	His	Arg	Glu	Ser	Ala
		515					520					525			
Gln	Ala	Ser	Ala	Thr	Tyr	Ser	Leu	Asn	Met	Ala	Gly	Met	Asn	Ile	Asn
		530					535					540			
Thr	His	Gly	Gly	Val	Trp	Arg	Thr	Arg	Asn	Asp	Gly	Val	Asn	Asp	Asp
545					550					555					560
Gly	Leu	Phe	Met	Ser	Val	Ser	Val	Ser	Tyr	Ala	Ser	Gln	Pro	Pro	Thr
				565					570					575	
Met	Thr	Gly	Ser	Asn	Arg	Tyr	Thr	Ser	Ala	Gly	Thr	Asp	Ile	His	Ser
			580						585				590		
Ser	Arg	Asn	Gln	Lys	Thr	Gln	Thr	Ser	Trp	Asn	Val	Asn	His	Val	Arg
		595					600					605			
Ser	Trp	Gln	Gln	Asp	Leu	Tyr	Arg	Glu	Leu	Ser	Val	Gly	Phe	Ser	Gly
	610						615					620			
Tyr	Asn	Asp	Asp	Ser	Trp	Ser	Gly	Ser	Leu	Gly	Gly	Arg	Met	Ser	Gly
625					630					635					640
Arg	Met	Gly	Glu	Leu	Ser	Ala	Thr	Ile	Ser	Asn	Ser	His	Gln	Arg	Asn
				645					650					655	
Ala	Gly	Ser	Ala	Ser	Ser	Leu	Thr	Ala	Gly	Tyr	Ser	Ser	Ser	Leu	Ala
			660					665					670		
Leu	Ser	Arg	Asn	Gly	Leu	Phe	Trp	Gly	Gly	Gly	Gln	Asp	Gly	Glu	Pro
		675					680					685			
Ala	Ser	Gly	Met	Ala	Val	Asn	Val	Glu	Ser	Glu	Gly	Asp	Glu	Gly	Ser
	690						695					700			
Ser	Gly	Lys	Val	Val	Ser	Val	Arg	Gly	Ser	Ser	Gln	Pro	Phe	Ser	Leu
705					710						715				720
Gly	Phe	Gly	Gln	Gln	Ser	Leu	Leu	Leu	Met	Glu	Gly	Tyr	Asn	Ala	Thr
				725					730					735	
Glu	Val	Thr	Ile	Glu	Asp	Ala	Gly	Val	Ser	Ser	Gln	Gly	Met	Ala	Gly
			740					745					750		
Val	Lys	Ala	Gly	Gly	Gly	Ser	Arg	Cys	Tyr	Phe	Leu	Thr	Pro	Gly	His
		755					760					765			
Leu	Leu	Val	His	Asn	Ile	Ser	Ala	Ser	Met	Ser	Arg	Leu	Tyr	Val	Gly
		770					775				780				
Arg	Val	Leu	Asp	Lys	Asp	Gly	Arg	Pro	Leu	Leu	Asp	Ala	Gln	Pro	Leu
785					790						795				800
Asn	Tyr	Pro	Phe	Leu	Ser	Leu	Gly	Pro	Ser	Gly	Arg	Phe	Ser	Leu	Gln
				805						810				815	

WO 00/73336

PCT/SE00/01079

51

Ser Glu His Lys Glu Ser Ser Leu Trp Leu Leu Ser Lys Asn Arg Ile
 820 825 830

Leu Arg Cys Pro Met Ser Val His Lys Arg Arg Asp Val Met Gln Val
 835 840 845

Val Gly Asp Val Arg Cys Glu Leu Ser Asp Val Asp Ala Leu Pro Gln
 850 855 860

Ala Leu Gln Ile Ser Pro Arg Val Ile Arg Leu Leu Asn Val Ala Gly
 865 870 875 880

Leu Leu Arg His Ser Val Gln Glu Ala
 885

<210> 5
 <211> 359
 <212> PRT
 <213> Salmonella typhi

<400> 5
 Met Ser Asn Lys Met Lys Trp Thr Ser Met Thr Ala His Trp Ser Ala
 1 5 10 15

Ile Ile Asn Phe Ile Arg Lys Tyr Val Tyr Pro Ala Arg Ile Ile Ala
 20 25 30

Ile Leu Leu Met Ala Gly Ala Thr Leu Pro Gln Val Ala Asp Ala Ile
 35 40 45

Thr Val Asp Leu Asn Tyr Asp Lys Asn Asn Val Ala Val Ile Thr Pro
 50 55 60

Val Trp Ser Gln Glu Trp Ser Val Ala Asn Val Leu Gly Gly Trp Val
 65 70 75 80

Cys Arg Ser Asn Arg Asn Glu Asn Glu Gly Ala Cys Glu Glu Thr His
 85 90 95

Leu Val Trp Trp Tyr Ala Phe Gly Ala Tyr Ser Lys Ile Arg Leu Arg
 100 105 110

Phe Arg Glu Gln Ile Ser His Ala Glu Ile Thr Leu Ile Leu Leu Gly
 115 120 125

Ser Val Arg Asp Ala Cys Tyr Thr Gly Val Ile Asn Met Asn Ala Ala
 130 135 140

Ala Cys Gln Trp Gly Arg Ser Leu Lys Leu Arg Ile Pro Ser Glu Glu
 145 150 155 160

Leu Ala Lys Ile Pro Thr Ser Gly Thr Trp Lys Ala Thr Leu Val Leu
 165 170 175

Asp Tyr Leu Gln Trp Gly Gly Asp Asp Pro Leu Gly Thr Ser Thr Thr
 180 185 190

Asp Ile Thr Leu Asn Val Thr Asp His Phe Ala Glu Asn Ala Ala Ile
 195 200 205

Tyr	Phe	Pro	Gln	Phe	Gly	Thr	Ala	Thr	Pro	Arg	Val	Asp	Leu	Asn	Leu	210	215	220
His	Arg	Met	Asn	Ala	Ser	Gln	Met	Ser	Gly	Arg	Ala	Asn	Leu	Asp	Met	225	230	235
Cys	Leu	Tyr	Asp	Gly	Gly	Val	Lys	Ala	Arg	Ser	Leu	Gln	Met	Lys	Ile	245	250	255
Glu	Gly	Ser	Asn	Lys	Ser	Gly	Thr	Gly	Phe	Gln	Val	Ile	Lys	Ser	Asp	260	265	270
Ser	Ala	Asp	Thr	Ile	Asp	Tyr	Ala	Val	Ser	Met	Asn	Tyr	Gly	Gly	Arg	275	280	285
Ser	Ile	Pro	Val	Thr	Arg	Gly	Val	Glu	Phe	Ser	Leu	Asp	Asn	Val	Asp	290	295	300
Lys	Ala	Ala	Thr	Arg	Pro	Val	Val	Leu	Pro	Gly	Gln	Arg	Gln	Ala	Val	305	310	315
Arg	Cys	Val	Pro	Val	Pro	Leu	Thr	Leu	Thr	Thr	Gln	Pro	Phe	Asn	Ile	325	330	335
Arg	Glu	Lys	Arg	Ser	Gly	Glu	Tyr	Gln	Gly	Thr	Leu	Thr	Val	Thr	Met	340	345	350
Leu	Met	Gly	Thr	Gln	Thr	Pro										355		

```
<210> 6
<211> 151
<212> PRT
<213> Salmonella typhi
```

```

<400> 6
Met Thr Val Tyr Leu Asp Asp Lys Asp Lys Glu Leu Leu Lys Glu Ile
  1             5             10             15
Gln Lys Asp Cys Ala Gln Thr Leu Trp Gln Leu Ala Tyr Lys Val Gly
      20             25             30
Leu Thr Pro Thr Pro Cys Phe Lys Arg Leu Lys Lys Leu Lys Asp Arg
      35             40             45
Gly Val Ile Ile Gly Gln Phe Ala Leu Leu Asp Lys Glu Lys Leu Gly
      50             55             60
Leu Ser Leu Asn Val Phe Ile Met Ile Asn Ile Ser Glu Glu Gln Tyr
      65             70             75             80
Ala Ser Ile Ser Glu Lys Ile Lys Ser Met Pro Glu Val Ile Ala Phe
      85             90             95
Tyr Arg Ile Ser Gly Ser Phe Asn Tyr Leu Met His Thr Val Phe Thr
      100             105             110

```

WO 00/73336

PCT/SE00/01079

53

Asp	Met	Asn	Asp	Tyr	Tyr	Ser	Phe	Tyr	Glu	Lys	Ile	Ile	Leu	Thr	Asn
		115					120					125			
Ser	Ser	Ile	Ser	Gly	Ser	Ala	Ser	Ser	Phe	Val	Leu	Glu	Gln	Ile	Lys
		130				135					140				
Glu	Thr	Asn	Glu	Leu	Ser	Val									
145					150										